SEVERE ACUTE RESPIRATORY SYNDROME AND INFLUENZA

SEVERE ACUTE RESPIRATORY SYNDROME AND INFLUENZA

“There is no question that there will be another influenza pandemic someday. We simply don't know when it will occur or whether it will be caused by the H5N1 avian influenza virus. It would be prudent to develop robust plans for dealing with such a pandemic.”[72]

Influenza A– and severe acute respiratory syndrome (SARS)–associated viruses are examples of respiratory viruses that may have rampant courses, high virulence, and high lethality. SARS struck like a bolt from the blue in 2002 to 2003 and was a grim reminder of our vulnerability to new infectious diseases. SARS affected mainly people in Asia, in the Pacific Rim, and in Canada. The causative agent is thought to be an RNA coronavirus that is passed on through contact and droplet spread. The virus is viable ex vivo for 24 to 48 hours. Many of the victims of the SARS outbreak were health workers, including anesthesiologists. The influenza pandemic of 1918 to 1919 was one of the major plagues to have affected humankind; it is estimated that Spanish flu left a trail of as many as 25 million corpses around the world in just 25 weeks. A new strain of avian influenza, the H5N1 strain, which is a subtype of influenza A, is now threatening humankind. Influenza is an RNA orthomyxovirus, which, like other RNA viruses, mutates at an alarming rate. The strain H5N1 is so named based on the capsular peptides, hemagglutinin, and neuraminidase. There are 16 known hemagglutinin subtypes and nine known neuraminidase subtypes of influenza A viruses. The Spanish flu was caused by an H1N1 strain of the virus, which continues to cause seasonal human influenza. According to the World Health Organization, pathogenic strains of H5N1 that infect humans may be fatal in approximately 66% of cases. Currently, H5N1 influenza A is passed from bird to human. The fear is that if there is recombination within a patient with concurrent H1N1 or H3N2 influenza A infection, the viruses may undergo recombination resulting in a lethal strain that can spread among humans ( Fig. 19-5 ). Patients with acute respiratory viral infections may require care by anesthesiologists for such procedures as emergency intubation, tracheostomy, chest tube placement, mechanical ventilator support, or general ICU care.

 

Management of Anesthesia

Preoperative

The anesthesiologist should assess the patient with an appreciation of the potential lethality of the infection. Both patient and their family should be counseled about the high risks associated with SARS-CoV. These viruses are highly contagious and frequently lethal; strict isolation should be enforced and precautions to protect health workers must be taken. The same may apply to a potential (recombinant or newly evolved) influenza strain. Ideally, infected patients should be cared for in rooms with negative pressure to decrease aerosolized spread and contagion. Barrier precautions include the use of full-body disposable oversuits, double gloves, goggles, and powered air-purifying respirators with high-efficiency particulate air filters. [78] [79] If these are not available, N95 masks (block 95% of particles) should be used rather than regular surgical masks. Filters should be placed in both limbs of breathing circuits to protect ventilators and anesthesia machines from contamination. All surfaces should be sterilized with alcohol and rooms should ideally not be used for other patients (if practical) for up to 48 hours after a person with SARS-CoV or H5N1 influenza A has been in the room. Even if it is not SARS or influenza, the same principles of infection control barrier precautions apply to any deadly contagious infection, whether occurring “naturally” or introduced by those with malevolent intent.

Intraoperative

Fears about contagion should not blind anesthesiologists to the high level of care required for these vulnerable patients. During the SARS outbreak in Hong Kong, fears about contagion may have affected patient management.[80] Experience from Canada has shown that when appropriate precautions are taken, spread of infection may be prevented. If mechanical ventilation is required, protective ventilation as for acute respiratory distress syndrome is indicated. Tidal volumes should be limited to 6 to 8 mL/kg lean body mass and mean airway pressure should be less than 30 cm H2O. Sudden cardiorespiratory compromise could be reflective of an expanding pneumothorax. Draining of pleural effusions may improve ventilation and gas exchange. Care should be taken with bronchoscopy as this is a particularly high-risk procedure that results in aerosolization of viral particles.

Signs and Symptoms

Symptoms include nonspecific complaints of viral infection such as cough, sore throat, headache, diarrhea, arthralgia, and muscle pain. In more severe cases, patients may present with respiratory distress, confusion (encephalitis), and hemoptysis. Signs may include fever, tachycardia, sweating, conjunctivitis, rash, tachypnea, use of accessory respiratory muscles, cyanosis, and pulmonary features of pneumonia, pleural effusions, or pneumothorax. A chest radiograph may show patchy infiltrates, areas of opacification, pneumothoraces, and evidence of pleural effusions. Both H5N1 influenza A virus and SARS-coronavirus (CoV) may cause acute lung injury and acute respiratory distress syndrome. Complications include multiorgan failure and severe sepsis

 

RENAL TRANSPLANTATION

RENAL TRANSPLANTATION

Candidates for renal transplantation are selected from patients with ESRD who are on established programs of long-term hemodialysis. In adults, the most common causes of end-stage renal failure are diabetes mellitus, glomerulonephritis, polycystic kidney disease, and systemic hypertension. Despite concerns about the recurrence of disease in the donor kidney, it has generally been only slowly progressive. A kidney from a cadaver donor can be preserved by perfusion at low temperatures for up to 48 hours, making its transplantation a semielective surgical procedure. Attempts are made to match HLA and ABO blood groups between donor and recipient. Paradoxically, the presence of certain common shared HLA in blood administered to a potential transplant recipient has been observed to induce tolerance to donor antigens and thus improve graft survival. The donor kidney is placed in the lower abdomen and receives its vascular supply from the iliac vessels. The ureter is anastomosed directly to the bladder. Immunosuppressive therapy is instituted during the perioperative period.

Management of Anesthesia

General Anesthesia

Although both regional and general anesthesia have been successfully used for renal transplantation, general anesthesia is most often selected. General anesthesia provides the advantage of mechanically maintaining the patient's ventilation, which may become compromised by surgical retraction in the area of the diaphragm. Drug selection is influenced by known side effects of anesthetic drugs (bowel distention from nitrous oxide, metabolism of sevoflurane to inorganic fluoride). Renal function after kidney transplantation is not predictably influenced by the volatile anesthetic administered. A common approach is to combine volatile anesthetics (isoflurane or desflurane) with nitrous oxide or short-acting opioids. Decreased cardiac output due to negative inotropic effects of volatile anesthetics is minimized to avoid jeopardizing the adequacy of tissue oxygen delivery (especially if anemia is present) and to promote renal perfusion. A high normal systemic blood pressure is required in the presence of euvolemia to maintain adequate urine flow. The selection of muscle relaxants is influenced by the dependence of many of these drugs on renal clearance. In this regard, atracurium, cisatracurium, and mivacurium are attractive selections, as their clearance from the plasma is independent of renal function. A newly transplanted but functioning kidney is able to clear neuromuscular-blocking drugs and the anticholinesterase drugs used for their reversal at the same rate as normal patients.

Central venous pressure monitoring is useful for guiding the rate and volume of crystalloid infusions. Optimal hydration during the intraoperative period is intended to optimize renal blood flow and improve early function of the transplanted kidney. Diuretics are often administered to facilitate urine formation by the newly transplanted kidney. In this regard, osmotic diuretics such as mannitol facilitate urine output and decrease excess tissue and intravascular fluid. Unlike the loop diuretic furosemide, mannitol does not depend on renal tubular concentrating mechanisms to produce diuresis.

When the vascular clamps are released, renal preservative solution from the transplanted kidney and venous drainage from the legs are also released into the circulation. These effluents contain potassium and acid metabolites but, in adults, seem to have minimal systemic effects. Nevertheless, cardiac arrest has been described after completion of the arterial anastomosis to the transplanted kidney and release of the vascular clamp. This event is most likely due to sudden hyperkalemia caused by washout of the potassium-containing preservative solutions from the newly perfused kidney. Unclamping may also be followed by hypotension due to the abrupt addition of up to 300 mL to the capacity of the intravascular fluid space and the release of vasodilating chemicals from previously ischemic tissues. When hypotension results from this change, the treatment is most often intravenous infusion of fluids.

Regional Anesthesia

The advantages of regional anesthesia compared with general anesthesia are the absence of a need for tracheal intubation or administration of neuromuscular blocking drugs. These advantages are negated, however, if regional anesthesia must be extensively supplemented with injected or inhaled drugs. Furthermore, blockade of the peripheral sympathetic nervous system, as produced by regional anesthesia, can complicate control of systemic blood pressure, especially considering the unpredictable intravascular fluid volume status of many of these patients. The use of regional anesthesia, particularly epidural anesthesia, is controversial in the presence of abnormal coagulation.

Postoperative Complications

The newly transplanted kidney may suffer acute immunologic rejection, which manifests in the vasculature of the transplanted kidney. It can be so rapid that inadequate circulation is evident almost immediately after the blood supply to the kidney is established. The only treatment for this acute rejection reaction is removal of the transplanted kidney, especially if the rejection process is accompanied by disseminated intravascular coagulation. A hematoma also may arise in the graft postoperatively, causing vascular or ureteral obstruction.

Delayed signs of graft rejection include fever, local tenderness, and deterioration of urine output. Treatment with high doses of corticosteroids and antilymphocyte globulin may be helpful. The acute tubular necrosis that occurs in the transplanted kidney secondary to prolonged ischemia usually responds to hemodialysis. Cyclosporine toxicity may also cause ARF. Ultrasonography and needle biopsy are performed to differentiate between the possible causes of kidney malfunction.

Opportunistic infections owing to long-term immunosuppression are common after renal transplantation. Long-term survival is unsatisfactory in renal transplant recipients who are immunosuppressed and who also carry hepatitis B surface antigen. The frequency of cancer is 30 to 100 times higher in transplant recipients than in the general population, presumably reflecting the loss of protective effects due to immunosuppression. Large-cell lymphoma is a well-recognized complication of transplantation, occurring almost exclusively in patients with evidence of Epstein-Barr virus infections.

 

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

PNEUMONIA

PNEUMONIA

Combined with influenza, community-acquired pneumonia is one of the 10 leading causes of death in the United States. S. pneumoniae is by far the most frequent cause of bacterial pneumonia in adults. Other bacteria that cause pneumonia include H. influenzae, Mycoplasma pneumoniae, S. aureus, Legionella pneumophilia, K. pneumoniae, and Chlamydia pneumoniae. S. pneumoniae usually causes typical pneumonia. Influenzavirus, M. pneumoniae, chlamydia, legionella, adenovirus, and other microorganisms may cause atypical pneumonia.[62]

Diagnosis

An initial chill, followed by abrupt onset of fever, chest pain, dyspnea, fatigue, rigors, cough, and copious sputum production often characterize bacterial pneumonia, although symptoms vary. Nonproductive cough is a feature of atypical pneumonias. A detailed history may suggest possible causative organisms. Hotels and whirlpools are associated with Legionnaires' disease (L. pneumoniae) outbreaks. Fungal pneumonia may occur with cave exploration (Histoplasma capsulatum) and diving (Scedosporium angiospermum). Chlamydia psittaci pneumonia may follow contact with birds and Q fever (Coxiella burnetti) contact with sheep. Alcoholism may increase the risk of bacterial aspiration such as K. pneumoniae. Patients who are immunocompromised, such as those with AIDS, are at risk of fungal pneumonia, such as Pneumocystis jiroveci pneumonia (PCP).

Posteroanterior and lateral chest radiographs may be extremely helpful in diagnosing pneumonia.[63] Diffuse infiltrates are suggestive of an atypical pneumonia whereas a lobar radiographic opacification is suggestive of a typical pneumonia. Atypical pneumonia occurs more frequently in young adults. Radiography is useful for detecting pleural effusions and multilobar involvement. Polymorphonuclear leukocytosis is typical, and arterial hypoxemia may occur in severe cases of bacterial pneumonia. Arterial hypoxemia reflects intrapulmonary shunting of blood owing to perfusion of alveoli filled with inflammatory exudates.

Microscopic examination of sputum plus cultures and sensitivity testing may be helpful in suggesting the etiologic diagnosis of pneumonia and in guiding the selection of appropriate antibiotic treatment. S. pneumoniae and gram-negative organisms, such as H. influenzae, may be seen on sputum stain or culture. Unfortunately, sputum specimens are frequently inadequate and organisms do not invariably grow from sputum. Interpretation of sputum culture may be challenging, as there is frequent normal nasopharyngeal carriage of S. pneumoniae. If there is suspicion, sputum specimens should be sent for acid-fast bacilli (tuberculosis). Antigen detection in urine is a good test for L. pneumophilia. Blood antibody titers are helpful in diagnosing M. pneumoniae. Sputum polymerase chain reaction is useful for chlamydia.[62] Blood cultures are usually negative, but are important to rule our bacteremia. HIV is an important risk factor for pneumonia and should be tested for when pneumonia is suspected.

Management of Anesthesia

Anesthesia and surgery should ideally be deferred with acute infections. Patients with acute pneumonia are often dehydrated and may have renal insufficiency. However, overly aggressive volume resuscitation may worsen gas exchange and morbidity. Fluid management is therefore extremely challenging. Regional anesthesia may be superior. If general anesthesia is unavoidable, a protective ventilation strategy is appropriate with tidal volumes of 6 to 8 mL/kg ideal body mass and mean airway pressures less than 30 cm H2O. The anesthesiologist should suction secretions, send distal sputum specimens for Gram stain and culture, and ensure that appropriate antibiotics are administered both for the pneumonia and to cover the surgery.

Postoperative Pneumonia

Postoperative pneumonia occurs in approximately 20% of patients undergoing major thoracic, esophageal, or major upper abdominal surgery but is rare in other procedures in previously fit patients. Chronic respiratory disease increases the incidence of postoperative pneumonia threefold. Other risk factors include obesity, age older than 70 years, and operations lasting more than 2 hours.[67]

Lung Abscess

Lung abscess may develop after bacterial pneumonia. Alcohol abuse and poor dental hygiene are important risk factors. Septic pulmonary embolization, which is most common in intravenous drug abusers, may also result in formation of a lung abscess. A finding of an air-fluid level on the chest radiograph signifies rupture of the abscess into the bronchial tree, and foul-smelling sputum is characteristic. Antibiotics are the mainstay of treatment of a lung abscess. Surgery is indicated only when complications such as empyema occur. Thoracentesis is necessary to establish the diagnosis of empyema, and treatment requires chest tube drainage and antibiotics. Surgical drainage is necessary to treat chronic empyema.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

MANAGEMENT OF HEART FAILURE

MANAGEMENT OF HEART FAILURE

Current therapeutic strategies are aimed at reversing the pathophysiologic alterations present in heart failure and at interrupting the vicious circle of maladaptive mechanisms ( Fig. 6-3 ). Short-term therapeutic goals in patients with heart failure include relieving symptoms of circulatory congestion, increasing tissue perfusion, and improving the quality of life. However, management of heart failure involves more than the treatment of symptoms. The processes that contributed to the LV dysfunction may progress independently of the development of symptoms. Therefore, the long-term therapeutic goal is to prolong life by slowing or reversing the progression of ventricular remodeling.

Picture Hosted by Free Photo Hosting at <A href="http://www.iranxm.com/

Figure 6-3  Primary targets of treatment in heart failure. Treatment options for patients with heart failure affect the pathophysiologic mechanisms that are stimulated in heart failure. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers decrease afterload by interfering with the renin-angiotensin-aldosterone system, resulting in peripheral vasodilation. They also affect left ventricular hypertrophy, remodeling, and renal blood flow. Aldosterone production by the adrenal glands is increased in heart failure. It stimulates renal sodium retention and potassium excretion and promotes ventricular and vascular hypertrophy. Aldosterone antagonists counteract the many effects of aldosterone. Diuretics decrease preload by stimulating natriuresis in the kidneys. Digoxin affects the Na+K+ATPase pump in the myocardial cell, increasing contractility. Inotropes such as dobutamine and milrinone increase myocardial contractility. β-Blockers inhibit the sympathetic nervous system and adrenergic receptors. They slow the heart rate, decrease blood pressure, and have a direct beneficial effect on the myocardium by enhancing reverse remodeling. Selected agents that also block α-adrenergic receptors can cause vasodilation. Vasodilator therapy such as combination therapy with hydralazine and isosorbide dinitrate decreases afterload by counteracting peripheral vasoconstriction. Cardiac resynchronization therapy with biventricular pacing improves left ventricular function and favors reverse remodeling. Nesiritide (brain natriuretic peptide) decreases preload by stimulating diuresis and decreases afterload by vasodilation. Exercise improves peripheral blood flow by eventually counteracting peripheral vasoconstriction. It also improves skeletal-muscle physiology.  (Reproduced with permission from Jessup M, Brozena S: Heart failure. N Engl J Med 2003;348:2007–2018. Copyright © 2003 Massachusetts Medical Society. All rights reserved.)



Management of Chronic Heart Failure

The current recommended therapy of chronic heart failure is based on results of large, adequately powered, randomized trials and on the American College of Cardiology/American Heart Association and European Society of Cardiology guidelines for the diagnosis and treatment of chronic heart failure. According to these guidelines, treatment options include lifestyle modification, patient and family education, medical therapy, corrective surgery, implantable devices, and cardiac transplantation ( Fig. 6-4 ).

Picture Hosted by Free Photo Hosting at <A href="http://www.iranxm.com/

Figure 6-4  Stages of heart failure and treatment options for systolic heart failure. Patients with stage A heart failure are at high risk of heart failure but do not yet have structural heart disease or symptoms of heart failure. This group includes patients with hypertension, diabetes, coronary artery disease, previous exposure to cardiotoxic drugs, or a family history of cardiomyopathy. Patients with stage B heart failure have structural heart disease but no symptoms of heart failure. This group includes patients with left ventricular hypertrophy, previous myocardial infarction, left ventricular systolic dysfunction, or valvular heart disease, all of whom would be considered to have New York Heart Association (NYHA) class I symptoms. Patients with stage C heart failure have known structural heart disease and current or previous symptoms of heart failure. Their current symptoms may be classified as NYHA class I, II, III, or IV. Patients with stage D heart failure have refractory symptoms of heart failure at rest despite maximal medical therapy, are hospitalized, and require specialized interventions or hospice care. All such patients would be considered to have NYHA class IV symptoms. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; VAD, ventricular assist device.  (Reproduced with permission from Jessup M, Brozena S: Heart failure. N Engl J Med 2003;348:2007–2018. Copyright © 2003 Massachusetts Medical Society. All rights reserved.)



Lifestyle modifications are aimed at decreasing the risk of heart disease and include smoking cessation, a healthy diet with moderate sodium restriction, weight control, exercise, moderate alcohol consumption, and adequate glycemic control.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

Management of Acute Heart Failure

Management of Acute Heart Failure

Patients may experience acute heart failure as a result of decompensated chronic heart failure or de novo. Anesthesiologists deal with acute heart failure when caring for patients in overt heart failure who present for emergency surgery or patients who decompensate intraoperatively. Acute heart failure therapy has three phases: the emergency phase, the in-hospital management phase, and the predischarge phase. For the anesthesiologist, the emergency phase is of most interest and is the phase that is addressed here. The hemodynamic profile of acute heart failure is characterized by high ventricular filling pressures, low cardiac output, and hyper- or hypotension. Traditional therapy includes diuretics, vasodilators, inotropic drugs, mechanical assisted devices (intra-aortic balloon pump, ventricular assist device), and emergency cardiac surgery. Newer therapy includes calcium sensitizers, exogenous BNP, and nitric oxide synthase inhibitors.

Diuretics and Vasodilators

Loop diuretics can improve symptoms rapidly, but in high doses, they may have deleterious effects on clinical outcomes. It may be more desirable to use a combination of a low dose of loop diuretic with an intravenous vasodilator. Nitroglycerin and nitroprusside reduce LV filling pressure and systemic vascular resistance and increase stroke volume. However, nitroprusside may have a negative impact on clinical outcome in patients with acute myocardial infarction.

Inotropic Support

Positive inotropic drugs have been the mainstay of treatment for patients in cardiogenic shock. Their positive inotropic effect is produced via an increase in cyclic adenosine monophosphate, which promotes an increase in intracellular calcium levels and, thereby, an improvement in excitation-contraction coupling. Catecholamines (epinephrine, norepinephrine, dopamine, and dobutamine) do so by direct β-receptor stimulation, whereas phosphodiesterase inhibitors (amrinone, milrinone) block the degradation of cyclic adenosine monophosphate. Side effects of inotropic drugs include tachycardia, increased myocardial energy demand and oxygen consumption, dysrhythmias, worsening of DHF, and down-regulation of β-receptors. Long-term use of these drugs may result in cardiotoxicity and accelerate myocardial cell death.

Calcium Sensitizers

Myofilament calcium sensitizers are a new class of positive inotropic drugs that increase contractility without increasing intracellular levels of calcium. Therefore, there is no significant increase in myocardial oxygen consumption or heart rate and no propensity for dysrhythmias. The most widely used medication in this class is levosemindan. It is an inodilator increasing myocardial contractile strength and promoting dilation of systemic, pulmonary, and coronary arteries. It does not worsen diastolic function. Studies have shown that levosemindan may be particularly useful in the setting of myocardial ischemia. Levosemindan is included in the European guidelines for treatment of acute heart failure, but it is not yet available for use in the United States.

Exogenous B-Type Natriuretic Peptide

Nesiritide (Natrecor) is recombinant BNP that binds to both the A- and B-type natriuretic receptors. It promotes arterial, venous, and coronary vasodilation, thereby decreasing LVEDP and improving dyspnea. Nesiritide induces diuresis and natriuresis. It has many effects similar to nitroglycerin but generally produces less hypotension and more diuresis than nitroglycerin.

Nitric Oxide Synthase Inhibitors

The inflammatory cascade stimulated by heart failure results in production of a large amount of nitric oxide in the heart and vascular endothelium. These high levels of nitric oxide have a negative inotropic and profound vasodilatory effect leading to cardiogenic shock and vascular collapse. Inhibition of nitric oxide synthase should decrease these harmful effects. L-NAME (N-nitro-L-arginine methyl ester) is the principal drug in this class under investigation.

Mechanical Devices

If the etiology of acute heart failure is a large myocardial infarction, the insertion of an intra-aortic balloon pump should be considered. The intra-aortic balloon pump is a mechanical device inserted via the femoral artery and positioned just below the left subclavian artery. Its balloon inflates in diastole increasing aortic diastolic blood pressure and coronary perfusion pressure. The balloon deflates in systole creating a “suction” effect that enhances LV ejection. Complications of intra-aortic balloon pump placement include femoral artery or aortic dissection, bleeding, thrombosis, and infection.

In severe cardiogenic shock, emergency insertion of LV and/or right ventricular assist devices may be necessary for survival.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

EPIDERMOLYSIS BULLOSA

EPIDERMOLYSIS BULLOSA

Epidermolysis bullosa is a group of genetic diseases of mucous membranes and skin, particularly the oropharynx and esophagus. Epidermis bullosa can be categorized as simplex, junctional, and dystrophic. In the simplex type, epidermal cells are fragile and mutations of genes encoding keratin intermediate filament proteins underlie the fragility. In the dystrophic types (incidence approximately one in every 300,000 births), the genetic mutation appears to be in the gene encoding the type of collagen that is the major component of anchoring fibrils

Management of Anesthesia

Supplemental corticosteroids may be indicated during the perioperative period if patients have been on long-term treatment with these drugs. The main anesthetic concerns in patients with epidermolysis bullosa center on the serious complications that can occur if proper precautions are not taken during instrumentation. Avoidance of trauma to the skin and mucous membranes is crucial. Bulla formation can be caused by trauma from tape, blood pressure cuffs, tourniquets, adhesive electrodes, and rubbing the skin with alcohol wipes. Blood pressure cuffs should be padded with a loose cotton dressing. Electrodes should have the adhesive portion removed. Petroleum jelly gauze can help hold them in place. Anything that touches a patient should be well padded. Intravenous and intra-arterial catheters should be sutured or held in place with gauze wraps rather than tape. A nonadhesive pulse oximetry sensor should be used. A soft foam, sheepskin, or gel pad should be placed under the patient. All creases should be removed from the linen.

Trauma from the anesthetic face mask must be minimized by gentle application against the face. Lubrication of the face and mask with cortisol ointment, or indeed any lubricant, can be helpful. Upper airway instrumentation should be minimized because the squamous epithelium lining the oropharynx and esophagus is very susceptible to trauma. Frictional trauma to the oropharynx, such as that produced by an oral airway, can result in formation of large intraoral bullae and/or extensive hemorrhage from denuded mucosa. Nasal airways are equally hazardous. Esophageal stethoscopes should be avoided. Hemorrhage from ruptured oral bullae has been treated successfully with epinephrine-soaked gauze applied directly to the bullae.

Interestingly, endotracheal intubation has not been associated with laryngeal or tracheal complications in patients with epidermolysis bullosa dystrophica. Indeed, laryngeal involvement with this form of the disease is rare, and tracheal bullae have not been reported. This finding is consistent with the greater resistance of columnar epithelium to disruption compared to fragile squamous epithelium. Generous lubrication of the laryngoscope blade with cortisol ointment and/or petroleum jelly and selection of a smaller endotracheal tube than usual are recommended. Chronic scarring of the oral cavity can result in a narrow oral aperture and immobility of the tongue making tracheal intubation difficult. After intubation, the tube must be carefully immobilized with soft cloth bandages to prevent movement in the oropharynx, and the tube must be positioned so that it does not exert lateral forces at the corners of the mouth. Tape is not used to hold the endotracheal tube in place. It must be remembered that oropharyngeal suctioning can lead to life-threatening bulla formation. The risk of pulmonary aspiration may be increased in the presence of esophageal stricture.

Porphyria cutanea tarda has been reported to occur with increased frequency in patients with epidermolysis bullosa. This type of porphyria does not have the same implications for management of anesthesia, as does acute intermittent porphyria.

Propofol and ketamine are useful for avoiding airway manipulation when the operative procedure does not require controlled ventilation or skeletal muscle relaxation. Despite the presence of dystrophic skeletal muscle, there is no evidence that these patients are at increased risk of a hyperkalemic response when treated with succinylcholine. There are no known contraindications to the use of volatile anesthetics in these patients. As alternatives to general anesthesia, regional anesthetic techniques (spinal, epidural, brachial plexus block) have been recommended.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

Colorectal Cancer

Colorectal Cancer

Colon cancer is second only to lung cancer as a cause of cancer death in the United States. The incidence and mortality from this cancer has not changed appreciably during the past several decades. Almost all colorectal cancers are adenocarcinomas, and the disease generally occurs in adults older than 50 years.

Etiology

Most colorectal cancers arise from premalignant adenomatous polyps. Large polyps, especially those larger than 1.5 cm in diameter, are more likely to contain invasive cancer. Although adenomatous polyps are common (present in more than 30% of patients older than 50 years), less than 1% of adenomatous polyps ever become malignant. It is thought that adenomatous polyps require at least 5 years of growth before they become clinically significant. The evolution of normal colonic mucosa to a benign adenomatous polyp that contains cancer and then to life-threatening invasive cancer is associated with a series of genetic events that involve the mutational activation of a proto-oncogene and the loss of several genes that normally suppress tumorigenesis.

Most colorectal cancers appear to be related to diet, with the disease occurring in the greatest incidence among individuals in upper socioeconomic classes living in urban areas. There is a direct correlation between calories consumed, dietary fat and oil, and meat protein. Available data indicate that a high intake of animal fat is the dietary element that is most strongly associated with the risk of colon cancer. As many as 25% of patients with colorectal cancer have a family history of the disease. Inflammatory bowel disease is associated with an increased incidence of colorectal cancer. Cigarette smoking for longer than 35 years appears to increase the risk of colorectal cancer.

Diagnosis

The rationale for colorectal cancer screening is that early detection and removal of localized superficial tumors and precancerous lesions in asymptomatic individuals increases the cure rate. Screening programs (digital rectal examination, examination of the stool for occult blood, colonoscopy) appear to be particularly useful for persons who have first-degree relatives with a history of the disease, especially if these relatives developed the colorectal cancer before 55 years of age. There is evidence that annual or biennial fecal occult blood testing is associated with a decreased incidence of colorectal cancer.

Signs and Symptoms

The presenting signs and symptoms of colorectal cancer reflect the anatomic location of the cancer. Because stool is relatively liquid as it passes into the right colon through the ileocecal valve, tumors in the cecum and ascending colon can become large and markedly narrow the bowel lumen without causing obstructive symptoms. Ascending colon cancers frequently ulcerate, leading to chronic blood loss in the stool. These patients experience symptoms related to anemia, including fatigue and, in some patients, angina pectoris.

Stool becomes more concentrated as it passes into the transverse colon. Transverse colon cancers cause abdominal cramping, occasional bowel obstruction, and even perforation. Abdominal radiographs reveals characteristic abnormalities in the colonic gas pattern, reflecting narrowing of the lumen (“napkin ring lesion”). Colon cancers developing in the rectosigmoid portion of the large intestine result in tenesmus and thinner stools. Anemia is unusual despite the passage of bright red blood from the rectum (often attributable to hemorrhoids).

Colorectal cancers initially spread to regional lymph nodes and then through the portal venous circulation to the liver, which represents the most common visceral site of metastases. Colorectal cancers rarely spread to lung, bone, or brain in the absence of liver metastases. A preoperative increase in the serum concentration of carcinoembryonic antigen suggests that the tumor will recur following surgical resection. Carcinoembryonic antigen is a glycoprotein that is also increased in the presence of other cancers (stomach, pancreas, breast, lung) and nonmalignant conditions (alcoholic liver disease, inflammatory bowel disease, cigarette smoking, pancreatitis).

Treatment

The prognosis for patients with adenocarcinoma of the colorectum depends on the depth of tumor penetration into the bowel wall and the presence or absence of regional lymph node involvement and distant metastases (liver, lung, bone). Radical surgical resection, which includes the blood vessels and lymph nodes draining the involved bowel, offers the best potential for cure. Surgical management of cancers that arise in the distal rectum may necessitate a permanent sigmoid colostomy (abdominoperineal resection). Because most recurrences occur within 3 to 4 years, the cure rate for colorectal cancer is often estimated by 5-year survival rates.

Radiation therapy is a consideration in patients with rectal tumors since the risk of recurrence following surgery is significant. Postoperative radiation therapy causes transient diarrhea and cystitis, but permanent damage to the small intestine and bladder is uncommon. Use of chemotherapy in patients with advanced colorectal cancers rarely results in a satisfactory response.

Management of Anesthesia

Management of anesthesia for surgical resection of colorectal cancers may be influenced by anemia and the effects of metastatic lesions in liver, lung, bone, or brain. Chronic large bowel obstruction probably does not increase the risk of aspiration during induction of anesthesia, although abdominal distention could interfere with adequate ventilation and oxygenation. Blood transfusion during surgical resection of colorectal cancers has been alleged to be associated with a decrease in the length of patient survival. This could reflect immunosuppression produced by transfused blood. For this reason, careful review of the risks and benefits of blood transfusions in these patients is prudent.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

CIRRHOSIS

CIRRHOSIS

Cirrhosis can result from a large variety of chronic, progressive liver diseases. Most often cirrhosis is the result of excessive chronic alcohol ingestion or chronic viral hepatitis due to HBV or HCV infection. Scarring of the liver results in disruption of normal liver architecture, and regenerating parenchymal nodules are typically seen. The pattern of scarring seldom permits determination of a specific etiology, but other histologic features may provide clues as to the cause of the cirrhosis.

Diagnosis

Percutaneous liver biopsy establishes the diagnosis of cirrhosis. Computed tomography, magnetic resonance imaging, and hepatic ultrasonography with Doppler flow studies may reveal findings consistent with cirrhosis (splenomegaly, ascites, irregular liver surface). Upper gastrointestinal endoscopy can establish the presence of esophagogastric varices.

Management of Anesthesia

It is estimated that 5% to 10% of patients with cirrhosis require surgery in the last 2 years of life. Many trauma beds are occupied by patients who were injured while under the influence of alcohol. In those patients who abuse alcohol, the presence of ascites, sepsis, and chronic obstructive pulmonary disease preoperatively is associated with increased postoperative morbidity and mortality. Postoperative morbidity includes pneumonia, bleeding, sepsis, poor wound healing, and deterioration in liver function. The pathogenic mechanisms of these complications often includes subclinical cardiorespiratory insufficiency and immune incompetence. The complications of alcohol withdrawal can also affect perioperative morbidity.

Preoperative Preparation

Certain preoperative criteria correlate with surgical risk and postoperative outcome in patients with cirrhosis undergoing major surgery ( Table 11-6 ). Identifying co-existing problems that can be optimized preoperatively (cardiorespiratory function, coagulation status, renal function, intravascular fluid volume, electrolyte balance, nutrition) may decrease morbidity and mortality associated with elective surgery in patients with severe liver disease. Coagulation status should be evaluated and parenteral vitamin K administered if the prothrombin time is prolonged. Failure of parenteral vitamin K to improve synthesis of prothrombin suggests the presence of severe hepatocellular disease. Impaired prothrombin production due to biliary obstruction and the absence of bile salts that facilitate gastrointestinal absorption of vitamin K is promptly reversed by parenteral vitamin K therapy. Thrombocytopenia, which often accompanies severe liver disease, may require treatment. Hypoglycemia may be present, and administration of a glucose solution is a consideration perioperatively. There should be proper hydration and urine output prior to surgery. Hepatic blood flow is predictably decreased in patients with cirrhosis, and any further decrease due to anesthetic-induced depression of cardiac output or blood pressure could jeopardize hepatocyte oxygenation.


TABLE 11–6   -- Prediction of Perioperative Risk in the Patient with Liver Disease

Parameter

Low Risk

Moderate Risk

High Risk

Bilirubin (mg/dL)

<2

2–3

>3

Albumin (g/dL)

>3.5

3.0–3.5

<3

Prothrombin time (seconds prolonged)

1–4

4–6

>6

Encephalopathy

None

Moderate

Severe

Nutrition

Excellent

Good

Poor

Ascites

None

Moderate

Marked

Adapted from Strunin I: Preoperative assessment of the patient with liver dysfunction. Br J Anaesth 1978;50:25–34.

 

Chronic alcohol ingestion has been demonstrated to increase anesthetic requirements (MAC) for isoflurane most likely due to cross-tolerance. Accelerated metabolism of drugs in the presence of alcohol-induced microsomal enzyme induction can also alter the amount of anesthetic drug needed to achieve a certain anesthesia depth. Decreased protein binding of drugs in the presence of hypoalbuminemia could increase the pharmacologically active fraction of intravenous anesthetic drugs. Alcohol-induced cardiomyopathy could make patients unusually sensitive to the cardiac depressant effects of volatile anesthetics. There may be decreased responsiveness to catecholamines.

Intoxicated Alcoholic Patients

In contrast to a chronic but sober alcoholic patient, the acutely intoxicated patient requires less anesthetic because there are additive depressant effects from the alcohol and the anesthetic drugs. Acutely intoxicated patients are also ill equipped to withstand stress and acute surgical blood loss. Furthermore, alcohol may decrease the tolerance of the brain to hypoxia. Intoxicated patients may be more vulnerable to regurgitation of gastric contents since alcohol delays gastric emptying and decreases lower esophageal sphincter tone. Surgical bleeding may reflect alcohol-induced interference with platelet aggregation. Alcohol, even in moderate doses, causes increased plasma catecholamine concentrations, most likely reflecting inhibition of neurotransmitter uptake back into presynaptic nerve endings.

Intraoperative Management

Optimal anesthetic drug choices or techniques in the presence of liver disease are unknown. It is important to remember, however, that a constant feature of chronic liver disease is decreased hepatic blood flow due to portal hypertension. As a result, hepatic blood flow and hepatocyte oxygenation are more dependent on hepatic artery blood flow than normally. The hepatic artery may provide more than 50% of the oxygen supply by vasodilating during periods of decreased portal vein blood flow. Hepatic blood flow and hepatocyte oxygenation seem to be well maintained during administration of isoflurane, desflurane, and sevoflurane but not halothane. However, the ability of the hepatic artery to vasodilate in response to a decrease in portal vein blood flow can be blunted by volatile anesthetics, especially halothane and especially in high concentrations. It is prudent to limit the dose of volatile anesthetic to minimize the likelihood of a persistent decrease in mean arterial pressure because intraoperative hypotension may be associated with increased postoperative morbidity and mortality. Intravenous anesthetic drugs are valuable adjuncts to volatile anesthetics with or without nitrous oxide, but cumulative drug effects are likely if liver disease is severe enough to slow metabolism of the intravenous anesthetics. Regardless of the drugs selected for anesthesia, postoperative liver dysfunction is likely to be exaggerated in patients with chronic liver disease, presumably due to the effects of anesthetic drugs and/or stress-induced activation of the sympathetic nervous system on hepatocyte oxygenation. Regional anesthesia can be useful in patients with advanced liver disease if the coagulation status is acceptable.

Muscle Relaxants

Hepatic clearance of muscle relaxants must be considered when selecting a particular neuromuscular blocker for administration to patients with cirrhosis. Succinylcholine or mivacurium are acceptable, although severe liver disease may decrease plasma cholinesterase activity and prolong the duration of action of these drugs. The increased volume of distribution that accompanies cirrhosis, especially with ascites, will result in the need for a larger initial dose of nondepolarizing muscle relaxant to produce the required plasma concentration. However, subsequent doses may be smaller due to decreased hepatic clearance and metabolism. Hepatic dysfunction does not alter the elimination half-time of atracurium or cisatracurium. The elimination half-time of vecuronium is not increased until the dose exceeds 0.1 mg/kg, consistent with the dependence of this drug on hepatic clearance. Altered protein binding of muscle relaxants is insignificant as a mechanism of an altered response in patients with cirrhosis.

Monitoring

Monitoring of arterial blood gases and urine output is often necessary. The need for invasive intraoperative monitoring is determined by the extent and urgency of the surgery. Management of anesthesia for surgical creation of a portocaval shunt includes monitoring arterial pressure and cardiac filling pressures. Fluid administration must be carefully titrated to an endpoint such as central venous pressure, pulmonary artery occlusion pressure, and urine output. Intraoperative maintenance of an acceptable urine output may help decrease the risk of postoperative acute renal failure. When blood replacement is necessary, the stored blood should be administered as slowly as possible to compensate for the decreased clearance of citrate by the cirrhotic liver. Infusion of glucose may be necessary during the perioperative period to prevent hypoglycemia. A practical point is avoidance of unnecessary esophageal instrumentation (esophageal stethoscope, orogastric or nasogastric tube) in patients with known esophageal varices.

Postoperative Management

Regardless of the drugs selected for anesthesia, postoperative liver dysfunction/jaundice is likely in patients with chronic liver disease. Cholestasis and sepsis can also be causes of postoperative jaundice. Manifestations of alcohol withdrawal usually appear 24 to 72 hours after cessation of drinking and can constitute a medical emergency in the postoperative period.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

ACUTE LIVER FAILURE

ACUTE LIVER FAILURE

Acute hepatic failure is characterized by jaundice, hypoalbuminemia, coagulopathy, malnutrition, susceptibility to infection, and renal dysfunction in the clinical setting of acute hepatic disease. Fulminant hepatic failure refers to acute liver failure with superimposed hepatic encephalopathy that develops within 2 to 8 weeks of the onset of illness in a patient without preexisting liver disease. Viral hepatitis and drug-induced liver injury account for most cases of acute liver failure

Management of Anesthesia

Only surgery necessary to correct life-threatening problems should be considered in patients with acute liver failure. Preoperative correction of coagulation abnormalities with fresh frozen plasma may be indicated. Low doses of volatile anesthetics or even nitrous oxide alone may be sufficient to provide analgesia and amnesia in these critically ill patients. Intravenous anesthetics may have prolonged effects due to the marked reduction in metabolism of these drugs. Muscle relaxants may be needed to facilitate operative exposure or manage ventilation. When choosing a muscle relaxant, one must consider the impact of decreased hepatic function and associated renal dysfunction on the clearance of the drug. Because the plasma half-life of pseudocholinesterase is 14 days, it is unlikely that acute liver failure would be associated with a prolonged response to succinylcholine or mivacurium.

Administration of glucose is important, and plasma glucose measurement to confirm the absence of hypoglycemia is prudent. Blood should be administered as slowly as possible to minimize the likelihood of citrate intoxication. Monitoring arterial blood gases and electrolyte concentrations is helpful since these patients are vulnerable to development of arterial hypoxemia, metabolic acidosis, hypokalemia, hypocalcemia, and hypomagnesemia. Hypotension and its adverse effect on hepatic blood flow and hepatocyte oxygenation must be considered. Urine output is maintained with intravenous infusion of crystalloid or colloid and, if necessary, diuretic administration. Invasive monitoring is helpful for guiding overall hemodynamic management. These patients are vulnerable to infection, emphasizing the importance of aseptic technique during insertion of intravascular catheters. Lactulose therapy during the preoperative period may decrease the ammonia load and help prevent development of hepatic encephalopathy.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

TRAUMATIC BRAIN INJURY

TRAUMATIC BRAIN INJURY

Traumatic brain injury is the leading cause of disability and death in young adults in the United States. Brain injury may be caused by both closed head injury and penetrating injuries such as by bullets or foreign objects. Associated injuries, including cervical spine injury and thoracoabdominal trauma, frequently accompany acute head injury. Brain injury can be further exacerbated by systemic conditions related to trauma, including hypotension and hypoxia related to excessive bleeding, pulmonary contusion, aspiration, or adult respiratory distress syndrome.

Initial management of acute head injury patients includes immobilization of the cervical spine, establishment of a patent upper airway, and protection of the patient's lungs from aspiration of gastric contents, as well as maintaining perfusion of brain tissue by treating hypotension. The most useful diagnostic procedure, in terms of simplicity and rapidity, is CT, which should be performed as soon as possible. In this regard, CT has greatly facilitated identification of epidural or subdural hematomas. Routine CT may not be needed in patients with minor head trauma who meet the following criteria: no headache or vomiting, younger than 60 years of age, no intoxication, no deficits in short-term memory, no physical evidence of trauma above the clavicles, and no seizures.

Image Hosted by Free Picture Hosting at <A href="http://www.iranxm.com 

It is not unusual for patients with traumatic brain injury who initially are stable and awake or in light coma to deteriorate suddenly. Delayed hematoma formation or cerebral edema is often responsible for these changes. Uncontrolled brain swelling that may not respond to conventional management may also cause sudden neurologic deterioration. Delayed secondary injury at the cellular level is an important contributor to brain swelling and subsequent irreversible brain damage.

The Glasgow Coma Scale score provides a reproducible method for assessing the seriousness of brain injury (scores of < 8 points indicate severe injury) and for following the patient's neurologic status (see Table 10A-1 ). Head injury patients with scores less than 8 are by definition in coma, and approximately 50% of these patients die or remain in vegetative states. Type of head injury and age are important determinants of outcome in the presence of low scores. For example, patients with acute subdural hematomas have a poorer prognosis than do patients with diffuse brain contusion injury. Mortality in children with severe head injury is less than in adults.

Perioperative Management

Perioperative management of patients with acute head trauma, such as those following motor vehicle accidents, must consider the risks of secondary injury due to cerebral ischemia as well as injuries affecting organ systems other than the brain. CBF is usually initially decreased and then gradually increases with time. Factors contributing to poor outcome in head injury patients are increased ICP and systolic blood pressures less than 70 mm Hg. Normal autoregulation of CBF is often impaired in patients with acute head injury, but carbon dioxide reactivity is usually preserved. Control of increased ICP with mannitol or furosemide is indicated, and in some patients craniectomy is necessary. Hyperventilation, although effective in controlling ICP, may contribute to cerebral ischemia in head injury patients, and for this reason, it is a common recommendation to avoid hyperventilation unless necessary. Barbiturate coma may be useful in some patients as a means to control intracranial hypertension when other more conservative means have failed. In adults, induced mild hypothermia in patients with acute head injury has not been shown to improve outcome. Administration of hypertonic saline and mannitol may decrease brain volume. Associated lung injuries may impair oxygenation and ventilation in these patients and necessitate mechanical ventilation. Neurogenic pulmonary edema may also contribute to acute pulmonary dysfunction. The exact mechanism for this disorder is unknown but is thought to be related to hyperactivity of the sympathetic nervous system, which results in alterations in Starling forces in the lung and pulmonary edema. Coagulopathy occurs in head injury patients and may be enhanced by hypothermia and the need for massive blood transfusions. Disseminated intravascular coagulation can occur following severe head injury. It is thought to be related to the release of brain thromboplastin into the systemic circulation. This protein is known to activate the coagulation cascade. Replacement of clotting factors may also be necessary.

Management of Anesthesia

Patients with traumatic brain injury may require anesthesia for neurosurgical interventions such as hematoma drainage, decompressive craniectomy for cerebral edema, or spinal stabilization. Anesthesia may also be required for the treatment of a variety of non-neurologic problems such as the repair of limb fractures and intra-abdominal injuries. Management of anesthesia includes efforts to optimize CPP, minimize the occurrence of cerebral ischemia, and avoid drugs and techniques that could increase ICP. CPP is maintained above 70 mm Hg if possible, and hyperventilation is not used unless it is needed as a temporizing measure to control ICP. During surgical evacuation of acute epidural or subdural hematomas, systemic blood pressure may decrease precipitously at the time of surgical decompression and require aggressive resuscitation. Patients with severe head injury may experience impaired oxygenation and ventilation that complicates the intraoperative period. Adequate fluid resuscitation and replacement are important. Hypertonic crystalloid solutions, such as 3% saline, increase the plasma osmotic pressure and thus remove water from the brain's interstitial space. Hypotonic crystalloid solutions are avoided, as they decrease plasma osmotic pressure and increase cerebral edema even in normal brains. Glucose-containing solutions should be avoided unless specifically indicated (e.g., the treatment of laboratory-diagnosed hypoglycemia), out of concern for exacerbating neuronal injury in the setting of hyperglycemia.

Induction and Maintenance of Anesthesia

In hemodynamically stable patients, the induction of anesthesia with intravenous induction drugs and nondepolarizing muscle relaxants is acceptable. Fiberoptic intubation or tracheostomy should be considered in patients when there is added concern of either the inability to safely perform tracheal intubation via direct laryngoscopy, that a neurologic deficit may be further exacerbated (i.e., cervical spine fracture), or there is already evidence of airway compromise. In moribund patients, the establishment of a safe and effective airway takes priority over concerns for anesthetic selection, as drugs may not be needed. One should also be aware of the possible presence of hidden extracranial injuries (i.e., bone fractures, pneumothorax) as they may lead to problems such as excessive blood loss and perturbations in ventilation and circulation. Maintenance of anesthesia often includes continuous infusions of intravenous drugs or low-dose volatile anesthetics, keeping in mind the goal to optimize CPP and prevent increases in ICP. Nitrous oxide should be avoided because of the risk of pneumocephalus and concern for non-neurologic injuries such as pneumothorax. Among the volatile anesthetics, low-dose sevoflurane may be unique in minimally impairing cerebral autoregulation, although low-dose isoflurane is also a good choice. If acute brain swelling develops, correctable causes such as hypercapnia, arterial hypoxemia, systemic hypertension, and venous obstruction must be considered and corrected if present. Intra-arterial monitoring of systemic blood pressure is helpful, whereas time constraints may limit the use of CVP or pulmonary artery catheter monitoring.

Postoperative Period

During the postoperative period, it is common to maintain skeletal muscle paralysis to facilitate mechanical ventilation. Continuous monitoring of ICP is also useful in many patients.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

TURP Syndrome

TURP Syndrome

Benign prostatic hyperplasia is often treated surgically by transurethral resection of the prostate (TURP). This involves resection via a cystoscope with continuous irrigation of the bladder to aid visualization while removing blood and resected material. The irrigating fluid is a nonelectrolyte fluid containing glycine, sorbitol, or mannitol, and this fluid may be absorbed rapidly via open venous sinuses in the prostate gland, causing volume overload, hyponatremia, and hypo-osmolality. This is known as TURP syndrome. This syndrome is more likely to occur if resection is prolonged (>1 hour), if the irrigating fluid is suspended more than 40 cm above the operative field, or if the pressure in the bladder is allowed to increase above 15 cm H2O. TURP syndrome manifests principally with cardiovascular and neurologic signs and symptoms. Hypertension is common. Monitoring for development of this syndrome includes direct neurologic assessment in the patient under regional anesthesia or measurement of serum sodium concentration and osmolality in the patient under general anesthesia.

Treatment consists of terminating the surgical procedure so that no more fluid is absorbed, diuretics if needed for relief of cardiovascular symptoms, and hypertonic saline administration if severe neurologic symptoms are present or the serum sodium concentration is less than 120 mEq/L.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

Sitting Position and Venous Air Embolism

Sitting Position and Venous Air Embolism

Craniotomy to remove a supratentorial tumor is usually performed in the supine position with the patient's head elevated 10 to 15 degrees to facilitate cerebral venous drainage. Infratentorial tumors have more unusual patient positioning requirements and may be performed in the lateral, prone, or sitting position.

The sitting position deserves special attention since, other than for surgery on the shoulder and thyroid, it is rarely used for non-neurosurgical cases and has a variety of anesthetic implications. The sitting position is often used for exploration of the posterior cranial fossa, which may be necessary to resect intracranial tumors, clip aneurysms, decompress cranial nerves, or implant electrodes for cerebellar stimulation, as well as for surgery on the cervical spine and posterior cervical musculature. Advantages of the sitting position include excellent surgical exposure and enhanced cerebral venous and CSF drainage, thereby minimizing blood loss and reducing ICP. These advantages are offset by the decreases in systemic blood pressure and cardiac output produced by this position, and the potential hazard of venous air embolism. For these reasons, the lateral or prone position may be selected as an alternative. However, as long as no contraindication to the sitting position exists (i.e., patent foramen ovale), the outcome of patients managed in the sitting versus horizontal position is similar or superior to that of other positions. If the sitting position is used, it is mandatory to maintain a high index of suspicion for venous air embolism.

The postoperative complications that may occur after posterior fossa craniotomy include apnea due to hematoma formation, tension pneumocephalus, or cranial nerve injuries. Macroglossia is also a possibility and is presumed due to impaired venous drainage from the tongue. This is sometimes associated with excessive neck flexion and may be influenced by the use of multiple oral instruments (e.g., endotracheal tube, oral airway, esophageal stethoscope, transesophageal echocardiography probe) simultaneously.

Venous air embolism is a potential hazard whenever the operative site is above the level of the patient's heart, such that pressures in the exposed veins are subatmospheric. Although this complication is most often associated with neurosurgical procedures, venous air embolism may also occur during operations involving the neck, thorax, abdomen, and pelvis and during open heart procedures, repair of liver and vena cava lacerations, obstetric and gynecologic procedures, and total hip replacement. Patients undergoing intracranial surgery are at increased risk not only because the operative site is usually above the level of the patient's heart but also because veins in the skull may not collapse when cut, owing to their attachment to bone or dura. Indeed, the cut edge of cranial bone, including that associated with burr holes, is a common site for the entry of air into veins.

Presumably, when air enters the right atrium and ventricle, there is interference with right-sided cardiac output and blood flow into the pulmonary artery. Air that eventually enters the pulmonary artery may trigger pulmonary edema and reflex bronchoconstriction. Death is usually secondary to a vapor lock causing right-sided cardiac output to plummet, acute cor pulmonale, or arterial hypoxemia from combined cardiac and pulmonary insults.

Small quantities of air can sometimes pass through pulmonary vessels to reach the coronary and cerebral circulations; large quantities of air can travel directly to the systemic circulation through right-to-left intracardiac shunts created by a patent foramen ovale or true septal defects. This passage of air from the right to left circulation is known as paradoxical air embolism. For that reason, known foramen ovale or other cardiac defects that could possibly result in a right-to-left shunt are relative contraindications to use of the sitting position.

Fatal cerebral embolism, subsequent to entrainment of systemic venous air, has occurred even in the absence of identifiable shunt mechanisms or intracardiac defects. This may occur because of failure of contrast echocardiography to detect an existing patent foramen ovale or septal defect. There are many theoretical reasons for this failure of detection. One is that Valsalva or other provocative maneuvers are not always successful in mimicking the physiologic changes that occur during general anesthesia and true venous air embolus and, as such, may underestimate the potential for venous air to pass from the right to left circulations. Paradoxical air embolism can occur even in the absence of any detectable elevations of mean right atrial pressure compared to that of the left atrium. This occurs as a result of small differences in the timing of contraction of the various heart chambers. As a result, pressure gradients will transiently reverse, making the shunt bidirectional. An extremely brief right-to-left shunt could introduce a few air bubbles into the left-sided cardiac chambers and lead to severe consequences if those bubbles were to embolize to the brain. Also, various anesthetic drugs may diminish the ability of the pulmonary circulation to filter out air emboli and thus facilitate the passage of venous air emboli to the arterial circulation.

The use of the sitting position inherently predisposes neurosurgical patients to paradoxical air embolism, as the normal interatrial pressure gradient frequently becomes reversed in this position. When the likelihood of venous air embolism is increased, it is useful, but not mandatory, to place a right atrial catheter before beginning surgery. Death due to paradoxical air embolism results from obstruction of the coronary arteries by air, leading to myocardial ischemia and ventricular fibrillation. Neurologic damage may follow air embolism to the brain.

Early detection of venous air embolism is important for successful treatment. A Doppler sonography transducer placed over the right-sided cardiac structures is one of the most sensitive indicators of intracardiac air. Indeed, the small amount of air detected by the transducer is often clinically unimportant. In this regard, the transducer does not provide information as to the volume of air that has entered the venous circulation. Transesophageal echocardiography, by comparison, is also useful for both detecting and quantifying intracardiac air. A sudden decrease in the end-expired PaCO2 may reflect increased alveolar dead space and/or diminished cardiac output resulting from air embolus. An increase in right atrial and pulmonary artery pressures reflects acute cor pulmonale and correlates with abrupt decreases in the end-expired CO2. Although these changes are less sensitive indicators of the presence of air than Doppler sonography or transesophageal echocardiography, they reflect the size of the venous air embolism. Increased end-expired nitrogen concentrations identify and partially quantify venous air embolism. Changes in end-expired nitrogen concentrations often precede decreased end-expired PaCO2 or increased pulmonary artery pressures. During controlled ventilation of the lungs, sudden attempts by patients to initiate spontaneous breaths (“gasp reflex”) may be the first indication of venous air embolism. Hypotension, tachycardia, cardiac arrhythmias, and cyanosis are late signs of venous air embolism. Certainly detection of the characteristic “millwheel” murmur, as heard through an esophageal stethoscope, is a late sign of catastrophic venous air embolism.

Upon detection of venous air, the surgeon should flood the operative site with fluid, apply occlusive material to all bone edges, and attempt to identify any other sources of air entry (e.g., perforation of a venous sinus). Aspiration of air should be attempted through the right atrial catheter. The ideal location of the right atrial catheter tip is controversial, but evidence suggests that the junction of the superior vena cava with the right atrium is preferable, as this position appears to provide the most rapid aspiration of air. Right atrial multiorifice catheters permit aspiration of larger amounts of air than do single-orifice catheters. Because of its small lumen size and slow speed of blood return, a pulmonary artery catheter is not as useful for aspirating air but may provide additional evidence that venous air embolism has occurred by virtue of increased pulmonary artery pressures. Nitrous oxide is promptly discontinued to avoid increasing the size of any venous air bubbles. Indeed, elimination of nitrous oxide from the inhaled gases after detecting a venous air embolism often results in decreased pulmonary artery pressures. At the same time oxygen is substituted for nitrous oxide, it may be helpful to apply positive end-expiratory pressure or direct jugular venous compression to increase venous pressure at the surgical site. Despite the logic of this maneuver, the prophylactic use of positive end-expiratory pressure is not of value in preventing venous air embolism.

Extreme hypotension may require the support of perfusion pressure using sympathomimetic drugs. Likewise, marked decreases in cardiac output may require the infusion of β-adrenergic agonists such as dopamine or dobutamine. Bronchospasm is treated with β2-adrenergic agonists by aerosol (metered-dose inhaler) or the intravenous route. The traditional admonition to treat venous air embolism by placing the patient in the lateral position with the right chest uppermost is rarely possible or safe during intracranial operations. It is likely that valuable time, better spent aspirating air and supporting circulation, could be lost attempting to attain this position.

After successful treatment of small or modest venous air embolism, the surgical procedure can be resumed. However, the decision to reinstitute administration of nitrous oxide must be individualized. If it is decided not to use nitrous oxide, maintenance of an adequate depth of anesthesia requires administration of larger doses of volatile or intravenous anesthetics. If nitrous oxide is added to the inhaled gases, it is possible that residual air in the circulation could again produce symptoms.

Hyperbaric therapy may be useful in the treatment of both severe venous as well as paradoxical air embolism. Transfer of patients to a hyperbaric chamber in an attempt to decrease the size of air bubbles and to improve blood flow is likely to be helpful only if the transfer can be accomplished within 8 hours.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

SPINAL CORD TUMORS

SPINAL CORD TUMORS

Spinal cord tumors can be divided into two broad categories. Intramedullary tumors are located within the spinal cord proper and account for approximately 10% of tumors affecting the spinal column, with gliomas and ependymomas accounting for the vast majority of intramedullary tumors. Extramedullary tumors can be either intradural or extradural. Neurofibromas and meningiomas account for most of the intradural tumors. In contrast, metastatic lesions, usually from lung, breast, or prostate cancer, as well as myeloma, are the most common causes of extradural lesions. Other mass lesions of the spinal cord, including abscesses and hematomas, share many of the clinical signs and symptoms seen with tumors.

 

Spinal cord tumors typically present with symptoms of cord compression. Pain is a common finding and is usually aggravated by coughing or straining. Motor symptoms and sphincter disturbances may also occur. Sometimes spinal tenderness may be present. Diagnosis is usually based on symptoms and imaging of the spinal cord; magnetic resonance imaging is the technique of choice. Treatment and prognosis depend of the nature of the lesion and may include corticosteroids, radiation therapy, chemotherapy, or surgical decompression or excision.

Management of anesthesia involves ensuring adequate spinal cord oxygenation and perfusion. This is achieved by ensuring adequate PaO2 and by avoiding hypotension and anemia. Specifics of management will depend on the level of the lesion and the extent of neurologic impairment.

Tumors involving the cervical spinal cord may influence the approach used to secure the airway. Significant motion of the cervical spine could lead to further cord compromise via compression and decreased cord perfusion. With any form of disease that places the cervical spine in jeopardy for new injury, airway management should be similar to that discussed in the management of acute spinal cord injury. This may include in-line stabilization during direct laryngoscopy or awake fiberoptic intubation. If the approach to patient management is uncertain, it is useful, prior to administering sedatives or narcotics, to have the patient placed in position for airway management (e.g., on the operating room table) and then carefully move through the anticipated variations of head and neck movement prior to actual airway manipulation or induction of anesthesia. Exacerbation or induction of symptoms upon movement should tip the clinician toward fiberoptic laryngoscopy (with the head held in neutral position) or other options that would less likely cause movement-associated harm to the cord. For example, a light-wand or Bullard laryngoscope may facilitate intubation of the trachea without significant neck extension.

Safe resection of a tumor may require the use of intraoperative electrophysiologic monitoring of neurologic function. Techniques such as electromyography, somatosensory evoked potentials, and motor evoked potential monitoring have a variety of anesthetic implications. The preferred approach may vary from institution to institution. We refer readers to a variety of review articles discussing the intraoperative use of these monitoring modalities.

Succinylcholine should be used with caution in patients with spinal cord tumors given the risk of associated hyperkalemia. Also, neuromuscular monitoring with train-of-four should be performed on a neurologically intact extremity. Evidence of upper motor neuron impairment may lead to an up-regulation of acetylcholine receptors, thus making the extremity relatively resistant to nondepolarizing blockade. If there are any concerns regarding the possibility of altered responsiveness to neuromuscular block due to tumor-induced spinal cord dysfunction, monitoring train-of-four on the facial nerve is a reasonable option. However, one should be careful to monitor evoked muscle twitches, not direct muscle stimulation.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

PHEOCHROMOCYTOMA

PHEOCHROMOCYTOMA

Pheochromocytomas are catecholamine-secreting tumors that arise from chromaffin cells of the sympathoadrenal system. Pheochromocytomas account for less than 0.1% of all cases of hypertension in adults. Although they are an uncommon cause of hypertension, their detection is imperative since they have lethal potential and are one of the few truly curable forms of hypertension. Uncontrolled catecholamine release can result in malignant hypertension, cerebrovascular accidents, and myocardial infarctions. They present a great challenge to anesthesiologists both in the operating room and in the ICU. Before diagnostic urine screening tests became available and prior to the institution of preoperative α-adrenergic blockade (i.e., early to mid 1960s), 25% to 50% of hospital deaths in patients with a pheochromocytoma occurred during the induction of anesthesia or during surgical procedures for unrelated disorders.

The precise etiology of a pheochromocytoma is unknown. Pheochromocytomas are usually (90%) an isolated finding. Ten percent of pheochromocytomas are inherited (familial) as an autosomal dominant trait. Both sexes are equally affected, and the tumor can present at any age with the peak incidence occurring in the third to fifth decades of life. Ten percent of pheochromocytomas occur in children. Variable clinical presentations are responsible for difficulties in diagnosis. Familial pheochromocytomas usually occur as bilateral adrenal tumors or as extra-adrenal tumors that appear in the same anatomic site over successive generations. Recent advances in genetic testing allow for early identification of patients with a familial pheochromocytoma before signs and symptoms occur. Familial pheochromocytomas can also be part of the multiple endocrine neoplastic syndromes and can occur in association with several neuroectodermal dysplasias. Patients with multiple endocrine neoplastic 2a syndrome have a pheochromocytoma, medullary carcinoma of the thyroid, and hyperparathyroidism. Patients with multiple endocrine neoplastic 2b syndrome have a pheochromocytoma, medullary carcinoma of the thyroid, alimentary tract ganglioneuromatosis, thickened corneal nerves, and a marfanoid habitus. In multiple endocrine neoplastic 2a and 2b syndromes, pheochromocytomas are usually located bilaterally in the adrenal glands and are seldom malignant. Almost 100% of patients with the multiple endocrine neoplastic 2 syndromes have or will develop bilateral benign adrenal medullary pheochromocytomas. Of the neuroectodermal dysplasias, 10% to 25% of patients with von Hippel-Lindau syndrome (i.e., hemangioblastoma of the cerebellum and a retinal angioma) may have a pheochromocytoma, less than 1% of patients with von Recklinghausen’s disease (i.e., neurofibromatosis) have a pheochromocytoma, and patients with tuberous sclerosis and Sturge-Weber syndrome can have a pheochromocytoma.

Image Hosted by Free Picture Hosting at <A href="http://www.iranxm.com

Malignant spread usually proceeds via venous and lymphatic channels with a predilection for liver and bone, although spinal cord, lung, brain, and lymph nodes may also be affected. Metastatic spread from apparently benign primaries is well recognized. The incidence of malignancy is 10%, although improved diagnostic methods (i.e., 131I-metaiodobenzylguanidine [MIBG] scintigraphy) may yield a higher rate in the future. The 5-year survival rate for patients with malignancy is 44%. Following resection of benign disease, 5% to 10% of patients have a benign recurrence.

Eighty percent of pheochromocytomas are located in the adrenal medulla. The right gland is involved more often than the left. Twenty percent of pheochromocytomas are extra-adrenal in location, with the majority being located in the abdomen in association with the sympathetic ganglia. The organ of Zuckerkandl near the aortic bifurcation is the most common extra-adrenal site. Two percent of extra-adrenal pheochromocytomas occur in the neck and thorax. Failure of involution of chromaffin tissue in childhood is the best explanation for the development of extra-adrenal pheochromocytomas. Contrary to previous beliefs, most extra-adrenal pheochromocytomas follow a benign course. Adult pheochromocytomas are solid, highly vascular tumors usually 3 to 5 cm in diameter and average 100 g in weight (range, 1.0–4000 g). The average-size adult pheochromocytoma contains 100 to 800 mg of norepinephrine.

Pheochromocytomas are tumors of the SNS. The SNS remains intact and active in the presence of these tumors. The manifestations of a pheochromocytoma are the result of the hormones released by the tumor. Most pheochromocytomas secrete norepinephrine either alone or more commonly combined with a smaller amount of epinephrine in a ratio of 85:15, the inverse of the ratio secreted by the normal adrenal gland. Approximately 15% of tumors secrete predominantly epinephrine. Some dopamine-secreting pheochromocytomas have been described. Most pheochromocytomas are not under neurogenic control and secrete catecholamines autonomously.

Signs and Symptoms

Hypertension, continuous or paroxysmal, is the most frequent manifestation of the disease. Headache, sweating, pallor, and palpitations are other classic signs and symptoms. Most patients are symptomatic, and attacks range from infrequent (i.e., once a month or less) to numerous (i.e., many times per day) and may last from less than a minute to several hours. They may occur spontaneously or be precipitated by physical stimuli, psychic stimuli, or medications. Hypertension is present in more than 80% of adult patients. Paroxysmal hypertension associated with a normal blood pressure between crises occurs in 50% of patients. Thirty percent of patients will have sustained hypertension. Twenty-four–hour ambulatory blood pressure monitoring has shown that many crises are asymptomatic. Orthostatic hypotension is also a common finding and considered to be secondary to hypovolemia and impaired venous and arterial vasoconstrictor reflex responses. Hemodynamic signs depend on the predominant catecholamine secreted. With norepinephrine, α-adrenergic effects predominate, and patients usually have systolic and diastolic hypertension and a reflex bradycardia. With epinephrine, β-adrenergic effects predominate, and patients usually have systolic hypertension, diastolic hypotension, and tachycardia. Some patients remain normotensive in spite of high levels of circulating norepinephrine. The regulation of blood pressure in pheochromocytoma patients appears more complex than traditional views suggest. The extent of increases in arterial blood pressure appears to have little relation to the prevailing levels of circulating catecholamines. An imbalance between endogenous vasodilators (i.e., dopamine, serotonin, enkephalins, and vasoactive intestinal peptide) and circulating catecholamines may account for this. Despite the 10-fold higher levels of circulating catecholamines, the hemodynamics are not greatly different between patients with pheochromocytomas and patients with essential hypertension. Both groups have an increased systemic vascular resistance, usually a normal cardiac output, and a slightly decreased plasma volume. Long-term exposure to high levels of catecholamines does not appear to produce hemodynamic responses characteristic of acute administration. A desensitization of the cardiovascular system or a down-regulation of adrenergic receptors may explain this finding. The sensitivity of smooth muscle cells is decreased secondary to a decrease in the number of receptors or an alteration in receptor-effector coupling. The hypertensive crises do, however, mimic the hemodynamic responses of acute catecholamine administration. Blood vessels of pheochromocytoma patients usually require extremely high concentrations of catecholamines to constrict and produce hypertension.

A catecholamine-induced cardiomyopathy may also occur. The true incidence of clinically significant cardiomyopathies is unclear. A global reduction in myocardial pump function results from the net reduction in viable myofibrils and the down-regulation of β-receptors. The etiology appears multifactorial and includes catecholamine-induced permeability changes of the sarcolemmal membranes leading to excess calcium influx, toxicity from oxidized products of catecholamines, and damage by free radicals. In addition, high catecholamine levels affect the heart via coronary vasoconstriction through α-adrenergic pathways reducing coronary blood flow and potentially creating ischemia. Both dilated and hypertrophic cardiomyopathies, as well as left ventricular outflow tract obstruction, have been demonstrated echocardiographically. Echocardiographic findings are usually normal in patients without cardiac symptoms (dyspnea, chest pain) or other clinical evidence of cardiac involvement. Electrocardiogram abnormalities may include elevation or depression of the ST segment, flattening or inversion of T waves, prolongation of the QT interval, high or peaked P waves, left axis deviation, and arrhythmias. These changes are usually transient, diffuse, variable, and normalize with α- and/or β-blockade. The cardiomyopathy appears reversible if catecholamine stimulation is removed early before fibrosis has occurred. Distinct from a cardiomyopathy, pheochromocytoma patients may develop cardiac hypertrophy with congestive heart failure secondary to sustained hypertension.

Since pheochromocytomas are notoriously variable in their secretory activity, they have been called “great mimics,” and their presentation may be confused with thyrotoxicosis, malignant hypertension, diabetes mellitus, malignant carcinoid syndrome, or gram-negative septicemia. Although pheochromocytoma patients rarely have frank diabetes, most have an elevated blood glucose level secondary to catecholamine stimulation of glycogenolysis and an inhibition of insulin release.

 

Diagnosis

When a pheochromocytoma is clinically suspected, excess catecholamine secretion must be demonstrated. Various diagnostic tests have been suggested, but none is ideal. Regardless of which test is chosen, the clinical circumstances must be strictly controlled (i.e., for posture, exercise, emotion, medications) to yield reliable results. Concomitant medical conditions (i.e., alcoholism, hypothyroidism, hypovolemia) may yield misleading results.

The most sensitive test for high-risk patients (familial pheochromocytoma or classic symptoms) is plasma-free metanephrines. Catecholamines are metabolized to free metanephrines within tumor cells, and these metabolites are continuously released into the circulation. Plasma free normetanephrine greater than 400 pg/mL and/or metanephrine greater than 220 pg/mL is diagnostic of a pheochromocytoma. If normetanephrine is 112 to 400 pg/mL or metanephrine is 61 to 220 pg/mL, the diagnosis is equivocal. A pheochromocytoma is excluded if normetanephrine is less than 112 pg/mL and metanephrine is less than 61 pg/mL.

The determination of elevated urinary free catecholamine levels and their metabolites (i.e., metanephrine, normetanephrine, vanillylmandelic acid) is a frequently used diagnostic test. It is easy to perform and readily available; however, 24-hour collections can be inconvenient and unreliable. Measurement of vanillylmandelic acid is the oldest and least expensive test, but it is nonspecific. The determination of elevated metanephrines is the single best urine screening test. For patients with a low probability of having a pheochromocytoma, a 24-hour urine for metanephrines and catecholamines is sufficient.

Precisely executed measurement of plasma catecholamines is a favored initial test by many experts. The majority of patients have a significant elevation of norepinephrine, epinephrine, or both, although some patients with a pheochromocytoma have normal levels at rest. Plasma concentrations of total catecholamines greater than 2000 pg/mL are diagnostic of a pheochromocytoma. Values between 500 and 2000 pg/mL are equivocal, and 500 pg/mL or less rules out the diagnosis. In the majority of cases, the demonstration of increased levels of either plasma catecholamines or urinary free catecholamines and their metabolites should suffice to make the diagnosis. Results are equivocal in 5% to 10% of patients, and in these cases, the clonidine suppression test may be used. Clonidine is an α2-agonist that acts on the central nervous system to diminish efferent sympathetic outflow. In patients with a pheochromocytoma, increased plasma catecholamines result from tumor release, bypassing normal storage and release mechanisms. Clonidine acts to lower plasma catecholamines in patients without a pheochromocytoma while having no effect on catecholamine levels in pheochromocytoma patients.

In the past, provocative testing with histamine and tyramine was used to elicit excess catecholamine release from the tumor. However, the incidence of morbidity was considered too high, and these tests have been abandoned. A glucagon stimulation test is now considered to be the safest and most specific provocative test. Glucagon acts directly on the tumor to release catecholamines. This test is limited to patients with a diastolic blood pressure of less than 100 mm Hg. A positive test yields a plasma catecholamine increase of at least three times the baseline values or more than 2000 pg/mL within 1 to 3 minutes of glucagon administration. At present, most centers diagnose a pheochromocytoma by urine testing for free catecholamines and their metabolites and/or measuring plasma catecholamines and add the clonidine suppression test and/or the glucagon stimulation test in equivocal cases. Of these tests, which is the single most reliable one remains controversial.

Tumor location can be predicted by the pattern of catecholamine production ( Table 16-10 ). Specific radiographic tests can pinpoint the location. CT and MRI are the optimal noninvasive anatomic adrenal imaging studies. CT detects more than 95% of adrenal masses greater than 1.0 cm in diameter. MRI offers advantages over CT that include better differentiation of small adrenal lesions, better differentiation among different types of adrenal lesions, no intravenous contrast is needed, and no radiation exposure occurs. With certain MRI sequences, pheochromocytomas have high signal intensity and light up brightly. In contrast to CT and MRI, which provide primarily anatomic information,131I-MIBG and 123I-MIBG provide functional information. MIBG is an analogue of guanethidine, similar in structure to norepinephrine, and taken up by adrenergic neurons and concentrated in catecholamine-secreting tumors. MIBG is detected by scintigraphy. This is a physiologic test that localizes based on pharmacologic activity. It is especially useful in detecting extra-adrenal pheochromocytomas, metastatic deposits, and confirming that an adrenal mass is a functional pheochromocytoma. MIBG can screen the entire body with exquisite contrast and is the initial localizing procedure of choice at many institutions. CT, MRI, and 131I-MIBG scintigraphy are complementary studies in localizing pheochromocytomas. A positron emission scan and selective venous catheterization with sampling of catecholamines from the adrenal vein and other sites are other useful tests.

Management of Anesthesia

Preoperative Management

There are no controlled, randomized, prospective clinical studies on the value of adrenergic blockade for pheochromocytoma patients in the perioperative period. However, following the introduction of α-adrenergic blockers during the preoperative period, the mortality from excision of a pheochromocytoma decreased from 40% to 60% in 1951 to 0% to 6% in 1967. Some authors attribute this result more to advances in anesthetic techniques, monitoring techniques, and the availability of fast-acting medications than to the use of α-blockers. Since most pheochromocytomas secrete predominantly norepinephrine, medical therapy has depended on α-blockade to lower blood pressure, increase intravascular volume, prevent paroxysmal hypertensive episodes, allow resensitization of adrenergic receptors, and decrease myocardial dysfunction. Although a significantly reduced intravascular volume may accompany a pheochromocytoma, the majority of patients have a normal or only slightly decreased intravascular volume. α-Blockade appears to protect myocardial performance and tissue oxygenation from adverse catecholamine effects.

Phenoxybenzamine is the most frequently prescribed α-blocker for preoperative use. It is a noncompetitive α1-antagonist with some α2-blocking properties. As a noncompetitive blocker, it is difficult for excess catecholamines to overcome the blockade. Its long duration of action permits oral dosing only twice daily. The usual starting regimen is 10 to 20 mg twice daily, with most patients requiring 60 to 250 mg/day. The goal of therapy is normotension, a resolution of symptoms, elimination of ST-T changes on the electrocardiogram, and elimination of arrhythmias. Overtreatment can result in severe orthostatic hypotension. The optimal duration of α-blockade therapy is undetermined and may range from 3 days to 2 weeks or longer. Because of its prolonged effect on α-receptors, it has been recommended to discontinue it 24 to 48 hours before surgery to avoid vascular unresponsiveness immediately following removal of the tumor. Some anesthesiologists administer only one half to two thirds of the morning dose preceding surgery to address similar concerns. Some surgeons request its discontinuation 48 hours preoperatively to allow them to use hypertensive episodes intraoperatively as cues to localize areas of metastasis. However, regardless of the completeness of α-blockade preoperatively, significant hypertension usually occurs with manipulation of the tumor. Unfortunately, being an α1,2-blocker, phenoxybenzamine may enhance catecholamine secretion through α2-blockade, which will result in tachycardia.

Prazocin, a pure α1-competitive blocker, can be used instead of phenoxybenzamine. It is shorter acting, causes less tachycardia, and is easier to titrate to a desired end point than phenoxybenzamine. Initial doses of 1.0 mg three times daily may be increased to 8 to 12 mg/day to obtain the desired effect. It has been criticized for its failure to prevent hypertensive episodes adequately in the preoperative period, although it has strong advocates. Other α1-blockers include doxazosin and terazosin. Doxazosin at doses of 2 to 6 mg/day may be as effective in controlling hypertension as phenoxybenzamine and causes fewer side effects before (tachycardia) and after (hypotension) surgical removal.

If tachycardia (i.e., heart rates > 120 bpm) or other arrhythmias result following α2-blockade from phenoxybenzamine, a β-adrenergic blocker is prescribed. A nonselective β-blocker should never be administered prior to α-blockade because blockade of vasodilatory β2-receptors results in unopposed α-agonism, resulting in vasoconstriction and hypertensive crises. Propranolol, a nonselective β1,2-blocker with a half-life greater than 4 hours, is most frequently used. Most patients require 80 to 120 mg/day. In some patients with epinephrine-secreting pheochromocytomas, doses up to 480 mg/day may be needed. β-Blockers must be used cautiously since a small but significant number of patients have an underlying cardiomyopathy and congestive heart failure may be precipitated. Atenolol, metoprolol, and labetalol have been used successfully, although experience is limited and complications have been reported with the latter. The degree of α- and β-blockade provided by labetalol (i.e., β effects exceed α effects) may not be appropriate for certain pheochromocytoma patients. In very rare circumstances, β-blockade has been selected before α-blockade. A patient with a solely epinephrine-secreting pheochromocytoma and coronary artery disease may benefit greatly from the β1-selective agent esmolol. Esmolol has a fast onset and short elimination half-life and can be administered intravenously in the immediate preoperative period.

α-Methylparatyrosine (metyrosine) inhibits the rate-limiting enzyme tyrosine hydroxylase of the catecholamine synthetic pathway and may decrease catecholamine production by 50% to 80%. Usual doses range from 250 mg twice daily to 3 to 4 g/day. It is especially useful for malignant and inoperable tumors. Side effects including extrapyramidal reactions and crystalluria have limited its use. In combination with phenoxybenzamine during the preoperative period, it has been shown to facilitate intraoperative hemodynamic management.

The calcium channel blockers and the ACE inhibitors may be used to control hypertension. Calcium is a trigger for catecholamine release from the tumor and excess calcium entry into myocardial cells contributes to the catecholamine mediated cardiomyopathy. Nifedipine, diltiazem, and verapamil have all been used to control preoperative hypertension as has captopril, the ACE inhibitor. An α1-blocker plus a calcium channel blocker (verapamil 120–240 mg every day or nifedipine 30–90 mg every day) is an effective combination for resistant cases.

Intraoperative Management

Elective surgery is recommended whenever possible. Optimal preparation with α-adrenergic blockade ± β-blockade ± α-methylparatyrosine and correction of possible hypovolemia are essential. Intraoperative goals include avoiding drugs or maneuvers that may provoke catecholamine release or potentiate catecholamine actions and maintaining cardiovascular stability, preferably with short-acting drugs. The periods of greatest danger occur secondary to hypertension and/or arrhythmias during anesthetic induction, intubation, surgical incision, abdominal exploration and particularly during tumor manipulation, and secondary to hypotension following ligation of the tumor’s venous drainage. Intraoperative monitoring should include standard monitoring devices plus an arterial catheter, a central venous pressure or pulmonary arterial catheter, and a urinary catheter. If available, transesophageal echocardiography provides additional valuable information on myocardial function. An arterial catheter enables monitoring of blood pressure on a beat-to-beat basis in addition to drawing arterial blood for necessary laboratory tests (e.g., hematocrit/hemoglobin, arterial blood gases, glucose). A central venous pressure catheter is usually sufficient for patients without cardiac symptoms or other clinical evidence of cardiac involvement. A pulmonary artery catheter may be necessary to manage the large fluid requirements, major volume shifts, and possible underlying myocardial dysfunction in patients with very active tumors. Significant fluid requirements needed to prevent hypotension after tumor removal may indicate altered pressure-volume relationships induced by sudden catecholamine withdrawal. A large positive fluid balance is usually required to keep intravascular volumes within a normal range.

Intraoperative ultrasonography can be used to localize small, functional tumors and to perform adrenal-sparing procedures or partial adrenalectomies. Adrenal-sparing procedures are particularly valuable when removing bilateral adrenal pheochromocytomas. Laparoscopy can be used for tumors less than 4 to 5 cm in size. Hypertension frequently occurs during pneumoperitoneum as well as during adrenal manipulation.

Virtually every anesthetic technique for pheochromocytoma resection has been advocated or discredited based on anecdotal reports. Both general ± regional anesthesia have been successfully administered. Medications can cause a hypertensive response via (1) direct stimulation of tumor cells, (2) stimulation of the SNS, (3) release of accumulated catecholamine stores in nerve endings, (4) interfering with neuronal uptake of catecholamines, and (5) inducing hypersensitivity of catecholamine receptors or potentiating the effect of catecholamines on arterioles. Although all anesthetic drugs have been used with some degree of success, certain drugs should theoretically be avoided to prevent possible adverse hemodynamic responses. Morphine and atracurium can cause histamine release, which may provoke release of catecholamines from the tumor. Atropine, pancuronium, and succinylcholine are examples of vagolytic or sympathomimetic drugs that may stimulate the SNS. Although halothane in high concentrations is effective in attenuating hemodynamic responses (i.e., hypertension, tachycardia) to anesthetic and surgical stimuli, it sensitizes the myocardium to catecholamines and should probably be avoided. Droperidol, chlorpromazine, metoclopramide, and ephedrine have all created significant hypertensive responses. Anesthetic drugs that appear safe include thiopental, etomidate, benzodiazepines, fentanyl, sufentanil, alfentanil, enflurane, isoflurane, nitrous oxide, vecuronium, and rocuronium. Despite these recommendations, the choice of anesthetic is not as crucial as the understanding with which the agents are used. Factors that stimulate catecholamine release such as fear, stress, pain, shivering, hypoxia, and hypercarbia must be minimized or avoided in the perioperative period.

Virtually all patients exhibit increases in systolic arterial pressure in excess of 200 mm Hg for periods of time intraoperatively irrespective of preoperative α-blockade. A number of antihypertensive drugs must be prepared and ready for immediate administration. Sodium nitroprusside, a direct vasodilator, is the agent of choice because of its potency, immediate onset of action, and short duration of action. Phentolamine, a competitive α-adrenergic blocker and a direct vasodilator, is effective, although tachyphylaxis and tachycardia are associated with its use. Nitroglycerin is effective but is required in large doses to control significant hypertensive episodes and may also cause tachycardia. Labetalol, with more β- than α-blocking properties, is preferred for predominantly epinephrine-secreting tumors. Magnesium sulfate inhibits release of catecholamines from the adrenal medulla and peripheral nerve terminals, reduces sensitivity of α-receptors to catechols, is a direct vasodilator, and is an antiarrhythmic. However, like all antihypertensive medications, it is suboptimal in controlling hypertension during tumor manipulation. Mixtures of antihypertensive drugs such as nitroprusside, esmolol, diltiazem, and phentolamine have been recommended to control refractory hypertension. Increasing the depth of anesthesia is also an option, although this approach may accentuate the hypotension accompanying tumor vein ligation.

Arrhythmias are usually ventricular in origin and managed with either lidocaine or β-blockers. Lidocaine is short acting and has minimal negative inotropic action. Although propranolol has been widely used, esmolol, a selective β1-blocker, offers several advantages. Esmolol has a rapid onset and is short acting (i.e., elimination half-life of 9 minutes), allowing adequate control of heart rate, and may also provide protection against catecholamine-induced cardiomyopathy and ischemia and the development of postoperative hypoglycemia. Amiodarone, an antiarrhythmic agent that prolongs the duration of the action potential of atrial and ventricular muscle, has been used as an alternative to β-blockers (metoprolol) to treat supraventricular tachycardia associated with hypercatecholaminemia.

Hypotension following tumor vein ligation is usually significant and occurs secondary to a combination of factors including an immediate decrease in plasma catecholamines (i.e., half-lives of norepinephrine and epinephrine are approximately 1–2 minutes), vasodilation from residual α-blockade with phenoxybenzamine, intraoperative fluid and blood loss, and increased anesthetic depth. Hypotension with systolic pressures in the 70s is not infrequent. To prevent precipitous hypotension, volume expansion to a pulmonary capillary wedge pressure of 16 to 18 mm Hg should be attained prior to tumor vein ligation. Lactated Ringer’s solution or physiologic saline are the recommended fluids for use prior to tumor removal and a dextrose-containing solution should be added after tumor removal. A decrease in anesthetic depth will also aid in controlling hypotension. With a decrease in plasma catecholamines immediately following resection, insulin levels increase and hypoglycemia may occur. Fortunately, significant blood loss is unusual during resection of most intra-abdominal pheochromocytomas. Intraoperative blood salvage resulting in postresection hypertension secondary to catecholamine-laden blood has been reported. Vasopressors (e.g., phenylephrine, norepinephrine) and inotropes (e.g., dopamine) should be ready for administration if hypotension is slow to respond to fluid resuscitation. Adequate fluid therapy is essential and is the major factor responsible for the reduction (i.e., < 2%) in operative mortality. Vasopressors and inotropes should be viewed as a secondary treatment modality. Residual α-adrenergic blockade and down-regulation of receptors make some patients much less responsive to vasopressors. Glucocorticoid therapy should be administered if a bilateral adrenalectomy is performed or if hypoadrenalism is a possibility.

Postoperative Management

The majority of patients become normotensive following complete tumor resection. Plasma catecholamine levels do not return to normal until 7 to 10 days after surgery due to a slow release of stored catecholamines from peripheral nerves. Fifty percent of patients are hypertensive for several days following surgery, and 25% to 30% of patients remain hypertensive indefinitely. This hypertension is sustained rather than paroxysmal, lower than before surgery, and not accompanied by the classic features of hypercatecholaminemia. The differential diagnosis for persistent hypertension includes a missed pheochromocytoma, surgical complications with subsequent renal ischemia, and underlying essential hypertension.

Hypotension is the most frequent cause of death in the immediate postoperative period. Large volumes of fluid are necessary since the peripheral vasculature is unresponsive to the reduced levels of catechols. In addition to the reduction in plasma catecholamines and third-space fluid losses, the residual effects of phenoxybenzamine and α-methylparatyrosine, secondary to long half-lives, are present for up to 36 hours. Vasopressor therapy may be necessary but is a secondary consideration. Steroid supplementation is necessary for patients who had bilateral adrenalectomies or if hypoadrenalism is suspected.

Hypoglycemia may occur because of excess insulin release and inadequate lipolysis and glycogenolysis. Nonselective β-blockers (e.g., propranolol) may aggravate hypoglycemia by decreasing sympathetic tone and masking signs of hypoglycemia. Dextrose-containing solutions should be included as part of the fluid therapy, and plasma glucose levels should be monitored for 24 hours.

Patients usually remain in the ICU for at least 24 hours. Adequate pain control is essential, although somnolence and an increased sensitivity to narcotic analgesics have been observed. The need for controlled ventilation is dictated by the extent of surgery, the site of surgery, and the patient’s medical condition.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

Parkinson's Disease

Parkinson's Disease

Parkinson's disease is a neurodegenerative disorder of unknown cause. Increasing age is the single most important risk factor in the development of this disease; however, an association between manganese exposure in welders as well as a variety of genetic associations have recently been identified. There is a characteristic loss of dopaminergic fibers normally present in the basal ganglia, and, as a result, regional dopamine concentrations are depleted. Dopamine is presumed to inhibit the rate of firing of the neurons that control the extrapyramidal motor system. Depletion of dopamine results in diminished inhibition of these neurons and unopposed stimulation by acetylcholine.

 

The classic triad of major signs of Parkinson's disease consists of skeletal muscle tremor, rigidity, and akinesia. Skeletal muscle rigidity first appears in the proximal muscles of the neck. The earliest manifestations may be loss of associated arm swings when walking and absence of head rotation when turning the body. Facial immobility is characterized by infrequent blinking and by a paucity of emotional responses. Tremors are characterized as rhythmic, alternating flexion and extension of the thumbs and other digits at a rate of four or five movements per second (“pill-rolling tremor”). Tremors are most prominent in resting limbs but tend to disappear during the course of voluntary movement. Seborrhea, oily skin, diaphragmatic spasms, and oculogyric crises are frequent. Dementia and depression are often present.

Treatment of Parkinson's disease is designed to increase the concentration of dopamine in the basal ganglia or to decrease the neuronal effects of acetylcholine. Replacement therapy with the dopamine precursor levodopa combined with a decarboxylase inhibitor, which prevents peripheral conversion of levodopa to dopamine and optimizes the amount of levodopa available to enter the central nervous system, is the standard medical treatment. Indeed, levodopa is the most effective treatment for Parkinson's disease, and early treatment with this drug prolongs life. Levodopa is also associated with a number of side effects including dyskinesias (i.e., the most serious side effect, developing in 80% of patients after 1 year of treatment) and psychiatric disturbances (including agitation, hallucinations, mania, and paranoia). Increased myocardial contractility and heart rate in treated patients may reflect increased levels of circulating dopamine converted from levodopa. Orthostatic hypotension may be prominent in treated patients. Gastrointestinal side effects of levodopa therapy include nausea and vomiting, most likely reflecting stimulation of the medullary chemoreceptor trigger zone.

Amantadine, an antiviral agent, is reported to help control the symptoms of Parkinson's disease; however, the mechanism for this effect is not fully understood. The type B monoamine oxidase inhibitor selegiline can also help control the symptoms of Parkinson's disease by inhibiting the catabolism of dopamine in the central nervous system. Selegiline has an advantage over nonspecific monoamine oxidase inhibitors since they are only weak inhibitors of type A monoamine oxidase, the isoenzyme found primarily in the gastrointestinal tract. Therefore, selegiline is not associated with tyramine-associated hypertensive crisis, which results when foods containing tyramine (i.e., cheese, wine) are consumed by those in whom type A monoamine oxidase is pharmacologically inhibited. Entry of tyramine into the systemic circulation in the setting of pharmacologically inhibited type A monoamine oxidase results in a hyperadrenergic state due to the inherent sympathomimetic activities of tyramine.

Surgical treatment of Parkinson's disease is reserved for disabling and medically refractory symptoms. Stimulation of the subthalamic nuclei via an implanted deep brain stimulator device may relieve or help to control tremor. Pallidotomy is associated with significant improvement in levodopa-induced dyskinesias, although the improvement may be short-lived. Fetal tissue transplantation for treatment of Parkinson's disease is based on the demonstration that implanted embryonic dopaminergic neurons can survive in recipients; however, the effectiveness of this treatment is currently not known.

Management of Anesthesia

Management of anesthesia in patients with Parkinson's disease is based on an understanding of the treatment of this disease and the associated potential adverse drug effects. The elimination half-time of levodopa and the dopamine it produces is brief, so interruption of therapy for more than 6 to 12 hours can result in an abrupt loss of therapeutic effects. Abrupt drug withdrawal can lead to skeletal muscle rigidity, which interferes with lung ventilation. In this regard, levodopa therapy, including the usual morning dose on the day of surgery, should be continued during the perioperative period. Oral levodopa can be administered approximately 20 minutes before inducing anesthesia and may be repeated intraoperatively and postoperatively via an oro- or nasogastric tube to minimize the likelihood of exacerbations.

The possibility of hypotension and cardiac arrhythmias must be considered during administration of anesthesia to patients treated with levodopa. Further, one must consider the ability of butyrophenones (e.g., droperidol, haloperidol) to antagonize the effects of dopamine in the basal ganglia. An acute dystonic reaction following administration of alfentanil has been speculated to reflect opioid-induced decreases in central dopaminergic transmission. Use of ketamine is questionable because of the possible provocation of exaggerated sympathetic nervous system responses. Nevertheless, ketamine has been administered safely to patients treated with levodopa. The choice of muscle relaxants does not seem to be influenced by the presence of Parkinson's disease.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

Multiple Sclerosis

Multiple Sclerosis

Multiple sclerosis is an autoimmune disease affecting the central nervous system that seems to occur in genetically susceptible persons. Although there is a high rate of concordance among twins and an increased risk if one has a first-degree relative with the disease as well as a geographic association (e.g., highest incidence in northern Europe, southern Australia, and North America), no clear genetic, environmental, or infectious causes have been identified. There is also no clear understanding of the immunopathogenic processes that determine the sites of tissue damage in the central nervous system, the variations in natural history, or the severity of disability caused by the disease. It is twice as common in women as in men. In women with multiple sclerosis, the rate of relapse decreases during pregnancy, especially in the third trimester, and increases during the first 3 months postpartum. Exposure to viral illnesses may trigger relapses. Pathologically, multiple sclerosis is characterized by diverse combinations of inflammation, demyelination, and axonal damage in the central nervous system. The loss of myelin covering the axons is followed by formation of demyelinative plaques. Peripheral nerves are not affected by multiple sclerosis.

Clinical manifestations of multiple sclerosis reflect its multifocal involvement. Its course may be subacute, with relapses followed by remissions, or chronic and progressive. Manifestations of multiple sclerosis reflect sites of demyelination in the central nervous system and spinal cord. For example, inflammation of the optic nerves (optic neuritis) causes visual disturbances, involvement of the cerebellum leads to gait disturbances, and lesions of the spinal cord cause limb paresthesias and weakness as well as urinary incontinence and sexual impotence. Optic neuritis is characterized by diminished visual acuity and defective pupillary reaction to light. Ascending spastic paresis of the skeletal muscles is often prominent. Intramedullary disease of the cervical cord is suggested by an electrical sensation that runs down the back into the legs in response to flexion of the neck (Lhermitte's sign). Typically, symptoms develop over the course of a few days, remain stable for a few weeks, and then improve. Because remyelination in the central nervous system probably does not occur, remission of symptoms most likely results from correction of transient chemical and physiologic disturbances that have interfered with nerve conduction in the absence of complete demyelination. Further, increases in body temperature can cause exacerbation of symptoms due to further alterations in nerve conduction in regions of demyelination. There is an increased incidence of seizure disorders in patients with multiple sclerosis.

The course of multiple sclerosis is characterized by exacerbations and remissions of symptoms at unpredictable intervals over a period of several years. Residual symptoms eventually persist during remissions, leading to severe disability from visual failure, ataxia, spastic skeletal muscle weakness, and urinary incontinence. Nevertheless, the disease in some patients remains benign, with infrequent, mild episodes of demyelination, followed by prolonged, occasionally permanent remissions. The onset of multiple sclerosis after 35 years of age is typically associated with slow disease progression.

The diagnosis of multiple sclerosis can be established with different degrees of confidence (e.g., probable or definite) on the basis of clinical features alone or clinical features in combination with oligoclonal abnormalities of immunoglobulins in the CSF, prolonged latency of evoked potentials reflecting slowing of nerve conduction due to demyelination, and signal changes in white matter seen on cranial MRI.

No treatment is curative for multiple sclerosis. Instead, treatment is directed at both symptom control and methods to slow the progression of disease. Corticosteroids, the principal treatment for acute relapses of multiple sclerosis, have immunomodulatory and anti-inflammatory effects that restore the blood-brain barrier, decrease edema, and possibly improve axonal conduction. Treatment with corticosteroids shortens the duration of the relapse and accelerates recovery, but whether the overall degree of recovery or progression of the disease is altered is not known. Interferon-β is the treatment of choice for patients with relapsing-remitting multiple sclerosis. The most common side effect of interferon-β therapy is transient influenza-like symptoms for 24 to 48 hours after injection. Slight increases in serum aminotransferase concentrations, leukopenia, or anemia may be present, and co-existing depression may be exaggerated. Glatiramer acetate is a mixture of random synthetic polypeptides synthesized to mimic myelin basic protein. This drug is an alternative to interferon-β and may be most useful for patients who become resistant to interferon-β treatment owing to serum interferon-β-neutralizing activity. Mitoxantrone is an immunosuppressive agent that functions by inhibiting lymphocyte proliferation. Because of severe cardiac toxicity, its use is limited to patients with rapidly progressive disease. Azathioprine is a purine analogue that depresses both cell-mediated and humoral immunity. Treatment with this drug may decrease the rate of relapses in multiple sclerosis but has no effect on the progression of disability. Azathioprine is considered when patients do not respond to therapy with interferon-β or glatiramer acetate. Low-dose methotrexate is relatively nontoxic and inhibits both cell-mediated and humoral immunity as a result of its anti-inflammatory effects. Patients with secondary progressive multiple sclerosis may benefit most from treatment with this drug.

Management of Anesthesia

Management of anesthesia in patients with multiple sclerosis must consider the impact of surgical stress on the natural progression of the disease. For example, regardless of the anesthetic technique or drugs selected for use during the perioperative period, it is possible that symptoms of multiple sclerosis will be exacerbated postoperatively. This may be due to factors such as infection and fever. In this regard, any increase in body temperature (e.g., as little as 1°C) that follows surgery may be more likely than drugs to be responsible for exacerbations of multiple sclerosis. It is possible that increased body temperature results in complete block of conduction in demyelinated nerves. Of note, the unpredictable cycle of clinical exacerbations and remissions could lead to erroneous conclusions that there are cause-and-effect relationship between disease severity and drugs or events present during the perioperative period.

The changing and unpredictable neurologic presentation in patients with multiple sclerosis during the perioperative period must be appreciated when selecting regional anesthetic techniques. Indeed, spinal anesthesia has been implicated in postoperative exacerbations of multiple sclerosis, whereas exacerbations of the disease after epidural anesthesia or peripheral nerve blocks have not been described. The mechanism by which spinal anesthesia might differ from epidural anesthesia is unknown but might reflect local anesthetic neurotoxicity. Specifically, it is speculated that the demyelination associated with multiple sclerosis renders the spinal cord more susceptible to the neurotoxic effects of local anesthetics. Epidural anesthesia may be less of a risk than spinal anesthesia because the concentration of local anesthetics in the white matter of the spinal cord is lower than after spinal anesthesia. Nevertheless, both epidural anesthesia and spinal anesthesia have been used in parturients with multiple sclerosis.

General anesthesia is the most often used technique in patients with multiple sclerosis. There are no unique interactions between multiple sclerosis and the drugs used to provide general anesthesia, and there is no evidence to support use of one inhaled or injected anesthetic drug over another. When selecting muscle relaxants, one should consider the possibility of exaggerated release of muscle potassium, causing hyperkalemia, following administration of succinylcholine to these patients. Prolonged responses to the paralyzing effects of nondepolarizing muscle relaxants would be consistent with co-existing skeletal muscle weakness (myasthenia-like) and decreased skeletal muscle mass. Conversely, resistance to the effects of nondepolarizing muscle relaxants has been observed, perhaps reflecting proliferation of extrajunctional cholinergic receptors characteristic of upper motor neuron lesions.

Corticosteroid supplementation during the perioperative period may be indicated in patients being treated long-term with these drugs. Efforts must be made to recognize and prevent even modest increases in body temperature (more than 1°C), as this change might exacerbate symptoms. Periodic neurologic evaluation during the postoperative period may be useful for detecting exacerbations.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

Lymphangioleiomyomatosis

Lymphangioleiomyomatosis

Lymphangioleiomyomatosis is the proliferation of smooth muscle in airways, lymphatics, and blood vessels that occurs in females of reproductive age. Pulmonary function tests show restrictive and obstructive lung disease with decreases in diffusing capacity. Lymphangioleiomyomatosis presents clinically as progressive dyspnea, hemoptysis, recurrent pneumothorax, and pleural effusions. Nearly all lymphangioleiomyomatosis cells express progesterone receptors. Progesterone or tamoxifen can be used for treatment, but there is progressive deterioration in pulmonary function, and most patients die within 10 years of the onset of symptoms.

Management of Anesthesia

Preoperative

Patients usually present with dyspnea and nonproductive cough. Cor pulmonale may be present. Coarse breath sounds with crepitations are heard on auscultation. A chest radiograph may show a ground glass or nodular pattern. Arterial blood gases reveal hypoxemia with normocarbia. Pulmonary function tests show restrictive ventilatory defects and CO diffusing capacity is decreased. A vital capacity of less than 15 mL/kg indicates severe pulmonary dysfunction. Infection should be treated, secretions cleared, and smoking stopped preoperatively.

Intraoperative

Patients with restrictive lung disease tolerate apneic periods very poorly due to their small FRC and low oxygen stores. General anesthesia, the supine position, and controlled ventilation all contribute to further decreases in FRC. Alterations in FRC and the risk of hypoxia continue into the postoperative period. Uptake of inhaled anesthetics is faster in these patients because of the small FRC. Peak airway pressures should be kept as low as possible to minimize the risk of barotrauma.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

INTRACRANIAL TUMORS

INTRACRANIAL TUMORS

Intracranial tumors may be classified as primary (those arising from the brain and its coverings) or metastatic. Tumors can originate from virtually any cell type within the central nervous system. Supratentorial tumors are more common in adults and often present with headache, seizures, or new neurologic deficits, whereas infratentorial tumors are more common in children and often present with obstructive hydrocephalus and ataxia. Treatment and prognosis depend both on the tumor type and location. Treatment may consist of surgical resection or debulking, chemotherapy, or radiation. Gamma knife irradiation differs from traditional radiation therapy in that multiple radiation sources are used, and by addressing the tumor from multiple angles, radiation to the tumor can be maximized while radiation dose to any single area of surrounding brain can be diminished. This same approach can be accomplished with the use of radiation produced by a linear accelerator.

Tumor Types

Astrocytoma

Astrocytes are the most prevalent neuroglial cell in the central nervous system and give rise to many types of infra- and supratentorial tumors. Well-differentiated (low-grade) gliomas are the least aggressive class of astrocytic-derived tumors. They often present in young adults with new-onset seizures. Upon imaging, they generally show minimal enhancement with contrast. Surgical or radiation treatment of low-grade gliomas usually results in symptom-free long-term survival.

Pilocytic astrocytomas usually affect children and young adults. They often arise in the cerebellum (cerebellar astrocytoma), cerebral hemispheres, hypothalamus, or optic pathways (optic glioma). The tumor usually appears as a contrast-enhancing, well-demarcated lesion with minimal to no surrounding edema. Because of its benign pathologic characteristics, prognosis following surgical resection is generally very good; however, the location of the lesion, such as within the brainstem, may preclude resection.

Anaplastic astrocytomas are poorly differentiated, usually appear as a contrast-enhancing lesion on imaging due to disruption of the blood-brain barrier, and usually evolve into glioblastoma multiforme. Treatment usually involves resection, radiation, or chemotherapy. Prognosis is intermediate between low-grade gliomas and glioblastoma multiforme.

Gliobastoma multiforme (grade IV glioma) accounts for 30% of all primary brain tumors in adults. Imaging usually reveals a ring-enhancing lesion due to central necrosis as well as surrounding edema. Treatment typically involves debulking combined with radiation and chemotherapy. Due to microscopic infiltration of normal brain by tumor cells, resection alone is usually inadequate. Instead, treatment usually consists of surgical debulking combined with chemotherapy and radiation and is aimed at palliation, not cure. Despite treatment, life expectancy is usually on the order of weeks.

Oligodendroglioma

Arising from myelin-producing cells within the central nervous system, oligodendrogliomas account for only 6% of primary intracranial tumors. Classically, seizures usually predate the appearance of tumor on imaging, often by many years. Calcifications within the tumor are common and are visualized on CT imaging. The tumor usually consists of a mixture of both oligodendrocytic and astrocytic cells. Treatment and prognosis depend on the pathologic features. Initial treatment involves resection since, early in the course, the tumor typically consists of primarily oligodendrocytic cells, which are radioresistant. Because of the presence of astrocytic cells, these tumors commonly behave more like anaplastic astrocytomas or glioblastoma multiforme later in their course.

Ependymoma

Arising from cells lining the ventricles and central canal of the spinal cord, ependymomas commonly present in childhood and young adulthood. Their most common location is the floor of the fourth ventricle. Symptoms include obstructive hydrocephalus, headache, nausea, vomiting, and ataxia. Treatment consists of resection and radiation. Tumor infiltration into surrounding tissues may preclude complete resection. Prognosis usually depends on the extent of resection.

Primitive Neuroectodermal Tumor

Primitive neuroectodermal tumor represents a diverse class of tumors including retinoblastoma, medulloblastoma, pineoblastoma, and neuroblastoma, all believed to arise from primitive neuroectodermal cells. Medulloblastoma is the most common pediatric primary malignant brain tumor and may disseminate via the CSF to encompass the spinal cord. Presentation of medulloblastoma is similar to ependymoma. Treatment usually involves a combination of resection and radiation given its high radiosensitivity. Prognosis is very good in children, if there is disappearance with treatment of both tumor on MRI and tumor cells within the CSF.

Meningioma

Meningiomas are usually extra-axial (arising outside of the brain proper), slow-growing, well-circumscribed, benign tumors arising from arachnoid cap cells, not the dura mater. Because of their slow-growing nature, they can be very large at the time of diagnosis. They can occur anywhere arachnoid cap cells exist, but are most common near the sagittal sinus, falx cerebri, and cerebral convexity. Tumors are usually apparent on plain radiographs and CT due to the presence of calcifications. On MRI and conventional angiography, these tumors often receive their blood supply from the external carotid artery. Surgical resection is the mainstay of treatment. Prognosis is usually excellent; however, some tumors may be recurrent and require additional resection. Malignant meningiomas are rare.

Pituitary Tumors

Pituitary adenomas usually arise from cells of the anterior pituitary gland. They may occur along with tumors of the parathyroids and pancreatic islet cells as part of multiple endocrine neoplasia type 1. Tumors are usually divided into functional (i.e., hormone secreting) and nonfunctional. The former usually present as a result of an endocrinologic disturbance related to the hormone secreted by the tumor. Functional tumors are usually smaller (<1 cm in diameter) at the time of diagnosis; hence, they are often called microadenomas. Macroadenomas are usually nonfunctional, present with symptoms related to their mass (i.e., headache or visual changes due to compression of the optic chiasm), and are larger at the time of diagnosis, usually greater than 1 cm in diameter. Panhypopituitarism may be caused by either tumor type due to compression of the normal functioning pituitary gland. Pituitary tumors may also present as apoplexy, which is the abrupt onset of headache, visual changes, ophthalmoplegia, and altered mental status secondary to hemorrhage, necrosis, or infarction within the tumor. Finally, tumors can invade the cavernous sinus or internal carotid artery or compress various cranial nerves, causing an array of symptoms. Treatment well may depend on tumor type. Prolactinomas are often initially treated medically with bromocriptine. Surgical resection via the transsphenoidal or open craniotomy approach is often curative for most pituitary tumors.

Acoustic Neuroma

Usually the result of a benign schwannoma involving the vestibular component of cranial nerve VIII within the internal auditory canal, an acoustic neuroma typically occurs as a single mass. However, bilateral tumors may occur as part of neurofibromatosis type 2. Common presenting symptoms include hearing loss, tinnitus, and disequilibrium. Larger tumors, which grow out of the internal auditory canal and into the cerebellopontine angle, may cause symptoms related to compression of cranial nerves, most commonly the facial nerve (cranial nerve VII) as well as the brainstem. Treatment usually consists of surgical resection with or without radiation therapy. Surgery usually involves intraoperative cranial nerve monitoring with electromyography or brainstem auditory evoked potentials. Prognosis is usually very good; however, recurrence of tumor is not uncommon.

Central Nervous System Lymphoma

This is a rare tumor that can arise as a primary brain tumor, also known as a microglioma, or via metastatic spread from a systemic lymphoma. Primary central nervous system lymphoma can occur anywhere within the brain but is most common in supratentorial locations, especially in deep gray matter or the corpus callosum. Primary central nervous system lymphoma is thought to be associated with a variety of systemic disorders including systemic lupus erythematosus, Sjögren's syndrome, rheumatoid arthritis, immunosuppressed states, and infection with Epstein-Barr virus. Symptoms depend on the location of the tumor. Diagnosis is made by imaging as well as biopsy. During biopsy, it may be reasonable to wait to administer corticosteroids, such as dexamethasone, until after pathologic findings are obtained since these tumors may be sensitive to steroids. As such, steroid-associated tumor lysis prior to performing a biopsy may result in failure to obtain an adequate sample to make the diagnosis. The mainstay of treatment is chemotherapy (including intraventricularly delivered drugs) and whole-brain radiation. Prognosis is poor despite treatment.

Metastatic Tumor

Metastatic brain tumors originate most often from primary sites in the lungs or breasts. Malignant melanoma, hypernephroma, and carcinoma of the colon are also likely to spread to the brain. Metastatic brain tumor is the likely diagnosis when more than one intracranial lesion is present.

Management of Anesthesia

Anesthetic management of patients undergoing tumor resection can be challenging since it may involve patients of any age group as well as a variety of intraoperative patient positions. Further, some procedures may be conducted with electrophysiologic monitoring, which may have implications for anesthetic choice and the use of muscle relaxants. Some procedures may even be conducted in awake patients to facilitate resection of a mass located near an eloquent region of brain, such as the motor cortex. Major goals during anesthesia include (1) maintenance of adequate perfusion and oxygenation of normal brain, (2) optimizing operative conditions to facilitate resection, (3) ensuring a rapid emergence from anesthesia at the conclusion of the procedure to facilitate neurologic assessment, and, when appropriate, (4) accommodating intraoperative electrophysiologic monitoring.

Preoperative Management

Preoperative evaluation of a patient with an intracranial tumor is directed toward identifying the presence or absence of increased ICP. Symptoms of increased ICP include nausea and vomiting, altered levels of consciousness, mydriasis and decreased reactivity of pupils to light, papilledema, bradycardia, systemic hypertension, and breathing disturbances. Evidence of midline shifts (>0.5 cm) on CT or MRI suggests the presence of increased ICP.

Patients with intracranial pathology may be extremely sensitive to the central nervous system depressant effects of opioids and sedatives. Drug-induced hypoventilation can lead to accumulation of arterial carbon dioxide and further increases in ICP. Likewise, drug-induced sedation can mask alterations in the levels of consciousness that accompany intracranial hypertension. Conversely, preoperative sedation can unmask subtle neurologic deficits that may not usually be apparent. This is thought to be a result of increased sensitivity of injured neurons to the depressant effects of various anesthetic and sedative agents. Considering all the potential adverse effects of preoperative medication, it is an inescapable conclusion that pharmacologic premedication should be used sparingly, if at all, in patients with intracranial tumors. Preoperative depressant drugs are particularly best avoided in patients with diminished levels of consciousness. In alert adult patients with intracranial tumors, benzodiazepines in small doses can provide anxiety relief without meaningfully affecting ventilation. Decisions to administer anticholinergic drugs or H2-receptor antagonists are not influenced by the presence or absence of increased ICP.

Induction of Anesthesia

Anesthesia induction is achieved with drugs (e.g., thiopental, etomidate, propofol) that produce a rapid, reliable onset of unconsciousness without increasing ICP. This is often followed by a nondepolarizing muscle relaxant to facilitate tracheal intubation. Administration of succinylcholine may be associated with modest, transient increases in ICP. Mechanical hyperventilation of the patient's lungs is initiated with the goal of decreasing the PaCO2 to near 35 mm Hg. Adequate depth of anesthesia and profound skeletal muscle paralysis should be achieved prior to laryngoscopy, as noxious stimulation or patient movement can abruptly increase CBF, CBV, and ICP.

Direct laryngoscopy for tracheal intubation is accomplished during profound skeletal muscle paralysis as confirmed by the absence of electrically evoked neuromuscular transmission. Additional doses of intravenous induction drugs, lidocaine 1.5 mg/kg IV, or potent short-acting opioids may blunt the responses laryngoscopy or other forms of intraoperative stimulation (e.g., placement of pinions, skin incision).

Abrupt, sustained increases in systemic blood pressure, particularly in areas of impaired cerebrovascular tone, may be accompanied by undesirable increases in CBF, CBV, and ICP, and followed by cerebral edema. Sustained hypotension must also be avoided, as brain ischemia can occur in the presence of decreased CPP. Skeletal muscle responses during tracheal intubation typically reflect inadequate anesthesia or incomplete skeletal muscle paralysis, both of which may confound management of ICP and brain volume. New-onset seizures or repeat episodes of seizures are another possible origin of unexpected movement. Following tracheal intubation, the patient's lungs are ventilated at a rate and tidal volume that maintain the PaCO2 near 35 mm Hg. Positive end-expiratory pressure has a highly variable effect on ICP, resulting in increases, decreases, or no change in ICP. Hence, it should be used with caution, with attention paid to the ICP, MAP, and CPP effects of the intervention.

Maintenance of Anesthesia

The maintenance of anesthesia in patients undergoing surgical resection of supratentorial brain tumors is often achieved by combining drugs of various classes, including nitrous oxide, volatile anesthetics, opioids, barbiturates, and propofol. Although modest cerebrovascular differences can be demonstrated among different combinations of drugs, there is no evidence that any particular combination is significantly different from another in terms of effects on ICP and short-term patient outcome.

The use of nitrous oxide is controversial if there is any potential for venous air embolism (e.g., operations performed with patients in the sitting position). Despite theoretical concerns, the incidence of venous air embolism in sitting patients is not influenced by nitrous oxide use. Once a venous air embolism has been detected, nitrous oxide use must be discontinued out of concern that the embolus volume will expand, exacerbating the physiologic consequences. Both nitrous oxide and the potent volatile anesthetics have the potential to increase CBV and ICP as a result of direct cerebral vasodilation. However, low concentrations of volatile anesthetics (0.6–1.0 MAC) may be useful for preventing or treating increases in systemic blood pressure related to noxious surgical stimulation. Additionally, volatile anesthetic–associated increases in anesthetic depth and diminution of the physiologic responses to noxious stimuli will help preserve CBV and ICP. Administration of peripheral vasodilating drugs, such as nitroprusside or nitroglycerin, may increase CBV and ICP despite accompanying decreases in systemic blood pressure. This, in turn, can dramatically reduce CPP, which is dependent on both MAP and ICP. For this reason, vasodilating drugs are best used after craniotomy and opening of the dura.

Spontaneous movement by patients undergoing surgical resection of brain tumors must be prevented. Such movement could result in dangerous increases in ICP, herniation of the brain, or bleeding at the operative site, making surgical exposure difficult. Therefore, in addition to adequate depths of anesthesia, skeletal muscle paralysis is typically maintained during intracranial surgery.

Fluid Therapy

Relatively iso-osmolar solutions (e.g., 0.9% saline, lactated Ringer's solution) do not adversely affect brain water or edema formation, provided there is an intact blood-brain barrier and they are used in modest doses. In contrast, free water in hypo-osmolar solutions (e.g, 0.45% sodium chloride) is rapidly distributed throughout body water, including brain water, and may adversely affect ICP management. Hyper-osmolar solutions, such as 3% sodium chloride, initially tend to decrease brain water by increasing the osmolarity of plasma. Regardless of the crystalloid solutions selected, any solution administered in large amounts can increase CBV and ICP in patients with brain tumors. Therefore, the rate of fluid infusion should be titrated to maintain euvolemia with measures taken to avoid hypervolemia. Intravascular fluid volume depletion due to blood loss during surgery should be corrected with packed red blood cells or colloid solutions supplemented with balanced salt solutions. Glucose-containing solutions should be used with caution since hyperglycemia, in the setting of central nervous system ischemia, will exacerbate neuronal injury and worsen outcome.

Monitoring

The insertion of a peripheral arterial catheter is useful for continuous monitoring of systemic blood pressure and repetitive blood sampling. Capnography can facilitate ventilation and PaCO2 management as well as detecting venous air embolism (see “Sitting Position and Venous Air Embolism”). Continuous ICP monitoring, although not routine, is of obvious value. Nasopharyngeal or esophageal temperature is monitored to prevent hyperthermia or uncontrolled hypothermia. A bladder catheter has utility for managing perioperative fluid volume. It is necessary if drug-induced diuresis is planned; in patients who have diabetes insipidus, syndrome of inappropriate antidiuretic hormone, or other aberrations of salt or water physiology; or if a lengthy surgical procedure is anticipated and bladder distention is a concern.

Intravenous access with large-bore catheters should be obtained, given the likelihood of bleeding and the need for transfusion or rapid administration of fluids. Central venous catheterization can be useful as reliable means of large-bore intravenous access, as well as a monitor of fluid status. Central venous cannulation also has utility during cases performed in the sitting position as a means to aspirate intracardiac air following venous air embolism. Transesophageal echocardiography can also be useful in sitting position cases to identify intravenous air and help assess cardiac function. Pulmonary artery catheterization should be considered in patients with cardiac disease.

A peripheral nerve stimulator is helpful for monitoring the persistence of drug-induced skeletal muscle weakness or paralysis. If paresis or paralysis of an extremity is associated with the brain tumor, it is important to appreciate resistance (decreased sensitivity) to nondepolarizing muscle relaxants in the paretic extremity, compared with the normal extremity ( Fig. 10A-4 ). Therefore, monitoring skeletal muscle paralysis on the paretic limb may be misleading. For example, the evoked response may be erroneously interpreted as inadequate skeletal muscle paralysis. Likewise, at the conclusion of surgery, the same response could be assumed to reflect recovery from the muscle relaxant when substantial neuromuscular block persists. In these instances, the altered muscle response to relaxants may reflect the proliferation of acetylcholine-responsive cholinergic receptors that can occur after denervation.

Monitoring the electrocardiographic activity is necessary to detect responses related to intracranial tumors or from surgery. Electrocardiographic changes can reflect increased ICP or, more importantly, surgical retraction or manipulation of the brainstem or cranial nerves. Indeed, the cardiovascular centers, respiratory control areas, and nuclei of the lower cranial nerves lie in close proximity in the brainstem. Manipulation of the brainstem may produce systemic hypertension and bradycardia or hypotension and tachycardia. Cardiac arrhythmias range from acute sinus arrhythmias to ventricular premature beats or ventricular tachycardia.

Postoperative Management

Ideally, the effects of anesthetics and muscle relaxants are dissipated or pharmacologically reversed at the conclusion of intracranial surgery. This facilitates monitoring the neurologic status and recognizing any adverse effects of the surgery. It is important to limit reaction to the tracheal tube as patients are awakening. Intraoperative use of narcotics and the optimal timing of extubation are of value. Lidocaine, 0.5 to 1.5 mg/kg IV, may also attenuate the physiologic response to the tracheal tube. However, it must be appreciated that this local anesthetic has general anesthetic properties and can produce central nervous system depression and reduce the activity of protective upper airway reflexes. If consciousness was depressed preoperatively or new-onset neurologic deficits are anticipated as a result of the surgical course, it may be best to delay tracheal extubation until return of airway reflexes are confirmed and spontaneous ventilation is sufficient to prevent CO2 retention. Hypothermia must be considered a possible cause of slow postoperative awakening. Other causes of delayed emergence from anesthesia include residual neuromuscular block, residual effects of drugs with sedative effects (i.e., narcotics, benzodiazepines, volatile anesthetics), or a primary central nervous system event such as ischemia, hematoma, and tension pneumocephalus.

Following anesthesia, preexisting neurologic deficits may be exacerbated by the sedative effects of anesthetic agents making a subtle preoperative deficit appear more severe. This differential awakening is thought to be due to increased sensitivity of injured neurons to the depressant effects of anesthetic agents. Often, these deficits will disappear and neurologic function will return to its baseline state with time. Any persistent new deficit that does not quickly resolve should be further investigated.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

Hyperthyroidism

Hyperthyroidism

Signs and Symptoms

Hyperthyroidism refers to hyperfunctioning of the thyroid gland with excessive secretion of active thyroid hormones. The majority of cases (i.e., 99%) of hyperthyroidism result from one of three pathologic processes: Graves’ disease, toxic multinodular goiter, or a toxic adenoma. Regardless of the etiology, the signs and symptoms of hyperthyroidism are those of a hypermetabolic state. The patient is anxious, restless, and hyperkinetic and may be emotionally unstable. The skin is warm and moist, the face is flushed, the hair is fine, and the nails are soft and fragile. The eyes exhibit a wide-eyed stare with retraction of the upper eyelids. The patient may demonstrate increased sweating and complain of heat intolerance. Wasting, weakness, and fatigue of the proximal limb muscles is common. The patient usually complains of extreme fatigue but an inability to sleep. Increased bone turnover and osteoporosis may occur. A fine tremor of the hands and hyperactive tendon reflexes are common. Weight loss despite an increased appetite occurs secondary to increased calorigenesis. Bowel movements are frequent and diarrhea is not uncommon. The cardiovascular system is most threatened with hypermetabolism of peripheral tissues, increased cardiac work with tachycardia, arrhythmias (commonly atrial) and palpitations, a hyperdynamic circulation, increased myocardial contractility and cardiac output, and cardiomegaly. The etiology of cardiac responses is due to the direct effects of T3 on the myocardium and the peripheral vasculature (see Table 16-8 ). Although cardiac failure rarely occurs, a thyrotoxic cardiomyopathy has been described with a lymphocytic and eosinophilic infiltration of the myocardium with fibrotic and fatty changes. Elderly patients with unexplained cardiac failure or rhythm disturbances, especially atrial in origin, should be evaluated for thyrotoxicosis.

Image Hosted by Free Picture Hosting at <A href="http://www.iranxm.com

Patients with subclinical hyperthyroidism are usually detected on routine laboratory screening. Most patients present with few if any signs or symptoms, although some may present with an elevated heart rate. Thyroid function tests reveal a normal T3 and T4 but a reduced TSH. Whether these patients should be treated is controversial. Benefits of treatment are not clearly established. If the TSH is between 0.1 and 0.5 mU/L, many clinicians will not treat. When the TSH drops below 0.1 mU/L, most patients receive treatment. Patients with subclinical hyperthyroidism are potentially at future risk of cardiac (atrial fibrillation) and central nervous system (emboli, cerebrovascular accident) complications.

Graves’ disease or toxic diffuse goiter occurs in 0.4% of the United States population and is the leading cause of hyperthyroidism. The disease typically occurs in females (female-to-male ratio is 7:1) between the ages of 20 and 40 years. Although the etiology is unknown, Graves’ disease appears to be a systemic autoimmune disease with thyroid-stimulating antibodies (long-acting thyroid stimulator, thyroid-stimulating immunoglobulins), binding to TSH receptors in the thyroid, activating adenyl cyclase and stimulating thyroid growth, vascularity, and hypersecretion of T4 and T3. The manifestations of the disease vary in intensity with the severity of the thyrotoxicosis, the age of the patient, the duration of the illness, and the involvement of other organ systems, especially cardiovascular. The disease is characterized by a classic triad of hyperthyroidism, exophthalmos, and dermopathy. The thyroid is usually diffusely enlarged, becoming two to three times normal size. Some glands secrete T4 and T3 at five to 15 times the normal amount. An ophthalmopathy occurs in 30% of cases and may include upper lid retraction, a wide-eyed stare, muscle weakness, proptosis, and an increase in intraocular pressure. Proptosis and muscle weakness are secondary to immunologic changes of extraocular muscles and retro-orbital tissues (i.e., edema, inflammation). When severe, the condition is termed malignant exophthalmos. Steroids, bilateral tarsorrhaphies, external radiation, or surgical decompression may be necessary in these cases. Fortunately, most cases are mild and follow a benign course and remit spontaneously. The dermopathy is characterized by edematous skin (pretibial myxedema) over the dorsum of the legs and feet and occurs in only 10% to 15% of cases.

Diagnosis

The diagnosis of Graves’ disease is confirmed by elevated F T4, T3, F T4 index, and R T3U and an elevated radioactive iodine uptake. The TSH level is often low, and thyroid-stimulating antibodies are increased. In severe hyperthyroidism, the basal metabolic rate is markedly increased (30%–60%).

Toxic multinodular goiters usually arise from long-standing simple goiters and therefore occur mostly in patients older than 50 years of age. They may produce the most extreme thyroid enlargements, with some weighing more than 2000 g. They may cause dysphagia from esophageal compression, and a choking sensation and possibly inspiratory stridor from tracheal compression, especially with extension of the mass into the thoracic inlet behind the sternum. In severe cases, superior vena cava obstruction syndrome may also occur. However, hypermetabolism is usually less severe than with Graves’ disease. There is no associated opthalmopathy or dermopathy. The diagnosis is confirmed by a thyroid scan demonstrating “hot” patchy foci throughout the gland or one or two “hot” nodules. Radioactive iodine uptake and serum T4 and T3 may only be slightly elevated. The goiter must be differentiated from a neoplasm, and a computed tomography (CT) scan and biopsy may be necessary.

A solitary toxic nodule (toxic adenoma) usually occurs in patients 30 to 40 years of age and may cause hyperthyroidism if the lesion exceeds 3 cm in diameter. The same diagnostic tests used for multinodular goiters are used for toxic adenomas.

Image Hosted by Free Picture Hosting at <A href="http://www.iranxm.com

An unusual presentation of thyrotoxicosis that may occur in association with Graves’ disease, multinodular goiter, or toxic adenoma is T3 toxicosis. In these patients, the serum T4 and F T4 are normal or low, while T3 is increased. These patients may be more likely to have a long-term remission after withdrawal of antithyroid drug therapy than patients with the usual form of thyrotoxicosis in whom production of both T4 and T3 is increased.

Treatment

The first line of treatment for hyperthyroidism is the antithyroid drug propylthiouracil (PTU) or methimazole (Tapazole). Methimazole is currently more popular because of its faster response time and its ability to be administered as a single daily dose. These agents interfere with the synthesis of thyroid hormones by inhibiting organification and coupling. PTU has the added advantage of inhibiting the peripheral conversion of T4 to T3. PTU is prescribed for adults as 200 to 300 mg orally every 8 to 12 hours and methimazole as 10 to 20 mg orally every 12 hours. A euthyroid state can almost always be achieved in 6 to 8 weeks with either drug if a sufficient dose is given. The delay in effect is secondary to the large store of hormones existing in the gland prior to initiating therapy. Once euthyroidism is achieved, the dose is reduced and continued for 6 to 12 months and in some cases for 24 months. After euthyroidism has been achieved, a natural remission of the disease will often occur, but only less than 40% of patients remain well indefinitely after discontinuation of medication. Side effects occur in 3% to 12% of patients, with agranulocytosis being the most serious.

Iodide in high concentration inhibits release of hormones from the hyperfunctioning gland. Its effects occur immediately but last for only several weeks. Therefore, iodide is usually reserved for preparing hyperthyroid patients for surgery, managing patients with actual or impending thyroid storm, or treating patients with severe thyrocardiac disease. There is no need to delay surgery in an otherwise well-controlled thyrotoxic patient to initiate iodide therapy. High concentrations of iodide decrease all phases of thyroid synthesis and release and result in reduced gland size and possibly a decrease in vascularity. Iodide is administered orally as an SSKI (saturated solution of potassium iodide) solution, three drops orally every 8 hours for 10 to 14 days. Antithyroid drug therapy should precede the initiation of iodide because iodide alone will increase thyroid hormone stores and exacerbate the thyrotoxic state. Although parenteral NaI has been withdrawn from clinical use, oral iodide is equally efficacious. The radiographic contrast dye ipodate or iopanoic acid (0.5–3.0 g every day) contains iodide and demonstrates beneficial effects similar to those of inorganic iodide. In addition, ipodate inhibits the peripheral conversion of T4 to T3 and may also antagonize thyroid hormone binding to receptors. It is especially useful in the preoperative preparation of the thyrotoxic patient, reducing T3 levels by 50% to 75% in 6 to 12 hours. Lithium carbonate 300 mg orally every 6 hours may be given in place of potassium iodide or ipodate if the patient is allergic to iodide.

β-Adrenergic antagonists do not affect the underlying thyroid pathology but may relieve signs and symptoms of increased adrenergic activity such as anxiety, sweating, heat intolerance, tremors, and tachycardia. Propranolol 40 to 80 mg orally every 6 to 8 hours, esmolol, metoprolol, and atenolol are effective. Propranolol has added features of impairing the peripheral conversion of T4 to T3 and reducing metabolic rate. For emergency use, intravenous propranolol in 0.2- to 1.0-mg boluses followed by an infusion or an intravenous esmolol 0.5 mg/kg bolus followed by an infusion is titrated to restore a normal heart rate.

Ablative therapy with radioactive 131I or surgery is recommended for patients with Graves’ disease in whom antithyroid drugs were ineffective or toxic or in whom a relapse occurred after 1 to 2 years of drug treatment and for patients with toxic multinodular goiter or a toxic adenoma. Also, patients who fail to follow medical regimens or fail to return for periodic examinations are candidates.

Radioactive 131I therapy is the treatment of choice for hyperthyroidism in many large series because it is simple, effective, and economical. Standard doses deliver approximately 8500 rad to the thyroid and destroy the follicular cells. The remission rate is 80% to 98%. A major disadvantage of therapy is that 40% to 70% of treated patients become hypothyroid within 10 years. Patients are usually made euthyroid by antithyroid drugs prior to radioactive iodine therapy to avoid possible thyrotoxicosis from a radiation-induced thyroiditis. Radioactive iodine therapy has replaced subtotal thyroidectomy as the standard form of therapy for patients with Graves’ disease requiring ablative therapy.

Surgery (i.e., subtotal thyroidectomy or possibly total thyroidectomy) results in prompt control of disease and a lower incidence of hypothyroidism (10%–30%) than radioactive iodine. Subtotal thyroidectomy corrects thyrotoxicosis in more than 95% of patients with a mortality rate of less than 0.1%. Complications from surgery are a major disadvantage of this form of therapy and include, in addition to hypothyroidism, hemorrhage with tracheal compression, unilateral or bilateral damage to the recurrent laryngeal nerve(s), damage to the motor branch of the superior laryngeal nerve, and damage to or inadvertent removal of the parathyroid glands.

Preparation of the hyperthyroid patient for surgery is extremely important. For elective surgery, all patients should be made euthyroid with a course of an antithyroid drug (PTU or methimazole) for 6 to 8 weeks preoperatively. A low TSH value should not be a contraindication to surgery. TSH values remain suppressed from prolonged hyperthyroidism in patients who have normalized T3 and T4 values. In addition, potassium iodide (SSKI solution) should be given for 7 to 14 days prior to surgery to reduce the gland’s vascularity and hormonal release. β-Adrenergic blockers may be added in the preoperative period to control heart rate. Optimal patient response should dictate the timing of surgery.

For emergency surgery, an antithyroid drug (PTU or methimazole) should be administered even though it has a limited effect if taken for less than 2 weeks. No intravenous preparation is available, so the drug must be taken orally, via a nasogastric tube, or rectally. The antithyroid drug should precede iodide by 2 to 3 hours. Sodium iopanoate 500 mg orally twice daily and an intravenous β-blocker, preferably propranol, are essential for effective management. Glucocorticoids (dexamethasone 2 mg IV every 6 hours) should be administered to decrease hormone release and reduce the peripheral conversion of T4 to T3. This combination of medications is effective for any thyrotoxic patient presenting for thyroid or nonthyroid surgery. Euthyroidism can be achieved surprisingly quickly in approximately 5 to 7 days.

The treatment of hyperthyroidism during pregnancy includes low doses of antithyroid drugs. However, these drugs do cross the placenta and can cause fetal hypothyroidism. If the mother remains euthyroid on small doses of an antithyroid drug, the occurrence of fetal hypothyroidism is rare. Radioactive iodine treatment is contraindicated during pregnancy, and oral iodide therapy causes fetal goiter and hypothyroidism and is therefore contraindicated. The long-term use of propranolol is controversial since intrauterine growth retardation has been attributed to its use. Fortunately, pregnancy appears to attenuate the severity of hyperthyroidism and doses of antithyroid drugs can be kept low (i.e., PTU < 200 mg/day). If doses greater than 300 mg/day of PTU are needed during the first trimester, a subtotal thyroidectomy should be performed in the second trimester. Thyroid storm occurring in pregnancy is managed the same as in the nonpregnant patient.

Management of Anesthesia

In managing hyperthyroid patients for surgery, euthyroidism should definitely be established preoperatively. In elective cases, this may mean waiting a substantial time (6–8 weeks) for antithyroid drugs to become effective. In emergency cases, the use of an intravenous β-blocker, ipodate, cortisol, or dexamethasone and PTU is usually necessary. The anesthesiologist should be prepared to manage thyroid storm, especially in patients with uncontrolled or poorly controlled disease who present for emergency surgery. Premedication may include the use of a barbiturate, benzodiazepine, and/or a narcotic. Anticholinergic drugs (i.e., atropine) should be avoided since they may precipitate tachycardia and alter heat-regulating mechanisms. Intraoperatively, the need for invasive monitoring is determined on an individual basis and depends on the type of surgery to be performed and the medical condition of the patient. Controlled studies in hyperthyroid animals demonstrate no clinically significant increase in anesthetic requirements (i.e., minimum alveolar concentration, [MAC]). Establishing adequate anesthetic depth is extremely important to avoid exaggerated sympathetic nervous system (SNS) responses. Drugs that stimulate the SNS should be avoided (i.e., ketamine, pancuronium, atropine, ephedrine, epinephrine). No controlled patient studies have demonstrated one preferred anesthetic technique or anesthetic agent(s). For induction, thiopental, secondary to its thiourylene nucleus, decreases the peripheral conversion of T4 to T3 and may have a slight advantage over other induction agents. Succinylcholine and the nondepolarizing muscle relaxants with limited hemodynamic effects (e.g., vecuronium, rocuronium) have been used safely for intubation. Eye protection (eyedrops, lubricant, eye pads) is important, especially for patients with proptosis. For maintenance of anesthesia, any of the potent inhalation agents may be used. A concern in hyperthyroid patients is organ toxicity secondary to an increase in drug metabolism. Although animal studies demonstrate an increase in hepatotoxicity in hyperthyroid rats following exposure to isoflurane, no alterations in liver function have been demonstrated postoperatively in hyperthyroid patients rendered euthyroid preoperatively and administered this agent for surgery. Nitrous oxide and opioids are safe and effective in hyperthyroid patients. Muscle relaxants should be chosen based on their interaction with the SNS and their hemodynamic effects. Also, hyperthyroid patients may have co-existing muscle disease (e.g., myasthenia gravis) with reduced requirements for the nondepolarizing muscle relaxants necessitating careful titration to effect. Reversal of muscle relaxants should include glycopyrrolate instead of atropine in combination with an acetylcholinesterase inhibitor. For the treatment of intraoperative hypotension, a direct-acting vasopressor (phenylephrine) is preferred. Ephedrine, epinephrine, norepinephrine, and dopamine are avoided or administered in extremely low doses to prevent exaggerated hemodynamic responses. Regional anesthesia can be safely performed and in fact may be a preferred technique. Epinephrine containing local anesthetic solutions should be avoided. Fluids and phenylephrine are used to treat hypotension secondary to SNS blockade.

Removal of the thyrotoxic gland does not mean immediate resolution of thyrotoxicosis. The T1/2 of T4 is 7 to 8 days; therefore, β-blocker therapy may need to be continued in the postoperative period. Antithyroid drug therapy can be discontinued.

Thyroid storm and malignant hyperthermia can present with similar intraoperative and postoperative signs and symptoms (i.e., hyperpyrexia, tachycardia, hypermetabolism). Differentiation between the two may be extremely difficult. The preoperative detection of thyrotoxicosis (tremors, diaphoresis, fatigue, tachypnea, tachycardia, fever, an enlarged thyroid) is very important. Although thyrotoxicosis is an uncommon adult endocrine disorder, it is very rare in children. Regardless, thyrotoxicosis should be considered in the differential diagnosis of malignant hyperthermia in any age group.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

Huntington's Disease

Huntington's Disease

Huntington's disease is a premature degenerative disease of the central nervous system characterized by marked atrophy of the caudate nucleus and, to a lesser degree, the putamen and globus pallidus. Biochemical abnormalities include deficiencies in the basal ganglia of acetylcholine (and its synthesizing enzyme choline acetyltransferase) and γ-aminobutyric acid. Selective loss of γ-aminobutyric acid may decrease inhibition of the dopamine nigrostriatal system. This disease is transmitted as an autosomal dominant trait, but its delayed appearance until 35 to 40 years of age interferes with effective genetic counseling. Identification of the genetic defect may be useful for disease risk prediction in those who have inherited the defective gene, as applied to both prenatal and postnatal (including adult) testing.

Manifestations of Huntington's disease consist of progressive dementia combined with choreoathetosis. Chorea is usually considered the first sign of Huntington's disease; hence, the former designation of this disease as Huntington's chorea. Behavioral changes (e.g, depression, aggressive outbursts, mood swings) may precede the onset of involuntary movement by several years. Involvement of the pharyngeal muscles makes these patients susceptible to pulmonary aspiration. The disease progresses over several years, and accompanying mental depression makes suicide a frequent cause of death. The duration of Huntington's disease, from clinical onset to death, averages 17 years.

Treatment of Huntington's disease is symptomatic and is directed at decreasing the choreiform movements. Haloperidol and other butyrophenones may be administered to control the chorea and emotional lability associated with the disease. The most useful therapy for controlling involuntary movements is with drugs that interfere with the neurotransmitter effects of dopamine either via antagonism (i.e., haloperidol, fluphenazine) or via depletion of dopamine stores (i.e., reserpine, tetrabenazine).

Experience with the management of anesthesia in patients with Huntington's chorea is too limited to recommend specific anesthetic drugs or techniques. Preoperative sedation using butyrophenones such as droperidol or haloperidol may be helpful in controlling choreiform movements. The increased likelihood of pulmonary aspiration must be considered if pharyngeal muscles are involved. Nitrous oxide and volatile anesthetic use is acceptable. Thiopental, succinylcholine, and mivacurium have been administered without adverse effects, but decreased plasma cholinesterase activity, with prolonged responses to succinylcholine, has been observed. Likewise, it has been suggested that these patients may be sensitive to the effects of nondepolarizing muscle relaxants.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

DEGENERATIVE DISEASES OF THE BRAIN

DEGENERATIVE DISEASES OF THE BRAIN

Degenerative diseases of the central nervous system usually involve neuronal malfunction or loss within specific anatomic regions and represent a diffuse group of disease states.

Alzheimer's Disease

Alzheimer's disease is a chronic neurodegenerative disorder. It is the most common cause of dementia in patients older than 65 years of age, and the fourth most common cause of death from disease in patients older than 65. Diffuse amyloid-rich senile plaques and neurofibrillary tangles are the hallmark pathologic findings. There are also changes in synapses and the activity of multiple major neurotransmitters, especially involving acetylcholine and central nervous system nicotinic receptors. Two types of Alzheimer's disease have been described: early onset and late onset. Early-onset Alzheimer's disease usually presents before age 60 and is thought to be due to missense mutations on up to three genes leading to an autosomal dominant mode of transmission. Late-onset Alzheimer's disease usually develops after age 60, and genetic transmission appears to play a relatively minor role in the risk of developing this disorder. With both forms of the disease, patients typically develop progressive cognitive impairment that can consist of problems with memory as well as apraxia, aphasia, and agnosia. Definitive diagnosis is usually made on postmortem examination, usually making premortem diagnosis of Alzheimer's disease one of exclusion. There is currently no cure for Alzheimer's disease, and treatment usually focuses on control of symptoms. Pharmacologic options include cholinesterase inhibitors, such as tacrine, donepezil, rivastigmine, and galantamine. Pharmacologic therapy should be combined with nonpharmacologic therapy including caregiver education and family support. Despite treatment, the prognosis for patients with Alzheimer's disease is poor.

Patients with Alzheimer's disease may present for a variety of surgical interventions that are common in the elderly population. Patients are often confused and sometimes uncooperative, making monitored anesthesia care or regional anesthesia challenging. However, there is probably no one single anesthesia technique or agent that is superior in this group of patients. Shorter acting sedative/hypnotic drugs, anesthetic agents, and narcotics are preferred since they may allow a more rapid return to baseline mental status. Finally, one should be aware of potential drug interactions, especially prolongation of the effect of succinylcholine and relative resistance to nondepolarizing muscle relaxants due to the use of cholinesterase inhibitors.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

Hallervorden-Spatz Disease

Hallervorden-Spatz Disease

Hallervorden-Spatz disease is a rare autosomal recessive disorder of the basal ganglia. It follows a slowly progressive course from its onset during late childhood to death in approximately 10 years. No specific laboratory tests are diagnostic for this condition, and no effective treatment is known. Dementia and dystonia with torticollis, as well as scoliosis, are commonly present. Dystonic posturing is likely to disappear with the induction of anesthesia, although skeletal muscle contractures and bony changes may accompany the chronic forms of the disease, leading to immobility of the temporomandibular joint and cervical spine, even in the presence of deep general anesthesia or drug-induced skeletal muscle paralysis.

Management of anesthesia must consider the possibility of being unable to position these patients optimally for tracheal intubation following the induction of anesthesia. Noxious stimulation, as produced by attempted awake tracheal intubation, can intensify dystonia. For these reasons, induction of anesthesia may be achieved by inhalation and maintenance of spontaneous ventilation. Administration of succinylcholine is questionable, as skeletal muscle wasting and diffuse axonal changes in the brain, which may involve the upper motor neurons, could accentuate the release of potassium; however, succinylcholine has been reported to have been used safely. Offsetting this centrally mediated propensity for muscle wasting may be that chronic muscle hyperactivity produces muscular and cardiovascular effects similar to that of a trained athlete. Any required skeletal muscle relaxation is probably best provided by increased concentrations of volatile anesthetics or administration of nondepolarizing neuromuscular blocking drugs. Emergence from anesthesia is predictably accompanied by return of dystonic posturing.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

Bronchiectasis

Bronchiectasis

Bronchiectasis is a chronic suppurative disease of the airways that, if sufficiently widespread, may cause expiratory airflow obstruction similar to that seen with COPD. Despite the availability of antibiotics, bronchiectasis is an important cause of chronic productive cough with purulent sputum and accounts for a significant number of patients who develop massive hemoptysis.

Pathophysiology

Bronchiectasis is characterized by a localized, irreversible dilation of a bronchus caused by destructive inflammatory processes involving the bronchial wall. Bacterial or mycobacterial infections are presumed to be responsible for most cases of bronchiectasis. The most important consequence of bronchiectatic destruction of airways is an increased susceptibility to recurrent or persistent bacterial infection, reflecting impaired mucociliary activity and pooling of mucus in dilated airways. Once bacterial superinfection is established, it is nearly impossible to eradicate and daily expectoration of purulent sputum persists.

Diagnosis

The history of a chronic cough productive of purulent sputum is highly suggestive of bronchiectasis. Digital clubbing occurs in most patients with significant bronchiectasis and is a valuable diagnostic clue, especially since this change is not characteristic of COPD. Pulmonary function changes vary considerably and range from no change to alterations characteristic of COPD or restrictive lung disease. Computed tomography provides excellent images of bronchiectatic airways and can be used to confirm the presence and extent of the disease.

Treatment

Bronchiectasis is treated by administration of antibiotics and postural drainage. Periodic sputum culture guides antibiotic selection. Pseudomonas is the most common organism cultured. Hemoptysis can be controlled with appropriate antibiotic therapy. However, massive hemoptysis (>200 mL over a 24-hour period) may require surgical resection of the involved lung or selective bronchial arterial embolization. Postural drainage is useful to assist in expectoration of secretions that pool distal to the diseased airways. Chest physiotherapy with chest percussion and vibration is another aid for bronchopulmonary drainage. Surgical resection has played a declining role in the management of bronchiectasis during the modern antibiotic era and is only considered in the rare instance when severe symptoms persist or recurrent complications occur.

Management of Anesthesia

Prior to elective surgery, the pulmonary status of patients with bronchiectasis is optimized by antibiotic therapy and postural drainage. Airway management might include use of a double-lumen endobronchial tube to prevent spillage of purulent sputum into normal areas of the lungs. Instrumentation of the nares should be avoided because of the high incidence of chronic sinusitis in these patients.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

Arteriovenous Fistula

Arteriovenous Fistula  

Arteriovenous (AV) fistulas are direct communications between an artery and a vein without an intervening nidus of vessels. They commonly occur between meningeal vessels within the dura mater or between the carotid artery and venous sinuses within the cavernous sinus. Some AV fistulas are thought to spontaneously occur. Many others are associated with a previous traumatic injury or, in the case of carotid-cavernous fistulas, are associated with previous (presumably silent) rupture of an intracavernous carotid artery aneurysm. Dural AV fistulas commonly present with pulsatile tinnitus or headache, and of note, an occipital bruit can be appreciated in 24% of cases given that the occipital artery is a common arterial feeder. Treatment options include angiographically guided embolization or surgical ligation, bearing in mind the risk of rapid blood loss associated with surgical treatment.

Patients with carotid-cavernous AV fistulas often present with orbital or retro-orbital pain, arterialization of the conjunctiva, or visual changes. Diagnosis is made by magnetic resonance or conventional angiography. Embolization is usually an effective option for treatment.

Management of Anesthesia

Surgical resection of low-flow vascular malformations (i.e., venous angiomas and cavernous angiomas) is generally not associated with the degree of both intraoperative and postoperative complications as associated with the resection of high-flow vascular lesions (i.e., AVMs and AV fistulas). Further, since AVMs are often associated with multiple feeding and draining vessels, unlike AV fistulas which involve a single feeding and a single draining vessel, surgical resection of AVMs often pose great clinical challenges during resection and postoperative care.

Preoperatively, the patient with an intracranial vascular malformation should be evaluated for evidence of cerebral ischemia or increased ICP. The nature of the malformations, such as size, location, mechanism of venous drainage, presence of associated aneurysms, and a history of treatment, should be elicited since these factors may help one to anticipate perioperative complications such as the risk of intraoperative bleeding as well as postoperative complications. Adjunct medications, including antiepileptics (if the patient has a concurrent seizure disorder), should be administered. Patients exposed to preoperative angiography may experience fluid and electrolyte abnormalities secondary to the administration of hypertonic contrast material.

In addition to standard monitors, an arterial catheter placed prior to the induction of anesthesia may be helpful in that it will allow rapid evaluation of systemic blood pressure. Blood pressure control is critical, given that hypotension may result in ischemia in hypoperfused areas and hypertension may increase the risk of rupture of an associated aneurysm, worsen intraoperative bleeding, or worsen intracranial hypertension. For embolization or surgical resection of a vascular malformation in an eloquent region of brain, monitored anesthesia care is an attractive option. For cases requiring general anesthesia, a smooth, hemodynamically stable induction of general anesthesia is paramount. Thiopental, propofol, or etomidate are all effective and safe induction agents. Muscle relaxation should be accomplished with a nondepolarizing neuromuscular blocking agent such as succinylcholine may induce further increases in ICP as well as cause hyperkalemia if motor deficits are present. Techniques to blunt the hemodynamic responses to stimulating events such as laryngoscopy, pinion placement, and incision, should be used. These may include the administration of lidocaine, short-acting β-adrenergic antagonists (i.e., esmolol), and nitroprusside or deepening the anesthetic state with either higher concentrations of volatile anesthetics, small doses of induction agents, short-acting opioids, or intravenous lidocaine. Given the risk of severe and rapid intraoperative hemorrhage, especially with AVMs and AV fistulas, adequate intravenous access is essential. Further, central venous access may be useful in these cases to monitor volume status or for rapid administration of large volumes of fluids or blood products. A pulmonary artery catheter or transesophageal echocardiography can be useful in patients with cardiac disease.

With large or high-flow vascular malformations, frequent communication with the surgeon is of paramount importance because impressions of the lesions and the surgical and anesthetic requirements for safe resection may change during the operation. This is due, in part, to somewhat less than definitive imaging assessment preoperatively or changing surgical requirements during various stages of resection of a large, complex lesion. Hemodynamic stability, optimal surgical conditions, and rapid emergence at the end of surgery are appropriate goals when selecting maintenance techniques. Both intravenous and volatile-based techniques are appropriate and agents should be selected on a case-by-case basis.

Hypotonic and glucose-containing solutions should be avoided, given that the former can exacerbate cerebral edema and the latter can worsen the outcome from neurologic ischemia. Mild hyperventilation (PaCO2 of 30–35 mm Hg) will help facilitate surgical exposure. Lumbar CSF drainage may also help to decrease intracranial volume and improve exposure. Cerebral edema can be a significant problem during AVM treatment. Because AVMs represent a high-flow, low-resistance vascular lesion, as arterial feeders are ligated during resection or embolization, blood flow is thus directed toward normal brain tissue, resulting in possible cerebral edema. Mechanisms to be considered for the treatment of cerebral edema include moderate hyperventilation as a temporizing measure, diuretics such as mannitol and furosemide, and blood pressure reductions. In extreme cases, high-dose barbiturate or propofol anesthesia, or temporary craniectomy, with postoperative ventilatory support, may be useful.

Most patients, however, should respond quite well to surgical resection, and emergence from anesthesia should be smooth and rapid. Agents such as β-adrenergic antagonists as well as lidocaine or nitroprusside can be used to control short-term hypertensive events. Prompt neurologic assessment should follow emergence.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

Acute Intrinsic Restrictive Lung Disease

Acute Intrinsic Restrictive Lung Disease

Pulmonary edema is due to leakage of intravascular fluid into the interstitium of the lungs and into the alveoli. Acute pulmonary edema can be caused by increased capillary pressure (hydrostatic or cardiogenic pulmonary edema) or by increased capillary permeability. Pulmonary edema typically manifests as bilateral symmetrical opacities on chest radiography. A perihilar distribution (“butterfly pattern”) of the lung opacity is common. However, this pattern of lung opacity is more commonly seen with increased capillary pressure than with increased capillary permeability. The presence of air bronchograms on chest radiograph suggests permeability pulmonary edema. Cardiogenic pulmonary edema is characterized by extreme dyspnea, tachypnea, and signs of sympathetic nervous system activation (hypertension, tachycardia, diaphoresis) that may be more pronounced than in patients with capillary permeability pulmonary edema. Pulmonary edema caused by increased capillary permeability is characterized by a high concentration of protein and secretory products in the edema fluid. Diffuse alveolar damage is typically present with the increased permeability pulmonary edema associated with acute respiratory distress syndrome (ARDS).

Aspiration Pneumonitis

Aspirated acidic gastric fluid is rapidly distributed throughout the lung and produces destruction of surfactant-producing cells and damage to the pulmonary capillary endothelium. As a result, there is atelectasis and leakage of intravascular fluid into the lungs producing capillary permeability pulmonary edema. The clinical picture is similar to that of ARDS. Arterial hypoxemia is typically present. In addition, there may be tachypnea, bronchospasm, and acute pulmonary hypertension. Chest radiographs may not demonstrate evidence of aspiration pneumonitis for 6 to 12 hours after the event. Evidence of aspiration, when it does appear, is most likely to be in the right lower lobe if the patient aspirated while in the supine position.

Measurement of gastric fluid pH is useful as it reflects the pH of the aspirated fluid. Measurement of tracheal aspirate pH is of no value because the aspirated gastric fluid is rapidly diluted by airway secretions. The aspirated gastric fluid is also rapidly distributed to peripheral lung regions so lung lavage is not useful unless there has been aspiration of particulate material.

Aspiration pneumonitis is best treated by delivery of supplemental oxygen and PEEP. Bronchodilation may be needed to relieve bronchospasm. There is no evidence that prophylactic antibiotics decrease the incidence of pulmonary infection or alter outcome. Corticosteroid treatment of aspiration pneumonitis is controversial. Despite the absence of confirmatory evidence that corticosteroids are beneficial, some will treat aspiration pneumonitis with very large doses of methylprednisolone or dexamethasone.

Neurogenic Pulmonary Edema

Neurogenic pulmonary edema develops in a small proportion of patients experiencing acute brain injury. Typically, this form of pulmonary edema occurs minutes to hours after central nervous system injury and may manifest during the perioperative period. There is a massive outpouring of sympathetic impulses from the injured central nervous system, resulting in generalized vasoconstriction and a shift of blood volume into the pulmonary circulation. Presumably, increased pulmonary capillary pressure leads to transudation of fluid into the interstitium and alveoli. Pulmonary hypertension and hypervolemia can also injure blood vessels in the lungs.

The association of pulmonary edema with a recent central nervous system injury should suggest the diagnosis of neurogenic pulmonary edema. The principal entity in the differential diagnosis is aspiration pneumonitis. Unlike neurogenic pulmonary edema, chemical pneumonitis resulting from aspiration frequently persists longer and is often complicated by secondary bacterial infection.

Treatment of neurogenic pulmonary edema is directed at the cause of the central nervous system injury, at decreasing intracranial pressure, and at support of oxygenation and ventilation. Diuretics should not be used unless there is hypervolemia because development of hypovolemic hypotension could aggravate the central nervous system injury.

Drug-Induced Pulmonary Edema

Acute noncardiogenic pulmonary edema can occur after administration of a number of drugs, especially opioids (heroin) and cocaine. High permeability pulmonary edema is suggested by high protein concentrations in the pulmonary edema fluid. Cocaine can also cause pulmonary vasoconstriction, acute myocardial ischemia, and myocardial infarction. There is no evidence that naloxone speeds resolution of opioid-induced pulmonary edema. Treatment of patients who develop drug-induced pulmonary edema is supportive and may include tracheal intubation for airway protection and mechanical ventilation.

High-Altitude Pulmonary Edema

High-altitude pulmonary edema may occur at heights ranging from 2500 to 5000 meters and is influenced by the rate of ascent to that altitude. The onset of symptoms is often gradual but typically occurs within 48 to 72 hours at high altitude. Fulminant pulmonary edema may be preceded by the less severe symptoms of acute mountain sickness. The etiology of this high permeability pulmonary edema is presumed to be hypoxic pulmonary vasoconstriction, which increases pulmonary vascular pressures. Treatment includes administration of oxygen and prompt descent from the high altitude. Inhalation of nitric oxide may improve oxygenation.

Reexpansion of Collapsed Lung

Rapid expansion of a collapsed lung may lead to pulmonary edema in that lung. The risk of reexpansion pulmonary edema after relieving a pneumothorax or pleural effusion is related to the amount of air or liquid that was present in the pleural space (>1 L increases the risk), the duration of collapse (> 24 hours), and the rapidity of reexpansion. High protein concentrations in the edema fluid suggest that enhanced capillary membrane permeability is important in the development of this form of pulmonary edema. Treatment of reexpansion pulmonary edema is supportive.

Negative-Pressure Pulmonary Edema

Negative-pressure pulmonary edema may follow relief of acute upper airway obstruction (postobstructive pulmonary edema) caused by postextubation laryngospasm, epiglottitis, tumors, obesity, hiccups, or obstructive sleep apnea in spontaneously breathing patients. The time at onset of pulmonary edema after relief of airway obstruction ranges from a few minutes to as long as 2 to 3 hours. Tachypnea, cough, and failure to maintain oxygen saturation above 95% are common presenting signs and may be confused with pulmonary aspiration or pulmonary embolism. It is possible that many cases of postoperative oxygen desaturation are due to unrecognized negative-pressure pulmonary edema.

The pathogenesis of negative-pressure pulmonary edema is related to the development of high negative intrapleural pressure by vigorous inspiratory efforts against an obstructed upper airway. High negative intrapleural pressure decreases the interstitial hydrostatic pressure, increases venous return, and increases left ventricular afterload. In addition, such negative pressure leads to intense sympathetic nervous system activation, hypertension, and central displacement of blood volume. Together these factors produce acute pulmonary edema by increasing the transcapillary pressure gradient.

Maintenance of a patent upper airway and administration of supplemental oxygen are sufficient treatment because this form of pulmonary edema is typically transient and self-limited. Mechanical ventilation may occasionally be needed for a brief period of time. Hemodynamic monitoring reveals normal right and left ventricular function. Central venous pressure and pulmonary artery occlusion pressure are normal. Radiographic evidence of pulmonary edema resolves within 12 to 24 hours.

Management of Anesthesia

Preoperative

Elective surgery should be delayed in patients with acute restrictive pulmonary disease, and every effort must be made to optimize cardiorespiratory function. Large pleural effusions may need to be drained. Persistent hypoxemia may require mechanical ventilation and PEEP. Hemodynamic monitoring may be useful in both the assessment and treatment of pulmonary edema.

Intraoperative

These patients are critically ill. Intraoperative management should be a continuation of critical care management and include a plan for intraoperative ventilator management. The best way to ventilate patients with acute respiratory failure and restrictive lung disease has not been determined by clinical trials. However, because the pathophysiology is similar to that of acute lung injury and because there is the risk of hemodynamic compromise and barotrauma with the use of large tidal volumes and high airway pressures, it is reasonable to ventilate with low tidal volumes (e.g., 6 mL/kg) with a compensatory increase in ventilatory rate (14–18 breaths per minute) attempting to keep the end-inspiratory plateau pressure less than 30 cm H2O. Typical anesthesia ventilators may not be adequate for patients with severe ARDS and more sophisticated intensive care unit ventilators may be needed in occasional patients. Patients with restrictive lung disease typically breathe rapidly and shallowly, so tachypnea is likely during the weaning process and should not be used as the sole reason for delaying extubation if gas exchange and other assessments are satisfactory.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

ACUTE CERVICAL SPINAL CORD INJURY

ACUTE CERVICAL SPINAL CORD INJURY

Cervical spine radiographs are obtained in a large fraction of patients who present with various forms of trauma for fear of missing occult cervical spine injuries. Nevertheless, the probability of cervical spine injury is minimal in patients who meet the following five criteria: (1) no midline cervical spine tenderness, (2) no focal neurologic deficits, (3) normal sensorium, (4) no intoxication, and (5) no painful distracting injury. Patients who meet these criteria do not require routine imaging studies to rule out occult cervical spine injury.

An estimated two thirds of trauma patients have multiple injuries that can interfere with cervical spine evaluation. Evaluation usually includes computed tomography or magnetic resonance imaging. Nevertheless, routine imaging may not be practical in some, considering the risk of transporting unstable patients. For this reason, standard radiographic views of the patient's cervical spine, often taken with a portable x-ray machine, are frequently relied on to evaluate the presence of cervical spine injury and associated instability. Regardless of the form of cervical spine imaging employed, the entire cervical spine including the body of the first thoracic vertebra must be seen and evaluated. Alignment of the vertebrae (lateral view), fractures (all views), and evaluation of disc and soft-tissue spaces are analyzed on the radiographic examination. The sensitivity of plain radiographs is less than 100%, and therefore the likelihood of cervical spine injury must be interpreted in conjunction with other clinical symptoms and risk factors. If there is any doubt, it is prudent to treat all acute cervical spinal injuries as potentially unstable.

Treatment of a cervical fracture dislocation entails immediate immobilization to limit neck flexion and extension. In addition, soft neck collars have almost no effect on limiting neck flexion, and neck extension is only modestly limited. Hard neck collars limit neck flexion and extension by only approximately 25%. Immobilization and traction as provided by halo-thoracic devices are most effective in preventing cervical spine movement. Manual in-line stabilization (the assistant's hands are placed on each side of the patient's face with the fingertips resting on the mastoid process with downward pressure against a firm table surface to hold the head immobile in a neutral position) is recommended to help minimize cervical spine flexion and extension during direct laryngoscopy for tracheal intubation.

Cervical spine movement during direct laryngoscopy is likely to be concentrated at the occipitoatlantoaxial area, suggesting an increased risk of spinal cord injury at this level in vulnerable patients, even with the use of manual in-line stabilization.

In addition to mechanical deformation of the spinal cord produced by movement of the neck in the presence of cervical spine injury, there is perhaps an even greater risk of compromise of the blood supply to the spinal cord produced by neck motion that elongates the cord, with resultant narrowing of the longitudinal blood vessels. In fact, maintenance of perfusion pressure may be more important than positioning for preventing spinal cord injury in the presence of cervical spine injury.

Management of Anesthesia

Patients with acute spinal cord transections often require special precautions during airway management. The key principle when performing direct laryngoscopy is to minimize neck movements during the procedure. However, fear of possible spinal cord compression (from an unstable cervical spine injury) must not prevent necessary airway intervention. Extensive clinical experience seems to support the use of direct laryngoscopy for orotracheal intubation provided that (1) maneuvers are taken to stabilize the head during the procedure (avoiding hyperextension of the patient's neck) and (2) evaluation of the patient's airway did not suggest the likelihood of any associated technical difficulty.

Topical anesthesia and awake fiberoptic laryngoscopy are an alternative to direct laryngoscopy if patients are cooperative and airway trauma—with ensuing blood, secretions, and anatomic deformities—does not preclude visualization with the fiberscope. Of note, coughing during both topicalization of the airway and fiberoptic intubation may result in cervical spine movement. It is reasonable to have an assistant maintain manual in-line stabilization of the cervical spine during both interventions. Another alternative is rapid-sequence induction of anesthesia with intravenous anesthetics and a muscle relaxant. When the cervical spine is unstable or there is a high index of suspicion for the presence of cervical spine injury, it is important to proceed carefully, as neck hyperextension could further damage the spinal cord. Nevertheless, there is no evidence of increased neurologic morbidity after elective or emergency orotracheal intubation of anesthetized or awake patients who have an unstable cervical spine if appropriate and safe steps are taken to minimize neck movement. Awake tracheostomy is reserved for the most challenging airway conditions, in which neck injury, combined with facial fractures or other severe anomalies of airway anatomy, make safely securing the airway by nonsurgical means difficult or unsafe. All factors considered, airway management in the presence of cervical spine injury should be dictated by common sense, not dogmatic approaches. Certainly, clinical experience supports the safety of a variety of techniques just described.

The absence of compensatory sympathetic nervous system responses makes patients with cervical or high thoracic spinal cord injury particularly vulnerable to dramatic decreases in systemic blood pressure following acute changes in body posture, blood loss, or positive airway pressure. To minimize these effects, liberal intravenous infusion of crystalloid solutions may be necessary to replete intravascular volume, which has been abruptly compromised by vasodilation. Likewise, acute blood loss should be replaced promptly. Electrocardiogram abnormalities are common during the acute phase of spinal cord injury, especially with cervical cord injuries. Breathing is best managed by mechanical ventilation, as abdominal and intercostal muscle weakness or paralysis, exacerbated by general anesthesia, increases the chances of respiratory failure with ensuing hypoxia and hypercapnia. Body temperature should be monitored and manipulated as patients tend to become poikilothermic below the spinal cord transection. Anesthetic maintenance is targeted at ensuring physiologic stability and facilitating tolerance of the tracheal tube. Volatile or injected anesthetics are satisfactory for this purpose. Nitrous oxide should be used with caution, given concerns for co-existing trauma and air entrainment in closed spaces (e.g., as occurs with basilar skull fracture or rib fracture, which could potentially contribute to pneumocephalus or pneumothorax, respectively). Arterial hypoxemia is common following spinal cord injury, emphasizing the need for continuous pulse oximetry and delivery of supplemental oxygen.

Muscle relaxant use should be determined by the operative site and the level of spinal cord transection. If muscle relaxants are necessary, the sympathomimetic effects of pancuronium makes this drug an attractive choice; however, other nondepolarizing muscle relaxants can be used safely. Succinylcholine is unlikely to provoke excessive release of potassium during the first few hours after spinal cord transection. Even in these instances, the benefits of succinylcholine, which include rapid onset of action and short duration of relaxation, should be weighed against potential side effects. Use of a nondepolarizing relaxant, with mask ventilation while employing cricoid pressure, is another alternative to airway management during anesthesia induction and prior to laryngoscopy. Benefits of the latter approach are that once the endotracheal tube is placed, the longer duration of the nondepolarizing relaxant has utility during patient positioning.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

Orthostatic Intolerance Syndrome

Orthostatic Intolerance Syndrome

Orthostatic intolerance syndrome is a chronic idiopathic disorder of primary autonomic system failure characterized by episodic or postural tachycardia occurring independent of alterations in systemic blood pressure. Orthostatic intolerance syndrome probably represents a variety of other entities including postural tachycardia syndrome, effort syndrome, hyperdynamic β-adrenergic state, hyperdynamic orthostatic tachycardia, idiopathic hypovolemia, irritable heart, mitral valve prolapse syndrome, neurocirculatory asthenia, and others. It is most often observed in young women. Symptoms often include palpitations, tremulousness, light-headedness, fatigue, and syncope. The pathophysiology of the orthostatic intolerance syndrome is unclear, although possible explanations include enhanced sensitivity of β1-adrenergic receptors, hypovolemia, excessive venous pooling during standing, primary dysautonomia, and lower extremity sympathetic nervous system denervation.

Medical treatment of patients with orthostatic intolerance syndrome includes attempts to increase the intravascular fluid volume (increased sodium and water intake, administration of mineralocorticoids) in order to increase venous return. Long-term administration of α1-adrenergic agonists, such as midodrine, may compensate for decreased sympathetic nervous system activity in the patient's lower extremities and blunt heart rate responses to standing by activating baroreceptor reflexes.

Management of anesthesia in patients with orthostatic intolerance syndrome includes preoperative administration of crystalloid solutions to expand the patient's intravascular fluid volume. Low-dose phenylephrine infusions may be cautiously administered, recognizing that lower extremity sympathetic nervous system denervation may cause up-regulation of α1-adrenergic receptors and contribute to receptor hypersensitivity. The combination of volume expansion and low-dose phenylephrine infusions should augment peripheral vascular tone, maintain systemic blood pressure, and decrease autonomic nervous system lability in the presence of vasodilating anesthetic drugs (volatile anesthetics) or techniques (epidural or spinal anesthesia). Neuraxial opioids have utility for postoperative pain management. β-Adrenergic antagonists may be useful for blunt tachycardia; however, care should be taken to avoid excessive hypotension, which might result from the use of these drugs.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

LOW-OUTPUT AND HIGH-OUTPUT HEART FAILURE

LOW-OUTPUT AND HIGH-OUTPUT HEART FAILURE

The normal cardiac index varies between 2.2 and 3.5 L/min/m2. It may be difficult to diagnose low-output heart failure because a patient may have a cardiac index that is nearly normal in the resting state but does not respond adequately to stress or exercise. The most common causes of low-output heart failure are CAD, cardiomyopathy, hypertension, valvular disease, and pericardial disease.

Causes of high cardiac output include anemia, pregnancy, arteriovenous fistulas, severe hyperthyroidism, beriberi, and Paget's disease. The ventricle fails not only because of the increased hemodynamic burden placed on it but also because of direct myocardial toxicity as caused by thyrotoxicosis and beriberi and myocardial anoxia caused by severe and prolonged anemia.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

LIVER TRANSPLANTATION

LIVER TRANSPLANTATION

Liver transplantation is the only curative therapy for patients with severe acute liver failure or end-stage liver disease with cirrhosis. In 2006, 6650 liver transplantations were performed in the United States, 40% of these for liver disease related to hepatitis C. At present, the typical 1-year survival rate for liver transplant recipients is approximately 85% and the 5-year survival rate is approximately 70%.

More than 90% of livers for transplantation are cadaveric organs. Live donor liver transplantation, which usually involves removal of an entire lobe of the liver (especially the right lobe) produces excellent results in children. However, adult-to-adult live donor liver transplantation is often more problematic due to size mismatching. The small-for-size syndrome is not uncommon and manifests as liver dysfunction within the first week after surgery. It appears that cirrhotic patients do better with a donor liver at least as large if not larger than their native liver.

Management of Anesthesia

Candidates for liver transplantation may present with severe multiorgan dysfunction. Many of the physiologic derangements, such as the coagulopathy, are not correctable until after successful liver transplantation. The likely presence of HBV or HBC in the transplant recipient must be considered by the health care providers.

The pharmacokinetics and pharmacodynamics of many drugs used in anesthesia are altered by severe liver disease. Changes in drug metabolism, protein binding, and volume of distribution are common. Induction of anesthesia can be affected by the presence of ascites compromising lung volumes and delaying gastric emptying. Hypoxemia and pulmonary aspiration are significant risks. Anesthesia can be maintained with opioids and/or inhaled anesthetics combined with muscle relaxants that are not dependent on hepatic clearance mechanisms (atracurium, cisatracurium). Nitrous oxide is usually avoided because of concerns regarding bowel distention that can compromise surgical exposure. Fluid warming devices and rapid infusion systems designed to deliver warmed fluids or blood products at rates exceeding 1 L per minute are routinely employed. Invasive monitoring of systemic blood pressure and cardiac filling pressures and placement of several large-bore intravenous catheters to optimize fluid replacement are important parts of anesthetic management. Surgery for removal of the native liver and implantation of the donor liver is characterized by three phases: the dissection phase, the anhepatic phase, and the reperfusion or neohepatic phase.

The dissection phase involves mobilizing the vascular structures around the liver (hepatic artery, portal vein, supra- and infrahepatic vena cava), isolating the common bile duct, and removing the native liver. Cardiovascular instability due to hemorrhage, venous pooling as a result of decreases in intra-abdominal pressure, and impaired venous return due to surgical retraction are not uncommon during this phase.

The anhepatic stage begins when the blood supply to the native liver is interrupted by clamping of the hepatic artery and portal vein. To avoid a marked decrease in venous return and cardiac output as well as splanchnic venous congestion during occlusion of the inferior vena cava, a venovenous bypass system is often used. Placement of the donor liver may require vigorous retraction near the diaphragm, leading to possible compromise of ventilation and oxygenation. Because of the lack of liver metabolic function during the anhepatic phase, metabolic acidosis, decreased drug metabolism, and citrate intoxication are likely. A calcium infusion may be needed to treat hypocalcemia.

The reperfusion or neohepatic phase begins after reanastomosis of the major vascular structures to the donor liver. Before removal of the vascular clamps, the allograft is flushed to remove air, debris, and preservative solutions. Despite this step, subsequent unclamping can cause significant hemodynamic instability, dysrhythmias, severe bradycardia, hypotension, and hyperkalemic cardiac arrest. Once the allograft begins to function, hemodynamic and metabolic stability are gradually restored and urine output increases. Recovery of the capacity to metabolize drugs occurs soon after reperfusion of the graft. Clotting parameters usually normalize with administration of clotting factors. Postoperative support of ventilation and oxygenation may be required.

Anesthetic Considerations in the Patient after Liver Transplantation

Potential adverse effects (systemic hypertension, anemia, thrombocytopenia) and drug interactions related to chronic immunosuppressive therapy are considered when planning the management of anesthesia in liver transplant recipients. Certainly these patients are at increased risk of infectious complications of any kind. If regional anesthesia or invasive hemodynamic monitoring are undertaken, strict aseptic technique is essential.

Liver function tests return to normal following successful liver transplantation. Liver transplantation also results in reversal of the hyperdynamic circulation that characterizes liver failure. Oxygenation improves, although intrapulmonary shunts may persist and contribute to ventilation-to-perfusion abnormalities. Normal physiologic mechanisms that protect hepatic blood flow are blunted after liver transplantation. The liver is normally an important source of autotransfusion of blood volume in shock states via a vasoconstrictive response, and this mechanism may be impaired after liver transplantation.

There is no evidence of an increased risk of developing hepatitis after administration of volatile anesthetics to liver transplant recipients.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

FAT EMBOLISM

FAT EMBOLISM

The syndrome of fat embolism typically appears 12 to 72 hours (lucid interval) after long-bone fractures, especially of the femur or tibia. Fat embolism syndrome has also been observed in association with acute pancreatitis, cardiopulmonary bypass, parenteral infusion of lipids, and liposuction. The triad of hypoxemia, mental confusion, and petechiae in patients with tibia or femur fractures should arouse suspicion of fat embolism. Associated pulmonary dysfunction may be limited to arterial hypoxemia (always present) or it may be fulminant, progressing from tachypnea to alveolar capillary leak and acute respiratory distress syndrome. Central nervous system dysfunction ranges from confusion to seizures and coma. Petechiae, especially over the neck, shoulders, and chest, occur in at least 50% of patients with clinical evidence of fat embolism and are thought to be caused by embolic fat rather than by thrombocytopenia or other disorders of coagulation. An increased serum lipase concentration or the presence of lipiduria is suggestive of fat embolism but may also occur after trauma in the absence of a fat embolism. Significant fever and tachycardia are often present. Magnetic resonance imaging can show the characteristic cerebral lesions during the acute stage of fat embolism syndrome.

The source of fat producing a fat embolism most likely represents disruption of the adipose architecture of bone marrow. The pathophysiology of fat embolism syndrome relates to obstruction of blood vessels by fat particles and the deleterious effects of free fatty acids released from the fat particles as a result of lipase activity. These free fatty acids can cause an acute, diffuse vasculitis especially of the cerebral and pulmonary vasculature. Treatment of fat embolism syndrome includes management of acute respiratory distress syndrome and immobilization of long-bone fractures. Prophylactic administration of corticosteroids for patients at risk may be useful, but the efficacy of corticosteroids for the established syndrome has not been documented. Conceptually, corticosteroids could decrease the incidence of fat embolism syndrome by limiting the endothelial damage caused by free fatty acids.

 

CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ACUTE RESPIRATORY FAILURE

CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ACUTE RESPIRATORY FAILURE

Patients with severe COPD often adapt to some degree of arterial hypoxemia and hypercarbia. Acute deterioration in lung function is most often triggered by events such as pneumonia, congestive heart failure, and increased metabolic production of carbon dioxide as produced by febrile states. The increasing hypoxemia and hypercarbia that accompany these exacerbations of COPD lead to increasing dyspnea and alterations in consciousness that may be associated with retention of secretions and a further deterioration in gas exchange. The vicious cycle can be interrupted by treating the event that initiated the acute deterioration and providing support to improve gas exchange until the underlying precipitating event has resolved.

Treatment

Analysis of arterial blood gases is crucial for proper treatment of acute exacerbations of COPD. Supplemental oxygen is administered to maintain the PaO2 above 60 mm Hg. Mild hypercarbia is common when oxygen is administered to patients with COPD and is acceptable as long as the pHa does not decrease below 7.2. Bronchopulmonary drainage is stimulated by encouragement to cough, administration of inhaled bronchodilators and systemic corticosteroids, and treatment of underlying infection with antibiotics. Acute exacerbations of COPD are often accompanied by persistent respiratory acidosis and excessive work of breathing.

Mechanical support of ventilation is necessary when hypercarbia is severe enough to decrease the pHa below 7.2 and when patients show signs of mental status deterioration or respiratory muscle fatigue. Tracheal intubation must be performed when there is hemodynamic instability or somnolence or secretions cannot be cleared. For patients who remain alert despite hypercarbia, delivery of positive-pressure ventilation via a tight-fitting face mask (noninvasive ventilation) is an alternative to tracheal intubation. The most common method of noninvasive ventilation delivers a specified amount of inspiratory pressure (15–20 cm H2O) combined with a low level of expiratory pressure (3–5 cm H2O) to decrease the effort required to trigger the ventilator. Advantages of noninvasive ventilation include a lower risk of nosocomial infection, shorter length of intensive care unit stay, decreased need for sedation, and decreased mortality. A complication of noninvasive ventilation with a face mask is skin necrosis over the bridge of the nose.

When tracheal intubation is required to treat acute exacerbations of COPD, the initial ventilator settings should include a large tidal volume and slow breathing rate. Patients with chronic hypercarbia should not have their PaCO2 decreased abruptly to normal because this can result in respiratory alkalosis and cardiac dysrhythmias. The ventilator should be adjusted to return the PaCO2 to the previous baseline level to avoid development of severe hyperinflation and significant auto-PEEP, which increases the risk of barotrauma, leads to erroneous interpretation of measurements from central venous and pulmonary artery catheters, increases the work of breathing, and interferes with venous return.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

CAROTID ENDARTERECTOMY

CAROTID ENDARTERECTOMY

Surgical treatment of symptomatic carotid artery stenosis greatly decreases the risk of stroke, especially in men with severe carotid stenosis. Two large randomized trials, The North American Symptomatic Carotid Endarterectomy Trial and the European Carotid Surgery Trial, both reported favorable results for symptomatic patients with high-grade stenosis (70%–90%) compared to medically managed patients. Data from transcranial Doppler and duplex ultrasonography studies suggest that carotid artery stenosis with a residual luminal diameter of 1.5 mm (70%–75% stenosis) represents the point at which a pressure drop occurs across the stenosis, that is, the stenosis becomes hemodynamically significant. Therefore, if collateral cerebral blood flow is not adequate, transient ischemic attacks and ischemic infarction can occur.

Surgical treatment for asymptomatic disease is still controversial. It appears that the absolute risk reduction is small (approximately 1% per year for the first few years) but is higher with longer follow-up. Thus, the stroke prevention results in this patient group can be durable, but any benefit of surgical correction of asymptomatic carotid stenosis is negated by a high perioperative complication rate. Only those centers with complication rates of 3% or less should contemplate performing carotid endarterectomy in asymptomatic patients.

Carotid angioplasty and stenting may become alternatives to carotid endarterectomy.

Preoperative Evaluation

In addition to the neurologic evaluation, patients scheduled for carotid endarterectomy should be examined for co-existing cardiovascular and renal disease. Predictably, patients with cerebrovascular occlusive disease have occlusive disease in other arteries. Ischemic heart disease is a major cause of morbidity and mortality following carotid endarterectomy. The reported incidence of perioperative myocardial infarction ranges from 0% to 4%. Patients with severe coronary artery disease and severe carotid occlusive disease present a dilemma. A staged approach with carotid endarterectomy first could result in significant morbidity/mortality from cardiac causes. On the other hand, coronary revascularization first may result in a higher incidence of stroke. No randomized studies have been performed to determine the benefit of combined versus staged procedures. The management of such a patient must be individualized.

Chronic essential hypertension is a common finding in patients with cerebrovascular disease. It is useful to establish the usual range of blood pressure for each patient preoperatively to provide a guide for acceptable perfusion pressures during anesthesia and surgery. The effect of a change in head position on cerebral function should also be ascertained. Extreme head rotation, flexion, or extension in patients with co-existing vertebral artery disease could lead to angulation or compression of that artery. Recognition of this response preoperatively allows hazardous head positions (especially hyperextension) to be avoided while patients are unconscious during general anesthesia

sufficiently awake to undergo neurologic examination.

Carotid endarterectomy can be performed under regional (cervical plexus block) or general anesthesia. Regional anesthesia allows a patient to remain awake to facilitate neurologic assessment during carotid artery cross-clamping. This technique requires patient cooperation. Blood pressure lability may be greater in patients undergoing carotid endarterectomy under general anesthesia. However, the anesthetic-induced decrease in cerebral metabolic oxygen consumption may provide some degree of cerebral protection. No particular anesthetic drug(s) can be recommended for induction and maintenance of general anesthesia. However, two goals must be met: maintenance of hemodynamic stability and prompt emergence allowing immediate assessment of neurologic status in the operating room.

Maintenance of an adequate blood pressure is important during carotid endarterectomy because autoregulation may be abnormal in these patients. Vasopressors or vasodilators may be needed to maintain an appropriate perfusion pressure during carotid cross-clamping. Surgical manipulation of the carotid sinus may cause marked alterations in heart rate and blood pressure. It is generally accepted that changes in regional cerebral blood flow associated with changes in PaCO2 are unpredictable in these patients. Therefore, maintenance of normocarbia is recommended.

Monitoring usually includes an intra-arterial catheter. Patients with poor left ventricular function and/or severe coronary artery disease might require a central venous or pulmonary artery catheter or transesophageal echocardiography, but this is not often necessary. The hemodynamic goals for cerebral and coronary perfusion are similar, and achievement of these goals benefits both organ systems. Particular care must be taken during central venous access attempts to prevent inadvertent carotid puncture that could cause a hematoma that compromises collateral blood flow during carotid cross-clamping.

When carotid endarterectomy is performed under general anesthesia, monitoring for cerebral ischemia, hypoperfusion, and cerebral emboli can be considered. The principal reason to monitor cerebral function in these patients is to select which patients would benefit from use of a carotid artery shunt during carotid cross-clamping. The standard electroencephalogram is a sensitive indicator of inadequate cerebral perfusion during carotid cross-clamping, and intraoperative neurologic complications correlate with the electroencephalographic changes of cerebral ischemia. However, the utility of electroencephalographic monitoring during carotid endarterectomy is limited by several factors: (1) electroencephalography may not detect subcortical or small cortical infarcts, (2) false-negative results are not uncommon (patients with previous strokes or transient ischemic attacks have a high incidence of false-negative test results), and (3) the electroencephalogram can be affected not only by cerebral ischemia but also by changes in temperature, blood pressure, and depth of anesthesia. Somatosensory evoked potential monitoring can detect specific changes produced by decreased regional cerebral blood flow, but it can be difficult to determine whether these changes are due to anesthesia, hypothermia, changes in blood pressure, or cerebral ischemia. Stump pressure (internal carotid artery back pressure) is a poor indicator of the adequacy of cerebral perfusion. Transcranial Doppler ultrasonography allows continuous monitoring of blood flow velocity and the presence of microembolic events. It could be used to determine the need for shunt placement, to recognize shunt malfunction, and to manage postoperative hyperperfusion. Overall, awake neurologic assessment is the simplest, most cost-effective, and most reliable method of cerebral function monitoring during carotid endarterectomy.

Postoperative Management and Complications

In the immediate postoperative period after carotid endarterectomy, patients must be observed for cardiac, airway, and neurologic complications. These include hyper- or hypotension, myocardial ischemia/infarction, development of significant soft-tissue edema or a hematoma in the neck, and the onset of neurologic signs and symptoms that signal a new stroke or acute thrombosis at the endarterectomy site.

Hypertension is frequently observed during the immediate postoperative period, often in patients with co-existing essential hypertension. The increase in blood pressure often reaches a maximum 2 to 3 hours after surgery and may persist for 24 hours. Hypertension should be treated to avoid the hazards of cerebral edema and myocardial ischemia. The incidence of new neurologic deficits is increased threefold in patients who are hypertensive postoperatively. Continuous infusion of nitroprusside or nitroglycerin and the use of longer acting drugs such as hydralazine or labetalol are options for blood pressure control. The mechanism of this postoperative hypertension may be related to altered activity of the carotid sinus or loss of carotid sinus function due to denervation during surgery.

Hypotension is also commonly observed during the immediate postoperative period. This hypotension can be explained based on carotid sinus hypersensitivity. The carotid sinus previously “shielded” by atheromatous plaque is now able to perceive blood pressure oscillations more clearly and goes through a period of hyperresponsiveness to these stimuli. Hypotension due to carotid sinus hypersensitivity is usually treated with vasopressors such as phenylephrine. It typically resolves within 12 to 24 hours.

Cranial nerve dysfunction is possible after carotid endarterectomy with most injuries being transient. Patients should be examined for evidence of hypoglossal, recurrent laryngeal, or superior laryngeal nerve injury. Such injury may produce difficulty swallowing or protecting the airway and could result in aspiration.

Carotid body denervation can also occur after carotid artery surgery and impair the cardiac and ventilatory responses to hypoxemia. This can be clinically significant after bilateral carotid endarterectomy or with administration of narcotics.

Endovascular Treatment of Carotid Disease

The technique of carotid artery stenting is under development for the treatment of carotid artery disease. It may become the leading alternative to carotid endarterectomy. The major complication of carotid stenting is microembolization of atherosclerotic material into the cerebral circulation during the procedure. Embolic protection devices for use during carotid stenting have been developed to prevent or decrease the risk of embolization of this material and therefore to decrease the risk of stroke. The Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) study is the first randomized multicenter trial comparing the safety and efficacy of carotid stenting with embolic protection to carotid endarterectomy in high-risk patients. The main finding of this trial was that the results of carotid artery stenting with the use of an emboli protection device were similar to the results of carotid endarterectomy in the prevention of stroke, death, or myocardial infarction among patients for whom surgery poses an increased risk.

The Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST) and Stent-Supported Percutaneous Angioplasty of the Carotid Artery vs. Endarterectomy Trial, when completed, will provide more data regarding clinical outcomes in low- to medium-risk patient populations and help establish guidelines for the use of endovascular techniques in the treatment of carotid artery occlusive disease.

Copyright © 2008 Elsevier Inc. All rights reserved. - www.mdconsult.com

 

Anesthesia for Correction of Cardiac Arrhythmias

Anesthesia for Correction of Cardiac Arrhythmias

Samuel A. Irefin

Key Points

  

1.   

Cardiac arrhythmias are caused by disorders of impulse formation or disorders of impulse conduction, or both. Cardiac arrhythmia may be life-threatening because of a reduction in cardiac output, reduction in myocardial blood flow, or precipitation of a more serious arrhythmia.

  

2.   

Radiofrequency ablation is the therapy of choice for many types of cardiac arrhythmias.

  

3.   

Electrophysiologic studies are used to map out normal and abnormal intracardiac structures. In this process, the mechanism of arrhythmia is delineated, and ablation can be performed at the same time.

  

4.   

Pacing technologies have been developed to treat heart failure resulting in increases in pulse pressure, left ventricular stroke volume, cardiac index, and wedge pressure.

  

5.   

Implantable pacemakers are placed for treatment of symptomatic bradycardia with the ability to respond to changing hemodynamic demands.

  

6.   

The development of implantable cardioverter-defibrillators (ICDs) to terminate ventricular tachyarrhythmias by delivering high-voltage shocks to the ventricle has revolutionized therapy for cardiac arrhythmias.

  

7.   

The main purpose of ICD placement is to prevent sudden cardiac death resulting from hemodynamically unstable ventricular arrhythmias.

  

8.   

An ICD also can be placed for cardiac resynchronization. Cardiac resynchronization therapy has been shown to improve heart failure symptoms, quality of life, exercise capacity, and electrocardiographic variables.

  

9.   

Anesthetic management of patients for correction of cardiac arrhythmias depends on associated comorbid illness and the procedure that is planned.

Cardiac arrhythmias are caused by disorders of impulse formation or disorders of impulse conduction, or both. Disorders of impulse formation include enhancement or depression of automaticity, parasystolic activity, and triggered activity. Disorders of conduction include decremental conduction, re-entry, entry block, exit block, concealed conduction, and supernormal conduction.[1]

At the present time, radiofrequency catheter ablation has replaced antiarrhythmic drug therapy as the treatment of choice for many types of cardiac arrhythmias. Before the 1980s, cardiac electrophysiology was primarily used to confirm mechanisms of arrhythmias, with management mainly by pharmacologic means. As a result of shortcomings in antiarrhythmic drug therapy (including the results of randomized trials), radiofrequency ablation and implantable cardioverter-defibrillators (ICDs) were developed. [2] [3]

Historical Perspectives

The treatment of cardiac arrhythmias with device-based therapy may have begun in 1899, when Prevost and Batteli[4] noted almost as an afterthought that direct electric shock could terminate ventricular fibrillation in dogs. Hooker and colleagues[5] showed 3 decades later that the passage of electric current across the heart can initiate and terminate ventricular fibrillation. In 1947, Beck saved the first human life by the successful use of cardiac defibrillation in a 14-year-old boy, who developed ventricular fibrillation during a thoracic procedure and went on to achieve full recovery.[6] These early achievements provided the foundation for the landmark work of Mirowski and Mower,[6a] which ultimately led to the development of ICDs in humans in 1980.

Scope of Cardiac Arrhythmias

Cardiac arrhythmias are common (see Chapters 42 and 43 [Chapter 42] [Chapter 43] ). Some cardiac arrhythmias are life-threatening, and others are merely a nuisance. Cardiac arrhythmias are caused by abnormalities in impulse formation or conduction that lead to slow or fast, regular or irregular heart rhythms. At the present time, it is not difficult to treat slow rhythms because available pacemakers are able to adapt slow function to the needs of the body.[7] The situation is different, however, for patients with rapid rhythms. Rapid rhythms may originate anywhere in the heart and result from various mechanisms. These mechanisms may be focal, meaning that the abnormal impulse formation is confined to a small area, or they may be the result of an impulse running in a circuit composed of several interconnected cardiac cells. Such a circuit may be small or large, as in atrial flutter and in arrhythmias in which the normal atrioventricular conduction system and an extra connection between the atrium and the ventricle are incorporated into the circuit of the arrhythmia.[8]

Pharmacologic interventions originally were used in attempts to terminate and prevent rapid rhythms. It has become clear in the past several decades, however, that antiarrhythmic drugs may have serious side effects and sometimes may even facilitate the occurrence of life-threatening arrhythmias and sudden death.[9] As a result of these effects, techniques were developed for localizing the site of origin or pathway of an arrhythmia and then isolating or destroying the tissue that is responsible. By employing an intracardiac catheter, it is now possible to determine the site of origin or pathway of an arrhythmia and cure the rhythm disturbance by applying through the catheter radiofrequency, laser, ultrasound, or microwave energy or freezing temperatures to the tissue causing the arrhythmia.

Heart failure is a major problem in elderly patients (see Chapter 71 ). Although pharmacologic treatment of heart failure has improved, outcome generally remains poor. New pacing technologies may now be used to treat selected patients with heart failure. For many years, permanent pacing has been used to treat symptomatic bradycardia, and pacing may alleviate heart failure when associated with heart block. Several studies have examined the use of conventional dual-chamber atrioventricular–right ventricular pacing for treatment of heart failure in the absence of symptomatic bradycardia or heart block. [3] [10] Biventricular pacing aims to restore synchronous cardiac contraction. Studies have shown that when ventricular desynchrony is reduced, the heart is able to contract more efficiently and increase left ventricular ejection fraction and cardiac output, while working less and consuming less oxygen.[11] In addition, re-establishment of left ventricular synchrony can increase left ventricular filling times, decrease pulmonary capillary wedge pressure, and reduce mitral regurgitation.

Normal Cardiac Rhythm

In the normal heart, the dominant impulse arises in the sinus node with a rate of 60 to 100 beats/min. During sleep, the rate may decrease to 30 to 50 beats/min.[12] Episodes of sinus pauses up to 3 seconds, sinoatrial block, junctional rhythms, and first-degree and second-degree atrioventricular nodal block that occur often enough (especially in trained athletes) are considered to be normal variants.[7]

The impulses generated from the sinoatrial node propagate along three intra-atrial conduction pathways: the anterior, middle, and posterior internodal tracts. These tracts are not discrete pathways, but groups of cells that conduct slightly faster than the atrial myocardium.[13] The internodal tracts give rise to interatrial fibers. The electric impulse, whether propagated in the atrial myocardium or along the internodal tracts, converges on the atrioventricular junction. The atrioventricular node located in the atrioventricular junction ultimately receives the impulses generated from the sinoatrial node. The impulses are delayed in the atrioventricular node before they are finally distributed to the ventricular myocardium via the His-Purkinje system.

Normally, the heart rate increases with exercise to at least 85% of the age-predicted maximum of 220 minus age in years; failure to do so is termed chronotropic incompetence. Sinus arrhythmia is defined as sinus rhythm with P-to-P variations of more than 10%. Sinus arrhythmia is due to cyclic variations in vagal tone commonly related to respiration (the rate is faster with inspiration and slower with expiration).[14] Sinus arrhythmia disappears with exercise, breath-holding, and atropine, and is more likely to be seen in individuals who do not have heart disease.[15]

Cardiac Arrhythmias

Cardiac arrhythmia is caused by a disorder of impulse generation, impulse conduction, or a combination of both. Cardiac arrhythmia may be life-threatening because of a reduction in cardiac output, reduction in myocardial blood flow, or precipitation of a more serious arrhythmia.[16] Arrhythmias may be described based on (1) rate (bradycardia or tachycardia); (2) rhythm (regular or irregular); (3) origin of impulse (supraventricular, ventricular, or artificial pacemaker); (4) impulse conduction (atrioventricular, ventriculoatrial, or block); (5) ventricular rate; or (6) special phenomena (e.g., pre-excitation).

Re-entry is a common electrophysiologic mechanism that predisposes to most ventricular arrhythmias and to most supraventricular tachyarrhythmias. The most common mechanism of re-entry is based on the model originally proposed by Erlanger and Schmitt and later modified by Wit.[1] This model postulates the presence of a ring or loop of cardiac tissue that is functionally separate from neighboring tissue and the presence of transient or permanent unidirectional block in a portion of the loop. Unidirectional block may be anatomic in origin (e.g., bundle branches, fibrosis, dual pathways, atrioventricular node plus accessory pathway) or functional (e.g., ischemia, drug effect).

Atrial flutter is a macro-re-entrant arrhythmia identified by flutter waves, often best seen in the inferior leads at 250 to 350 beats/min. Patients often present with a 2 : 1 atrioventricular conduction with a ventricular rate of 150 beats/min, although the atrioventricular conduction ratio can change abruptly.

Atrial fibrillation is a narrow-complex tachyarrhythmia and is the most common in the general population. The prevalence of atrial fibrillation in the general population increases exponentially with age, from 0.9% in individuals age 40 to 5.9% in individuals older than age 65. The most important risk factors for development of atrial fibrillation in the general population are structural heart disease, valvular heart disease, and left ventricular hypertrophy.[17]

Ventricular tachyarrhythmia is defined as three or more consecutive ectopic beats at a rate greater than 100 beats/min.[18] Ventricular tachyarrhythmia is traditionally classified as nonsustained or sustained. Sustained ventricular tachyarrhythmia is defined as ventricular tachyarrhythmia lasting more than 30 seconds. Nonsustained ventricular tachyarrhythmia is defined as ventricular tachyarrhythmia that terminates spontaneously within 30 seconds. Sustained ventricular tachyarrhythmia also is traditionally classified as monomorphic (one site of origin) or polymorphic (two or more sites of origin).[18] Monomorphic ventricular tachyarrhythmia usually results from re-entry, and the site of re-entry depends in part on the type of heart disease. In patients with coronary artery disease, the re-entry circuit is usually located in ventricular myocardium, whereas in dilated cardiomyopathy with left bundle branch block, bundle branch re-entry is common.[19] Monomorphic ventricular tachyarrhythmia may occur in individuals with an otherwise normal heart, whereas polymorphic ventricular tachyarrhythmia may occur in acquired states that produce a marked prolongation of the Q–T interval. Nonsustained ventricular tachyarrhythmia is frequently asymptomatic, but may produce palpitations, weakness, and presyncope.[19]

Torsades de pointes is a French term translated as “twisting of the points.” It is a syndrome composed of polymorphic ventricular tachyarrhythmia. It may be due to various medications or electrolyte imbalances. Torsades de pointes is usually paroxysmal, but is frequently symptomatic and often produces loss of consciousness. It occasionally degenerates to ventricular fibrillation.

Ventricular fibrillation accounts for 80% to 85% of sudden cardiac deaths.[19] Ventricular fibrillation is usually preceded by ventricular tachyarrhythmia, but also may occur as a primary arrhythmia. More recent studies suggest that ventricular fibrillation results from multiple wavelengths that disperse randomly, using the leading circle form of re-entry.[19] The most common cause of ventricular fibrillation is acute myocardial infarction. It also is observed in patients with chronic ischemic heart disease, hypoxia resulting from any cause, acidosis, hypokalemia, and massive hemorrhage.

Indications for Correction of Cardiac Arrhythmias

Intracardiac electrophysiologic studies can give valuable information about normal and abnormal electrophysiology of intracardiac structures (see Chapters 42, 43, and 97 [Chapter 42] [Chapter 43] [Chapter 97] ). These studies are used to confirm the mechanism of an arrhythmia, to delineate its anatomic substrate, and to ablate it. The electric stability of the ventricles also can be assessed, as can the effects of an antiarrhythmic regimen.

In addition, pacing technologies have been developed to treat heart failure with promising results, leading to improvement in morbidity and mortality in these patients. Hemodynamic responses to biventricular pacing include an increase in the rate of elevation of left ventricular pressure and increases in pulse pressure, left ventricular stroke work, cardiac index, and wedge pressure.[20] Cardiac resynchronization therapy improves ventricular function without increasing myocardial energy consumption, in contrast to the effect of inotropic agents, such as dobutamine.[11] In addition, cardiac resynchronization therapy may reverse left ventricular remodeling over time.[21]

Permanent Pacing

Indications for pacemaker therapy have increased in recent years and now include the treatment of bradyarrhythmias and heart failure according to the American College of Cardiology and American Heart Association guidelines.[22] These guidelines discuss indications for pacing in patients with sinus node dysfunction, acquired atrioventricular block, chronic bifascicular and trifascicular block, hypersensitive carotid sinus, and neurally mediated syndromes. The guidelines serve to direct the treating physician in selecting which patients would benefit from device therapy.

A Swedish team led by Sennings and Elmqvist implanted the first pacemaker in 1958.[23] A thoracotomy was required, and pacing was done through electrodes sutured to the epicardium. In these early systems, significant problems with changes in pacing threshold, lead infection, and lead breakage were common. Transvenous lead implantation subsequently developed by Furman would resolve many of these issues.[24] In 1958, Furman successfully paced an elderly patient with a catheter electrode inserted transvenously. Other investigators took on the challenge of solving various technical problems, such as device miniaturization, longer life batteries, and stable, reliable lead material.[25]

As the indication for implantation expanded from atrioventricular conduction disturbances to management of sinus node dysfunction, the need for implantable pacemakers grew in proportion.[25] Technology evolved rapidly with the development of lithium-iodide batteries that had greater longevity. Electronic advances then led to major miniaturization using integrated circuits as opposed to discrete components. Lead materials used in today's pacemaker rely on silicone and polyurethane, which are more biocompatible and reliable than earlier materials. With all these technical refinements, present-day pacemakers are small and can pace reliably for 8 to 10 years before generator replacement is needed.

The primary functional challenge for contemporary pacemakers is to maintain the heart rate based on circulatory needs, pacing in a manner that mimics the natural physiology of excitation and conduction. In a healthy heart, the sinus node is modulated by the autonomic nervous system, and its rate is determined by a multiplicity of factors, such as physical activity, emotion, and blood pressure. Not only the rate, but also the activation sequence and atrioventricular conduction time vary with demand; these requirements also must be considered. Rate is controlled by pacemaker discharge, and the excitation and conduction sequence depend on the placement of pacing electrodes.

Approximately 120,000 pacemakers are implanted each year in the United States. Indication for implantation for most of these cases is sick sinus syndrome. Other indications include atrioventricular block, carotid sinus hypersensitivity, malignant vasodepressor syndrome, and hypertrophic cardiomyopathy.[26]

The primary purpose of implantable pacemakers is to treat symptomatic bradycardia. With the extraordinary developments that have occurred in pacemaker therapy for the traditional indication, bradycardia, new uses are now beginning to be explored. Pacemakers have progressed from large, fixed-rate, single-chamber devices to multiprogrammable, multichamber devices with the ability to respond to changing hemodynamic demands. As technology advances, other possible uses are likely to be conceived.

Resynchronization Therapy

Cardiac resynchronization therapy has been shown to improve heart failure symptoms, quality of life, exercise capacity, hospitalization, and echocardiographic variables.[27] Based on the available data, cardiac resynchronization therapy is indicated in patients with drug-refractory, symptomatic New York Heart Association functional class III and IV heart failure of either ischemic or nonischemic origin.[28] In addition, these patients are protected from associated risk of sudden cardiac death when combined with an ICD system.[29]

The development of an automatic internal defibrillator or ICD began in the 1960s. External cardiac defibrillation was increasingly being used in coronary care units for the treatment of ventricular fibrillation and sudden cardiac death. Although the idea of automatic external defibrillation had been discussed initially by Zycoto, Mirowski and colleagues[30] were the first to champion and begin practical development of an automatic internal device. In 1969, Mirowski and Mower developed the prototype of today's automatic internal defibrillator.[31]

The primary goal of all defibrillators is to terminate ventricular tachyarrhythmias by delivering high-voltage shocks to the ventricle. As with implantable pacemakers, defibrillating devices need to be small and reliable, and to have adequate longevity. ICDs have evolved not only to perform this function, but also to take on additional tasks, such as antitachycardia pacing of the ventricle, dual-chamber pacing, and termination of atrial tachyarrhythmias.

A key difference between pacing and defibrillation of the heart is that for pacing; only a very small mass of myocardium needs to be stimulated, whereas for defibrillation, most, if not all, of the myocardium must be stimulated. Because the myocardium is easily excitable throughout diastole, a small wave of depolarization during pacing can readily propagate throughout the whole heart. In contrast, during ventricular fibrillation, there are usually multiple re-entrant wave fronts that are continuously changing in location and size that must be quelled. To defibrillate successfully, most of these wavefronts have to be interrupted simultaneously; to achieve this, one needs to capture most of the tissue that is in a state of relative refractoriness.[32] One unique property of defibrillation success is that it is probabilistic.[33] The same energy that can defibrillate the heart on one occasion may be unsuccessful at another time.

The main purpose of ICD placement is to prevent death from hemodynamically unstable ventricular tachyarrhythmias. Although advances in technology have made these devices much more flexible in terms of arrhythmia detection and electric therapy potions, their main purpose is to reduce sudden cardiac death, which claims approximately 300,000 lives in the United States annually. Secondary prevention of sudden cardiac death in patients who have survived cardiac arrest is another major indication for ICD placement. In such patients and especially in patients of this group for whom no reversible or curable cause can be found, ICD implantation has been repeatedly documented to provide a major mortality benefit.[34] Interest in managing atrial tachyarrhythmias also has grown significantly in recent years. It is now recognized that about 30% of patients with ventricular tachyarrhythmia also have atrial tachyarrhythmias.[35] Such atrially initiated tachyarrhythmias can worsen patient symptoms, can result in inappropriate ventricular shocks, and may be responsible for initiating ventricular tachyarrhythmias that can exacerbate other pathologies, such as heart failure. New strategies for treatment and prevention of atrial tachyarrhythmias are incorporated into devices that are capable of defibrillation and antitachycardia pacing in the atrium and the ventricle, in addition to combined dual-chamber pacing.[36]

The relative ease of ICD implantation and longevity of current defibrillators have made them a valuable tool in primary prevention. Patients no longer must survive a cardiac arrest to justify the risk of ICD implantation.

Preoperative Evaluation

Most patients who require pacemaker or ICD placement have significant cardiovascular disease. In addition, correction of cardiac arrhythmia may require radiofrequency catheter ablation. Radiofrequency catheter ablation has proved highly effective in the treatment of atrioventricular nodal re-entrant and accessory pathway tachycardias. Indications for pacemaker and ICD placement continue to evolve as the utility of these devices continues to increase. Although most pacemaker placement is done with local anesthetic infiltration, ICD placement may require monitored anesthesia care or in some cases general anesthesia. The modern ICD unit is capable of delivering the full spectrum of therapy for ventricular tachyarrhythmias and for bradycardia therapy with dual-chamber pacing/sensing, rate modulation, and mode-switching features.

As mentioned earlier, there are two common indications for ICD placement. One is continued ventricular tachyarrhythmias despite adequate drug therapy. Another indication is history of sudden cardiac arrest that is not associated with myocardial infarction.

Preoperative evaluation processes necessary for placement of an ICD should be complete by the time the decision is made to place the device (see Chapters 34 and 35 [Chapter 34] [Chapter 35] ). These patients need a thorough preoperative evaluation. This evaluation includes electrophysiologic testing to determine the inducibility of ventricular tachycardia and electrophysiologically guided drug therapy. Preoperative pulmonary function tests may be necessary in patients on amiodarone to evaluate possible toxicity of this drug, which can result in chronic obstructive pulmonary disease or interstitial lung disease. In some instances, the underlying pathophysiology of malignant ventricular arrhythmias is related to ischemic or idiopathic cardiomyopathy.[37] These patients often present with poor left ventricular function and higher incidence of congestive heart failure. Patients with a history of congestive heart failure should be in optimal condition before surgery.

Generally, all patients who present for correction of cardiac arrhythmia require preoperative evaluations including electrocardiogram, chest radiograph, hemoglobin, and electrolytes. Patients should be NPO (have nothing by mouth) at least 8 hours before the procedure. In addition, patients who require device and lead extractions because of malfunction or infection may require blood product transfusions during the procedure. Consequently, type and crossmatch of blood products is frequently necessary for these procedures.

Anesthetic Considerations

Pacemakers

Permanent implantable pacemakers have been the standard modality of treatment for patients with all types of bradyarrhythmias. A significant number of these patients present with sick sinus syndrome and are older. Consequently, devices are placed under general anesthesia in these patients. As a result of more recent advances in pacemaker technology, these devices now can be placed as a therapeutic modality to alter hemodynamic states. Surgeons used to be primarily responsible for device insertion. Now the task falls under the services of cardiologists. Device placement is commonly performed in the cardiac catheterization suite under local anesthesia on an outpatient basis. Complicated high-risk patients now present for pacemaker insertion, however, in addition to more recent indications by the American College of Cardiology/American Heart Association for these devices. In light of these increased indications, the expertise of anesthesiologists is needed for monitoring and perioperative care of these patients.

Monitored Anesthesia Care

Currently, most pacemaker insertions are performed by cardiologists. Most of these cases are performed under local anesthesia with sedation. Depending on the level of training, administration of sedatives and analgesics can be provided by nurses.

In instances that require deeper sedation for a patient's comfort or for critically ill patients with hemodynamic instability, monitored anesthesia care by an anesthesiologist may be required). Adequate monitoring and resuscitation equipment is required in such situations. The goal of monitored anesthesia care is to provide analgesia, sedation, and anxiolysis, while ensuring rapid recovery with minimal or no side effects. Any sedative-hypnotic medication may be used during monitored anesthesia care with a wide variety of delivery systems.[38] Subanesthetic concentrations of inhaled agents also have been used to supplement local anesthetics. Newer drugs, such as centrally mediated α2-agonists, have been shown to produce anxiolysis, sedation, and reduced requirements for supplemental analgesic medications during monitored anesthesia care.

General Anesthesia

Patients requiring pacemaker placement rarely require general anesthesia for placement. If general anesthesia is required, it should be directed toward underlying cardiac pathophysiology, indications, complications, and hemodynamic goals. Immediate access to life-support equipment, such as a cardiac defibrillator and a transcutaneous pacemaker, is necessary if the device is being placed under general anesthesia.

Implantable Cardioverter-Defibrillator

Since the 1980s, indications for use and implantation of ICDs have steadily increased. Over the past 2 decades, ICDs have undergone a significant evolution. In the 1970s and 1980s, ICD placement usually required thoracotomy for placement of epicardial patches.

Preoperative Evaluation

As mentioned earlier, common indications for ICD implantation include continued ventricular tachyarrhythmias unresponsive to adequate pharmacotherapy and history of sudden cardiac arrest unassociated with myocardial infarction. Newer indications include patients with various forms of the congenital long QT syndrome.[39] Patients with long QT syndrome who have already survived an episode of cardiac arrest or documented polymorphic ventricular tachyarrhythmia, especially if on pharmacotherapy at the time, are increasingly being evaluated as ICD candidates. In addition, patients with hypertrophic cardiomyopathies and without a history of sudden death are usually evaluated for ICD placement.[40] In these patients, sustained ventricular arrhythmias, nonexertional syncope, or a strong family history of sudden death with early age of presentation strongly indicates ICD implantation.

In all instances, the evaluation that is necessary for ICD implantation is completed by the time the decision is made to place the device (see Chapters 34 and 35 [Chapter 34] [Chapter 35] ). Electrophysiologic studies may have been done to determine the forms of arrhythmias present. When the pathophysiology of ventricular arrhythmias is related to idiopathic or ischemic cardiomyopathy,[41] these patients may present with poor left ventricular function and a high incidence of congestive heart failure. Consequently, they should be optimized as much as possible preoperatively.

Anesthetic Considerations

In the 1980s, ICD implantation was done with epicardial leads via thoracotomy under general anesthesia with one-lung ventilation. The technologic development of implantable ICDs with transvenous lead systems has simplified their implantation. Consequently, it was reasoned that ICDs can be placed under deep sedation with little or no intervention by the anesthesiologist analogous to what is needed for pacemaker placement.[42] Placement of an ICD under general anesthesia may be safer and more comfortable for the patient, however. Patients who present for ICD placement are often critically ill with cardiopulmonary comorbidity. It is not unusual for these patients to present with ejection fractions less than 30% and to require vasopressors to support hemodynamics during the procedure. In addition, some form of general anesthesia is necessary for intraoperative testing of defibrillating thresholds.

Monitored Anesthesia Care

Small, new-generation devices and transvenous lead systems lend themselves to the use of local anesthesia and intravenous sedation for ICD implantation. Midazolam and fentanyl are usually the drugs of choice when an ICD is placed under monitored anesthesia care (see Chapter 78 ). Monitoring includes pulse oximetry, five-lead electrocardiogram, and noninvasive blood pressure. Depth of anesthesia is monitored clinically. One of the major aspects of ICD placement is testing the device. Testing the device may require deep sedation or general anesthesia because the shocks that are associated with this procedure can be very painful. The presence of an anesthesiology team may be necessary for ICD placement under monitored anesthesia care.

General Anesthesia

Most patients who present for ICD placement typically have comorbidities such as ventricular tachycardia, congestive heart failure with ejection fraction less than 30%, coronary artery disease, pulmonary hypertension, chronic renal insufficiency, or valvular heart disease. These patients may be unable to lie flat for the prolonged period necessary for placement of the ICD. In addition, they may require close hemodynamic monitoring during the testing of the device. General anesthesia should be considered in these patients. When general anesthesia is chosen, in addition to standard monitoring, an arterial line may be added. External cardioverter-defibrillator pads are required for all ICD placements. These are employed in cases where an implanted defibrillator fails. General anesthesia also may be requested for anxious and extremely nervous patients. Because pacemakers and ICDs are placed percutaneously, anesthesiologists must be vigilant to possible complications, such as myocardial infarction, stroke, possible cardiac injury (perforation/tamponade), and pneumothorax from subclavian vascular access.

Extraction of Devices

As a result of continued growth and expanding indications for pacemakers and ICD placement, leads may require extraction because of mechanical dysfunction, the need to upgrade to more complex devices, or local or systemic infection. Lead extractions are probably one of the most challenging procedures that a cardiac electrophysiologist has to face today.

Indications for lead extractions can be divided into two categories—patient-related and lead-related. Patient-related indications include infection, ineffective therapy (high defibrillation threshold), perforation, migration, embolization, induction of arrhythmias, venous thrombosis, unrelenting pain, device interactions, and device upgrades.[43] Lead-related indications include lead recalls, lead failure, and lead interactions.[44]

Lead extraction is performed via powered sheaths through which energy is delivered to the tip in the form of excimer laser light or electrocautery. These systems burn through scar tissue adherent to the wall of the lead throughout its course. The potential for life-threatening complications, such as lead fracture, venous or myocardial rupture, and tamponade, makes general anesthesia with invasive monitors a prudent choice for lead extractions.

Postoperative Care

Postoperative care of patients with pacemaker or ICD implantation depends on various factors surrounding the implantation of the device (see Chapter 85 ). As mentioned earlier, most of these patients are quite ill with significant comorbidities. It is not unusual for patients to have congestive hart failure with an ejection fraction less than 30% as a result of poor left ventricular function. Consequently, it is imperative to have these patients monitored in the postanesthesia care unit, especially if the device is placed or extracted under general anesthesia. The spectrum of recovery sites after these procedures may vary from postprocedure units to a coronary intensive care unit. Most of these procedures are done on an outpatient basis; anesthesia is tailored to ensure rapid recovery after implantation.

Correction of Cardiac Arrhythmias with Ablation Therapy

Catheter ablation is a safe and curative option for most cardiac arrhythmias, with 85% to 98% cure rates among the arrhythmias treated most frequently.[45] The rate of major complications is less than 3%.[45] Cardiac ablation therapy involves the delivery of energy through a catheter that is usually placed in the endocardial position in the heart, destroying myocardial tissue that is responsible for the tachyarrhythmia. Multiple electrodes are inserted to locate the arrhythmia and ablate it. Usually the diagnostic portions of the ablation study are done during the same procedure.[46] The efficacy of catheter ablation depends on the accurate identification of the site of origin of the arrhythmia. When the site is identified, the electrode catheter is positioned in direct contact with the site of the arrhythmia, and radiofrequency energy is delivered through the catheter to destroy it.

The current that is generated by radiofrequency is alternating current, and is delivered at cycle lengths of 300 to 750 kHz when used for catheter ablation.[47] It causes resistive heating of the tissue in contact with the electrode. The degree of tissue heating is inversely proportional to the radius to the fourth power.[48] Consequently, the lesions created by radiofrequency energy are small. Although electric injury may be a contributing factor, the primary mechanism of tissue destruction by radiofrequency current is thermal injury. Acute lesions created by a radiofrequency current consist of a central zone of coagulation necrosis surrounded by a zone of hemorrhage and inflammation.[49]

Cardiac arrhythmias that can be treated with radiofrequency ablation include paroxysmal supraventricular tachycardia, Wolff-Parkinson-White syndrome, atrial flutter, atrial fibrillation, and idiopathic ventricular tachycardia. Most cardiac arrhythmias that are treated with radiofrequency ablation are not life-threatening, but have a significant impact on a patient's quality of life.[50] Advantages of radiofrequency ablation of cardiac arrhythmias include relief of symptoms, improvement in functional capacity and quality of life, and elimination of the need for lifelong antiarrhythmic drug therapy. The principal disadvantage is the risk of complications, which varies depending on the type of ablation procedure and skill of the operator.

Anesthetic Considerations

Catheter ablation was introduced into clinical practice in 1982. Initially, ablation was performed with direct electric shocks.[51] As a result of several advantages over direct current, radiofrequency ablation has replaced direct current ablation. These advantages include the absence of skeletal and cardiac muscle stimulation, minimal discomfort during delivery of energy, the possibility of performing the procedure in conscious patients, and the discrete nature of resulting lesions.[49]

Most cardiac ablation therapy for correction of arrhythmias can be performed under moderate sedation or monitored anesthesia care. In some of these cases, deep sedation may be required as the case progresses. In a few cases, general anesthesia may be required if the patient is anxious or cannot tolerate lying in the supine position for an extended period. General anesthesia may be implemented for these patients with standard American Society of Anesthesiologists monitors with adequate vascular access. Catheter ablation is the first-choice treatment for most cardiac arrhythmias. It is a safe treatment and is usually effective as a single procedure. Because it is curative in many patients, it is offered to all patients who would otherwise be committed to long-term drug therapy.

Future Trends

Correction of cardiac tachyarrhythmias has improved dramatically in the past 2 decades. Emphasis has shifted from pharmacologic therapy to nonpharmacologic therapy of tachyarrhythmias; this has led to a significant increase in the numbers of radiofrequency catheter ablations and defibrillator implantations. These developments were triggered by technologic advances that showed superiority of these procedures over the use of antiarrhythmic drugs.[52] As a result, treatment of supraventricular tachycardias and tachycardias involving accessory atrioventricular pathways will probably remain the domain of catheter ablation. The cure rates of patients treated with catheter ablation is very high. In addition, treatment of life-threatening ventricular tachyarrhythmia will remain in the domain of ICDs for the foreseeable future. The role of ICD therapy has been clearly defined with respect to prolongation of life and has been expanded to include primary prophylaxis of sudden death in high-risk populations.[53]

As a result of these developments, the presence of an anesthesiology team will continue to grow in cardiology suites. Patients who are being cared for in these areas are sicker with significant comorbidities. The role of conscious sedation will continue to diminish in the performance of these procedures. These patients will require full monitoring and care under the direction of an anesthesiologist.